{
  "bill_id": "NE2025000L77",
  "source_url": "http://custom.statenet.com/public/resources.cgi?id=ID:bill:NE2025000L77&cuiq=93d84396-c63b-526a-b152-38b7f79b4cfd&client_md=e4f6fea4-27b4-5d41-b7d3-766fe52569f0",
  "versions": [
    {
      "date": "01/09/2025",
      "label": "Introduced",
      "url": "https://custom.statenet.com/public/resources.cgi?mode=show_text&id=ID:bill:NE2025000L77&verid=NE2025000L77_20250109_0_I&",
      "raw_html": "<html>\n<head>\n<title>Bill Resource</title>\n\n<!--   <link href=\"https://custom.statenet.com/network/Common/css/extregtext.css\" rel=\"stylesheet\" type=\"text/css\" />-->\n   <link href=\"https://custom.statenet.com/network/Common/css/xmltext-2.0.css\" rel=\"stylesheet\" type=\"text/css\" />\n   <link href=\"https://custom.statenet.com/network/Common/css/additional-text.css\" rel=\"stylesheet\" type=\"text/css\" />\n\n\t<style type=\"text/css\">\n<!--\n\ntd, body {\n     background-color: white;\n\tfont-family: Verdana, Arial, Helvetica, sans-serif;\n\tfont-size: 12px;\n}\n\n.resourceContainer {\n   border: 1px solid black;\n}\n-->\n</style>\n</head>\n<body>\n\n    <div style=\"width: 750px; margin: auto\">\n       <div style=\"font-size: .8em;margin-bottom: 10px\"><table width=\"100%\"><tr><td align=\"left\" style=\"font-size: .8em;\"><div>The following has special meaning:</div>\n<div><u class=\"amendmentInsertedText\">green underline denotes added text</u></div>\n<div><strike class=\"amendmentDeletedText\">red struck out text denotes deleted text</strike></div></td> <td align=\"right\"><a href=\"https://www.lexisnexis.com/statenet/\"><img alt=\"Powered by State Net\" src=\"https://custom.statenet.com/network/poweredby.gif\" /></a></td></tr></table></div><table id=\"text-identifier\"><tr><td class=\"key\">2025 NE L 77</td> <td><table><tr><td class=\"label\">Author:</td> <td>Bostar</td></tr> <tr><td class=\"label\">Version:</td> <td>Introduced</td></tr> <tr><td class=\"label\">Version Date:</td> <td>01/09/2025</td></tr></table></td></tr></table><div class=\"documentBody\">\n  <a name=\"head_document_section\"></a><div class=\"head\">\n   <p class=\"center\">LEGISLATURE OF NEBRASKA</p>\n   <p class=\"center\">ONE HUNDRED NINTH LEGISLATURE</p>\n   <p class=\"center\">FIRST SESSION</p>\n   <p class=\"center\">\n    <b>LEGISLATIVE BILL 77</b>\n   </p>\n   <p class=\"left\">Introduced by Bostar, 29.</p>\n   <p class=\"left\">Read first time January 09, 2025</p>\n   <p class=\"left\">Committee:</p>\n  </div>\n  <a name=\"code_document_section\"></a><div class=\"code\">\n   <p class=\"left\">A BILL FOR AN ACT relating to insurance; to adopt the Ensuring Transparency in Prior Authorization Act; to provide operative dates; and to provide severability.</p>\n  </div>\n  <a name=\"text_document_section\"></a><div class=\"text\">\n   <span>\n    <p class=\"left\">Be it enacted by the people of the State of Nebraska,</p>\n   </span>\n   <p class=\"indent\">\n    <b>Section 1. </b>\n    <u class=\"amendmentInsertedText\">Sections 1 to 14 of this act shall be known and may be cited as the Ensuring Transparency in Prior Authorization Act.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 2. </b>\n    <u class=\"amendmentInsertedText\">For purposes of the Ensuring Transparency in Prior Authorization Act, unless the context otherwise requires:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(1) Adverse determination means a determination by a health carrier or its designated utilization review entity that an admission, the availability of care, a continued stay, or other health care service has been reviewed and, based upon the information provided, does not meet the health carrier&#39;s requirements for medical necessity, appropriateness, health care setting, level of care, or effectiveness, and the requested health care service is therefore denied, reduced, or terminated;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Chronic condition means a condition that lasts one year or more and requires ongoing medical attention or limits activities of daily living or both;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) Clinical criteria means the written policies, written screening procedures, determination rules, determination abstracts, clinical protocols, practice guidelines, medical protocols, and any other criteria or rationale used by the utilization review entity to determine the necessity and appropriateness of health care services;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4) Department means the Department of Insurance;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(5) Emergency health care services, with respect to an emergency medical condition as defined in 42 U.S.C. 300gg-111, means:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) A medical screening examination, as required under the Emergency Medical Treatment and Labor Act, or as would be required under such act if such act applied to an independent freestanding emergency department, that is within the capability of the emergency department of a hospital or of an independent freestanding emergency department, as applicable, including ancillary services routinely available to the emergency department to evaluate such emergency medical condition; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) Within the capabilities of the staff and facilities available at the hospital or the independent freestanding emergency department, as applicable, such further medical examination and treatment as are required under the Emergency Medical Treatment and Labor Act, or as would be required under such act if such act applied to an independent freestanding emergency department, to stabilize the patient, regardless of the department of the hospital in which such further examination or treatment is furnished;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(6) Emergency Medical Treatment and Labor Act means section 1867 of the Social Security Act, 42 U.S.C. 1395dd, and associated regulations;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(7) Enrollee means an individual who is enrolled in a health benefit plan, including covered dependents;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(8) Health benefit plan means a policy, contract, certificate, or agreement offered or issued by a health carrier to provide, deliver, arrange for, pay for, or reimburse any of the costs of health care services;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(9) Health care provider has the same meaning as in section 44-1303;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(10) Health care services means any services provided by a health care provider, or by an individual working for or under the supervision of a health care provider, that relate to the diagnosis, assessment, prevention, treatment, or care of any human illness, disease, injury, or condition. The term also includes the provision, administration, or prescription of pharmaceutical products or services, the provision of mental health and substance use disorder services, and the provision of durable medical equipment;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(11) Health carrier means an entity subject to the insurance laws and regulations of this state, or subject to the jurisdiction of the Director of Insurance, that contracts or offers to contract to provide, deliver, arrange for, pay for, or reimburse any of the costs of health care services, including a sickness and accident insurance company, a health maintenance organization, a nonprofit hospital and health service corporation, or any other entity providing a plan of health insurance, health benefits, or health care services. Health carrier does not include a managed care organization;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(12) Medically necessary means services or supplies provided by a health care provider that are:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) Appropriate for the symptoms and diagnosis or treatment of the enrollee&#39;s condition, illness, disease, or injury;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) In accordance with standards of good medical practice;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) Not primarily for the convenience of the enrollee or the enrollee&#39;s health care provider; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(d) The most appropriate supply or level of service that can safely be provided to the enrollee;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(13) Notice means communication delivered either electronically or through the United States Postal Service or a common carrier;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(14) Physician means an individual licensed under the Medicine and Surgery Practice Act to practice medicine and surgery or osteopathic medicine and surgery or an individual with an equivalent license from another United States jurisdiction;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(15) Prior authorization means the process by which utilization review entities determine the medical necessity and medical appropriateness of otherwise covered health care services prior to the rendering of such health care services. The term includes authorization, pre-certification, and any other term that would be a reliable determination by a health benefit plan;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(16) Urgent health care service means a health care service with respect to which the application of the time periods prescribed under the Ensuring Transparency in Prior Authorization Act for making a nonexpedited prior authorization could, in the opinion of a physician with knowledge of the enrollee&#39;s medical condition:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) Seriously jeopardize the life or health of the enrollee or the ability of the enrollee to regain maximum function; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) Subject the enrollee to severe pain that cannot be adequately managed without the care or treatment that is the subject of the utilization review;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(17) Utilization review entity means an individual or entity that performs prior authorization for a health benefit plan; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(18) Value-based arrangement means an agreement between a health carrier and a health care provider that rewards the provider for quality, effectiveness, or efficiency through shared cost savings.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 3. </b>\n    <u class=\"amendmentInsertedText\">(1) A utilization review entity, including any third-party entity utilized by the health carrier, shall make any current prior authorization requirements and restrictions, including written clinical criteria, readily accessible on its website to enrollees and health care providers. Prior authorization requirements shall be described in detail but also in easily understandable language. Prior authorization requirements shall also be made available on the website in a machine-readable format no later than January 1, 2027.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) If a utilization review entity intends either to implement a new prior authorization requirement or restriction or to amend an existing requirement or restriction, the utilization review entity shall:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) Ensure that the new or amended requirement or restriction is not implemented unless the utilization review entity&#39;s website has been updated to reflect the new or amended requirement or restriction; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) Provide contracted health care providers who are credentialed to perform the affected health care service, or enrollees who have a chronic condition and are already receiving such service, notice of the new or amended requirement or restriction no less than sixty days before the requirement or restriction is implemented.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 4. </b>\n    <u class=\"amendmentInsertedText\">(1) A utilization review entity shall ensure that all adverse determinations are made by a physician. Such physician shall:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) Possess a current and valid nonrestricted license in a United States jurisdiction;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) Have the appropriate training, knowledge, or expertise to apply appropriate clinical guidelines to the health care service being requested; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) Make the adverse determination under the clinical direction of one of the utilization review entity&#39;s medical directors who is responsible for the provision of health care services provided to enrollees of Nebraska. All such medical directors must be physicians licensed in a United States jurisdiction.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) When an adverse determination is issued or a prior authorization is canceled or voided, the utilization review entity shall provide written notice to the requesting health care provider. The notice shall include the reason for denial, citing written clinical criteria.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3)(a) If an adverse determination questions the medical necessity, the appropriateness, or the experimental or investigational nature of a health care service, or if physician review is required due to the age of the patient, the utilization review entity shall include in the notice of adverse determination the name and telephone number of a physician acting on behalf of the utilization review entity with whom the requesting health care provider, or the provider&#39;s designated proxy, shall have a reasonable opportunity to discuss the patient&#39;s treatment plan and the clinical basis for the intervention.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) The requesting health care provider, or the provider&#39;s designated proxy, shall have the opportunity to contact such physician at the telephone number provided within one business day of receipt of the adverse determination for an urgent health care service or within three business days of receipt of the adverse determination for a nonurgent health care service, to engage in a discussion of the patient&#39;s treatment plan and the clinical basis for the intervention. If the physician does not respond to the requesting health care provider, or the provider&#39;s designated proxy, within the required timeframe, the utilization review entity shall be deemed to have failed to provide a reasonable opportunity for discussion as required under subdivision (3)(a) of this section and the prior authorization request shall be deemed approved.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) Following any discussion under subdivision (3)(b) of this section, the utilization review entity shall notify the requesting health care provider whether or not the adverse determination decision remains the same or the health care service is approved. The notice under this subdivision shall be provided (i) within one business day of the discussion between the requesting health care provider and physician for an urgent health care service or (ii) within two business days of the discussion between the requesting health care provider and physician for a nonurgent health care service.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(d) A discussion under subdivision (3)(b) of this section shall not replace or eliminate the opportunity for any internal grievance or appeal process provided by the utilization review entity.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 5. </b>\n    <u class=\"amendmentInsertedText\">A utilization review entity shall ensure that all appeals of an adverse determination are reviewed by a physician. Such physician shall:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(1) Possess a current and valid unrestricted license in a United States jurisdiction;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Be of the same or similar specialty as a physician who typically manages the medical condition in question, which means that either:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) The physician maintains board certification for the same or similar specialty; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) The physician&#39;s training and experience (i) includes treating the condition, (ii) includes treating complications that may result from the service or procedure, and (iii) is sufficient for the physician to determine if the service or procedure is medically necessary or clinically appropriate;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) Not have been directly involved in making the adverse determination;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4) Not have any financial interest in the outcome of the appeal; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(5) Consider all known clinical aspects of the health care service under review, including, but not limited to, a review of those medical records which are pertinent and relevant to the active condition provided to the utilization review entity by the enrollee&#39;s health care provider, or a health care facility, and any pertinent medical literature provided to the utilization review entity by the health care provider.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 6. </b>\n    <u class=\"amendmentInsertedText\">(1) On or before November 1, 2025, the department shall approve a uniform prior authorization request form for prescription drugs, devices, and durable medical equipment and a uniform prior authorization request form for all other health care procedures, treatments, and services. The uniform prior authorization request forms shall not exceed two printed pages in length. This two-page limit does not apply to or include a health care provider&#39;s notes or documentation that the provider submits in support of a prior authorization request.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Beginning January 1, 2026, all health care providers shall use only the approved uniform prior authorization request forms and all health benefit plans and utilization review entities shall accept and process prior authorization requests submitted using such forms.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) This section does not prohibit a health carrier from using a prior authorization methodology that uses an Internet webpage, an Internet webpage portal, or a similar web-based system if the methodology is consistent with the uniform prior authorization request forms approved by the department pursuant to this section.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 7. </b>\n    <u class=\"amendmentInsertedText\">(1) If a utilization review entity requires prior authorization of a health care service, the utilization review entity shall make a prior authorization or adverse determination and provide notice of its decision to the enrollee and the enrollee&#39;s health care provider in accordance with the following timeframes:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) For purposes of approving a prior authorization for urgent health care services, within twelve hours of obtaining all necessary information to make the prior authorization or adverse determination; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) For purposes of approving a prior authorization for nonurgent health care services, within three days of obtaining all necessary information to make the prior authorization or adverse determination.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) For purposes of this section, necessary information includes, but is not limited to, the results of any face-to-face clinical evaluation or second opinion that may be required.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) Health care services are deemed authorized if a utilization review entity fails to comply with the deadlines set forth in this section.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4) In the notice to the health care provider that a prior authorization has been approved, the utilization review entity shall include the duration of the prior authorization or the date by which the prior authorization will expire.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 8. </b>\n    <u class=\"amendmentInsertedText\">No utilization review entity shall require prior authorization of:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(1) Emergency confinement or an emergency health care service;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Pre-hospital transportation for the provision of emergency health care services or for transfers between facilities as required by the Emergency Medical Treatment and Labor Act;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) Cancer care that is consistent with guidelines of the National Comprehensive Cancer Network;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4) Services that have a rating of A or B from the United States Preventive Services Task Force, immunizations recommended by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention, or preventive services and screenings provided to women as described in 45 C.F.R. 147.130; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(5) Services covered through a value-based arrangement.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 9. </b>\n    <u class=\"amendmentInsertedText\">(1) A health benefit plan shall not revoke, limit, condition, or restrict a prior authorization if care is provided within sixty days from the date the health care provider received the prior authorization unless the enrollee was no longer eligible for care on the day care was provided.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) A health benefit plan shall pay a contracted health care provider at the contracted payment rate for a health care service provided by the health care provider per a prior authorization, unless:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) The health care provider knowingly and materially misrepresented the health care service in the prior authorization request with the specific intent to deceive and obtain an unlawful payment under the health benefit plan;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) The health care service was no longer a covered benefit on the day it was provided;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) The health care provider was no longer contracted with the patient&#39;s health benefit plan on the date the care was provided;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(d) The health care provider failed to meet the utilization review entity&#39;s timely filing requirements; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(e) The patient was no longer eligible for health care coverage on the day the care was provided.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 10. </b>\n    <u class=\"amendmentInsertedText\">(1) Except as otherwise provided in this section, prior authorization shall be valid for at least one year from the date the health care provider receives the prior authorization, and the authorization period shall be effective regardless of any changes in dosage for a prescription drug prescribed by the health care provider.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) If a prior authorization is required for a health care service, other than for inpatient acute care, for the treatment of a chronic condition of an enrollee, the prior authorization shall remain valid for the length of the treatment.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) If a prior authorization is required for inpatient acute care for the treatment of a chronic condition of an enrollee, the prior authorization shall remain valid for at least fourteen calendar days from the date the health care provider receives the prior authorization approval. If an enrollee requires inpatient acute care beyond the length of stay that was previously approved by the utilization review entity, then the utilization review entity shall evaluate any prior authorization requests for the continuation of inpatient acute care according to the provisions of the Ensuring Transparency in Prior Authorization Act. a utilization review entity shall not use any stricter criteria to determine medical necessity and appropriateness of the continuation of inpatient acute care than the criteria used to evaluate the initial request for authorization of inpatient acute care. A utilization review entity shall review any relevant and pertinent literature or data provided by the health care provider to determine the medical necessity and appropriateness of the requested length of stay or continuation of inpatient acute care. A prior authorization for the continuation of inpatient acute care shall remain valid for a maximum of fourteen calendar days from the date the health care provider receives the prior authorization approval. If a utilization review entity fails to respond to a health care provider&#39;s timely prior authorization request for the continuation of inpatient acute care before the termination of the previously approved length of stay, then the health benefit plan shall continue to compensate the health care provider at the contracted rate for inpatient acute care provided until the utilization review entity issues its determination on the prior authorization request. For purposes of this section, a timely prior authorization request for the continuation of inpatient acute care means a request that is submitted at least seventy-two hours prior to the termination of the previously approved prior authorization and includes all necessary information for the utilization review entity to make a determination. If a utilization review entity issues an adverse determination to a health care provider&#39;s prior authorization request for continuation of inpatient acute care and the health care provider appeals the adverse determination according to the provisions of the Ensuring Transparency in Prior Authorization Act, then the health benefit plan shall continue to compensate the health care provider at the contracted rate for inpatient acute care provided until the appeal has been finalized.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4) This section does not require a health benefit plan to cover care, treatment, or services for a health condition that the terms of coverage otherwise completely exclude from the policy&#39;s covered benefits without regard for whether the care, treatment, or services are medically necessary.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 11. </b>\n    <u class=\"amendmentInsertedText\">(1) On receipt of information documenting a prior authorization from the enrollee or from the enrollee&#39;s health care provider, a utilization review entity shall honor a prior authorization granted to an enrollee from a previous utilization review entity for at least the initial sixty days of an enrollee&#39;s coverage under a new health benefit plan. During such time period, a utilization review entity may perform its own review to grant a prior authorization.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) If there is a change in coverage of, or approval criteria for, a previously authorized health care service, the change in coverage or approval criteria does not affect an enrollee who received prior authorization before the effective date of the change for the remainder of the enrollee&#39;s plan year.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) A utilization review entity shall continue to honor a prior authorization it has granted to an enrollee when the enrollee changes products under the same health insurance company without any act on behalf of the health care provider.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 12. </b>\n    <u class=\"amendmentInsertedText\">(1) An artificial intelligence-based algorithm shall not be the sole basis of a utilization review entity&#39;s decision to deny, delay, or modify health care services based, in whole or in part, on medical necessity.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) A utilization review entity shall disclose to the department, to each health care provider in its network, to each enrollee, and on its public website if artificial intelligence-based algorithms are used or will be used in the utilization review process.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) The department may, at any time, audit a utilization review entity&#39;s automated utilization management system. The department may contract with a third-party entity to perform an audit pursuant to this section.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 13. </b>\n    <u class=\"amendmentInsertedText\">A utilization review entity shall not:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(1) Be compensated based on its volume of denials; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Base any incentive or penalty for a medical reviewer of such entity based on the volume of denials such reviewer issues or upholds.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 14. </b>\n    <u class=\"amendmentInsertedText\">(1) On or before March 1, 2027, and on or before March </u>1 <u class=\"amendmentInsertedText\">of each year thereafter, each health carrier shall report to the department, on a form prescribed by the department, the following data related to the health carrier&#39;s prior authorization practices and experience for the most recently completed calendar year:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) The number of prior authorization requests;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) The number of prior authorization requests denied;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) The number of appeals of adverse determinations received;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(d) The number of adverse determinations reversed on appeal;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(e) The ten individual health care services most frequently denied; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(f) The ten reasons most frequently used to deny prior authorization requests.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) On or before June 1, 2027, and on or before June 1 of each year thereafter, the department shall report the data collected pursuant to subsection (1) of this section. The report shall be posted on the department&#39;s website and shall be accessible to the public.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 15. </b> Sections 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, and 14 of this act become operative on January 1, 2026. The other sections of this act become operative on their effective date.</p>\n   <p class=\"indent\">\n    <b>Sec. 16. </b> If any section in this act or any part of any section is declared invalid or unconstitutional, the declaration shall not affect the validity or constitutionality of the remaining portions.</p>\n  </div>\n </div>\n    </div>\t\n<table cellpadding=0 cellspacing=0 width=\"100%\">\n   <tr>\n      <td>\n          Copyright &copy; 2025 State Net\n      </td>\n<BR>\n<!--???MOVED INTO resources.cgi      <td align=\"right\">\n          <img src=\"https://custom.statenet.com/network/poweredby.gif\" alt=\"Powered by State Net\">\n      </td>-->\n\n    </tr>\n</table>\n</body></html>\n",
      "markdown": "The following has special meaning: _green underline denotes added text_ ~~red struck out text denotes deleted text~~ | [![Powered by State Net](https://custom.statenet.com/network/poweredby.gif)](https://www.lexisnexis.com/statenet/)  \n---|---  \n  \n2025 NE L 77 | | Author: | Bostar  \n---|---  \nVersion: | Introduced  \nVersion Date: | 01/09/2025  \n  \nLEGISLATURE OF NEBRASKA\n\nONE HUNDRED NINTH LEGISLATURE\n\nFIRST SESSION\n\n**LEGISLATIVE BILL 77**\n\nIntroduced by Bostar, 29.\n\nRead first time January 09, 2025\n\nCommittee:\n\nA BILL FOR AN ACT relating to insurance; to adopt the Ensuring Transparency in\nPrior Authorization Act; to provide operative dates; and to provide\nseverability.\n\nBe it enacted by the people of the State of Nebraska,\n\n**Section 1.** _Sections 1 to 14 of this act shall be known and may be cited\nas the Ensuring Transparency in Prior Authorization Act._\n\n**Sec. 2.** _For purposes of the Ensuring Transparency in Prior Authorization\nAct, unless the context otherwise requires:_\n\n_(1) Adverse determination means a determination by a health carrier or its\ndesignated utilization review entity that an admission, the availability of\ncare, a continued stay, or other health care service has been reviewed and,\nbased upon the information provided, does not meet the health carrier 's\nrequirements for medical necessity, appropriateness, health care setting,\nlevel of care, or effectiveness, and the requested health care service is\ntherefore denied, reduced, or terminated;_\n\n_(2) Chronic condition means a condition that lasts one year or more and\nrequires ongoing medical attention or limits activities of daily living or\nboth;_\n\n_(3) Clinical criteria means the written policies, written screening\nprocedures, determination rules, determination abstracts, clinical protocols,\npractice guidelines, medical protocols, and any other criteria or rationale\nused by the utilization review entity to determine the necessity and\nappropriateness of health care services;_\n\n_(4) Department means the Department of Insurance;_\n\n_(5) Emergency health care services, with respect to an emergency medical\ncondition as defined in 42 U.S.C. 300gg-111, means:_\n\n_(a) A medical screening examination, as required under the Emergency Medical\nTreatment and Labor Act, or as would be required under such act if such act\napplied to an independent freestanding emergency department, that is within\nthe capability of the emergency department of a hospital or of an independent\nfreestanding emergency department, as applicable, including ancillary services\nroutinely available to the emergency department to evaluate such emergency\nmedical condition; and_\n\n_(b) Within the capabilities of the staff and facilities available at the\nhospital or the independent freestanding emergency department, as applicable,\nsuch further medical examination and treatment as are required under the\nEmergency Medical Treatment and Labor Act, or as would be required under such\nact if such act applied to an independent freestanding emergency department,\nto stabilize the patient, regardless of the department of the hospital in\nwhich such further examination or treatment is furnished;_\n\n_(6) Emergency Medical Treatment and Labor Act means section 1867 of the\nSocial Security Act, 42 U.S.C. 1395dd, and associated regulations;_\n\n_(7) Enrollee means an individual who is enrolled in a health benefit plan,\nincluding covered dependents;_\n\n_(8) Health benefit plan means a policy, contract, certificate, or agreement\noffered or issued by a health carrier to provide, deliver, arrange for, pay\nfor, or reimburse any of the costs of health care services;_\n\n_(9) Health care provider has the same meaning as in section 44-1303;_\n\n_(10) Health care services means any services provided by a health care\nprovider, or by an individual working for or under the supervision of a health\ncare provider, that relate to the diagnosis, assessment, prevention,\ntreatment, or care of any human illness, disease, injury, or condition. The\nterm also includes the provision, administration, or prescription of\npharmaceutical products or services, the provision of mental health and\nsubstance use disorder services, and the provision of durable medical\nequipment;_\n\n_(11) Health carrier means an entity subject to the insurance laws and\nregulations of this state, or subject to the jurisdiction of the Director of\nInsurance, that contracts or offers to contract to provide, deliver, arrange\nfor, pay for, or reimburse any of the costs of health care services, including\na sickness and accident insurance company, a health maintenance organization,\na nonprofit hospital and health service corporation, or any other entity\nproviding a plan of health insurance, health benefits, or health care\nservices. Health carrier does not include a managed care organization;_\n\n_(12) Medically necessary means services or supplies provided by a health care\nprovider that are:_\n\n_(a) Appropriate for the symptoms and diagnosis or treatment of the enrollee\n's condition, illness, disease, or injury;_\n\n_(b) In accordance with standards of good medical practice;_\n\n_(c) Not primarily for the convenience of the enrollee or the enrollee 's\nhealth care provider; and_\n\n_(d) The most appropriate supply or level of service that can safely be\nprovided to the enrollee;_\n\n_(13) Notice means communication delivered either electronically or through\nthe United States Postal Service or a common carrier;_\n\n_(14) Physician means an individual licensed under the Medicine and Surgery\nPractice Act to practice medicine and surgery or osteopathic medicine and\nsurgery or an individual with an equivalent license from another United States\njurisdiction;_\n\n_(15) Prior authorization means the process by which utilization review\nentities determine the medical necessity and medical appropriateness of\notherwise covered health care services prior to the rendering of such health\ncare services. The term includes authorization, pre-certification, and any\nother term that would be a reliable determination by a health benefit plan;_\n\n_(16) Urgent health care service means a health care service with respect to\nwhich the application of the time periods prescribed under the Ensuring\nTransparency in Prior Authorization Act for making a nonexpedited prior\nauthorization could, in the opinion of a physician with knowledge of the\nenrollee 's medical condition:_\n\n_(a) Seriously jeopardize the life or health of the enrollee or the ability of\nthe enrollee to regain maximum function; or_\n\n_(b) Subject the enrollee to severe pain that cannot be adequately managed\nwithout the care or treatment that is the subject of the utilization review;_\n\n_(17) Utilization review entity means an individual or entity that performs\nprior authorization for a health benefit plan; and_\n\n_(18) Value-based arrangement means an agreement between a health carrier and\na health care provider that rewards the provider for quality, effectiveness,\nor efficiency through shared cost savings._\n\n**Sec. 3.** _(1) A utilization review entity, including any third-party entity\nutilized by the health carrier, shall make any current prior authorization\nrequirements and restrictions, including written clinical criteria, readily\naccessible on its website to enrollees and health care providers. Prior\nauthorization requirements shall be described in detail but also in easily\nunderstandable language. Prior authorization requirements shall also be made\navailable on the website in a machine-readable format no later than January 1,\n2027._\n\n_(2) If a utilization review entity intends either to implement a new prior\nauthorization requirement or restriction or to amend an existing requirement\nor restriction, the utilization review entity shall:_\n\n_(a) Ensure that the new or amended requirement or restriction is not\nimplemented unless the utilization review entity 's website has been updated\nto reflect the new or amended requirement or restriction; and_\n\n_(b) Provide contracted health care providers who are credentialed to perform\nthe affected health care service, or enrollees who have a chronic condition\nand are already receiving such service, notice of the new or amended\nrequirement or restriction no less than sixty days before the requirement or\nrestriction is implemented._\n\n**Sec. 4.** _(1) A utilization review entity shall ensure that all adverse\ndeterminations are made by a physician. Such physician shall:_\n\n_(a) Possess a current and valid nonrestricted license in a United States\njurisdiction;_\n\n_(b) Have the appropriate training, knowledge, or expertise to apply\nappropriate clinical guidelines to the health care service being requested;\nand_\n\n_(c) Make the adverse determination under the clinical direction of one of the\nutilization review entity 's medical directors who is responsible for the\nprovision of health care services provided to enrollees of Nebraska. All such\nmedical directors must be physicians licensed in a United States\njurisdiction._\n\n_(2) When an adverse determination is issued or a prior authorization is\ncanceled or voided, the utilization review entity shall provide written notice\nto the requesting health care provider. The notice shall include the reason\nfor denial, citing written clinical criteria._\n\n_(3)(a) If an adverse determination questions the medical necessity, the\nappropriateness, or the experimental or investigational nature of a health\ncare service, or if physician review is required due to the age of the\npatient, the utilization review entity shall include in the notice of adverse\ndetermination the name and telephone number of a physician acting on behalf of\nthe utilization review entity with whom the requesting health care provider,\nor the provider 's designated proxy, shall have a reasonable opportunity to\ndiscuss the patient's treatment plan and the clinical basis for the\nintervention._\n\n_(b) The requesting health care provider, or the provider 's designated proxy,\nshall have the opportunity to contact such physician at the telephone number\nprovided within one business day of receipt of the adverse determination for\nan urgent health care service or within three business days of receipt of the\nadverse determination for a nonurgent health care service, to engage in a\ndiscussion of the patient's treatment plan and the clinical basis for the\nintervention. If the physician does not respond to the requesting health care\nprovider, or the provider's designated proxy, within the required timeframe,\nthe utilization review entity shall be deemed to have failed to provide a\nreasonable opportunity for discussion as required under subdivision (3)(a) of\nthis section and the prior authorization request shall be deemed approved._\n\n_(c) Following any discussion under subdivision (3)(b) of this section, the\nutilization review entity shall notify the requesting health care provider\nwhether or not the adverse determination decision remains the same or the\nhealth care service is approved. The notice under this subdivision shall be\nprovided (i) within one business day of the discussion between the requesting\nhealth care provider and physician for an urgent health care service or (ii)\nwithin two business days of the discussion between the requesting health care\nprovider and physician for a nonurgent health care service._\n\n_(d) A discussion under subdivision (3)(b) of this section shall not replace\nor eliminate the opportunity for any internal grievance or appeal process\nprovided by the utilization review entity._\n\n**Sec. 5.** _A utilization review entity shall ensure that all appeals of an\nadverse determination are reviewed by a physician. Such physician shall:_\n\n_(1) Possess a current and valid unrestricted license in a United States\njurisdiction;_\n\n_(2) Be of the same or similar specialty as a physician who typically manages\nthe medical condition in question, which means that either:_\n\n_(a) The physician maintains board certification for the same or similar\nspecialty; or_\n\n_(b) The physician 's training and experience (i) includes treating the\ncondition, (ii) includes treating complications that may result from the\nservice or procedure, and (iii) is sufficient for the physician to determine\nif the service or procedure is medically necessary or clinically appropriate;_\n\n_(3) Not have been directly involved in making the adverse determination;_\n\n_(4) Not have any financial interest in the outcome of the appeal; and_\n\n_(5) Consider all known clinical aspects of the health care service under\nreview, including, but not limited to, a review of those medical records which\nare pertinent and relevant to the active condition provided to the utilization\nreview entity by the enrollee 's health care provider, or a health care\nfacility, and any pertinent medical literature provided to the utilization\nreview entity by the health care provider._\n\n**Sec. 6.** _(1) On or before November 1, 2025, the department shall approve a\nuniform prior authorization request form for prescription drugs, devices, and\ndurable medical equipment and a uniform prior authorization request form for\nall other health care procedures, treatments, and services. The uniform prior\nauthorization request forms shall not exceed two printed pages in length. This\ntwo-page limit does not apply to or include a health care provider 's notes or\ndocumentation that the provider submits in support of a prior authorization\nrequest._\n\n_(2) Beginning January 1, 2026, all health care providers shall use only the\napproved uniform prior authorization request forms and all health benefit\nplans and utilization review entities shall accept and process prior\nauthorization requests submitted using such forms._\n\n_(3) This section does not prohibit a health carrier from using a prior\nauthorization methodology that uses an Internet webpage, an Internet webpage\nportal, or a similar web-based system if the methodology is consistent with\nthe uniform prior authorization request forms approved by the department\npursuant to this section._\n\n**Sec. 7.** _(1) If a utilization review entity requires prior authorization\nof a health care service, the utilization review entity shall make a prior\nauthorization or adverse determination and provide notice of its decision to\nthe enrollee and the enrollee 's health care provider in accordance with the\nfollowing timeframes:_\n\n_(a) For purposes of approving a prior authorization for urgent health care\nservices, within twelve hours of obtaining all necessary information to make\nthe prior authorization or adverse determination; or_\n\n_(b) For purposes of approving a prior authorization for nonurgent health care\nservices, within three days of obtaining all necessary information to make the\nprior authorization or adverse determination._\n\n_(2) For purposes of this section, necessary information includes, but is not\nlimited to, the results of any face-to-face clinical evaluation or second\nopinion that may be required._\n\n_(3) Health care services are deemed authorized if a utilization review entity\nfails to comply with the deadlines set forth in this section._\n\n_(4) In the notice to the health care provider that a prior authorization has\nbeen approved, the utilization review entity shall include the duration of the\nprior authorization or the date by which the prior authorization will expire._\n\n**Sec. 8.** _No utilization review entity shall require prior authorization\nof:_\n\n_(1) Emergency confinement or an emergency health care service;_\n\n_(2) Pre-hospital transportation for the provision of emergency health care\nservices or for transfers between facilities as required by the Emergency\nMedical Treatment and Labor Act;_\n\n_(3) Cancer care that is consistent with guidelines of the National\nComprehensive Cancer Network;_\n\n_(4) Services that have a rating of A or B from the United States Preventive\nServices Task Force, immunizations recommended by the Advisory Committee on\nImmunization Practices of the Centers for Disease Control and Prevention, or\npreventive services and screenings provided to women as described in 45 C.F.R.\n147.130; or_\n\n_(5) Services covered through a value-based arrangement._\n\n**Sec. 9.** _(1) A health benefit plan shall not revoke, limit, condition, or\nrestrict a prior authorization if care is provided within sixty days from the\ndate the health care provider received the prior authorization unless the\nenrollee was no longer eligible for care on the day care was provided._\n\n_(2) A health benefit plan shall pay a contracted health care provider at the\ncontracted payment rate for a health care service provided by the health care\nprovider per a prior authorization, unless:_\n\n_(a) The health care provider knowingly and materially misrepresented the\nhealth care service in the prior authorization request with the specific\nintent to deceive and obtain an unlawful payment under the health benefit\nplan;_\n\n_(b) The health care service was no longer a covered benefit on the day it was\nprovided;_\n\n_(c) The health care provider was no longer contracted with the patient 's\nhealth benefit plan on the date the care was provided;_\n\n_(d) The health care provider failed to meet the utilization review entity 's\ntimely filing requirements; or_\n\n_(e) The patient was no longer eligible for health care coverage on the day\nthe care was provided._\n\n**Sec. 10.** _(1) Except as otherwise provided in this section, prior\nauthorization shall be valid for at least one year from the date the health\ncare provider receives the prior authorization, and the authorization period\nshall be effective regardless of any changes in dosage for a prescription drug\nprescribed by the health care provider._\n\n_(2) If a prior authorization is required for a health care service, other\nthan for inpatient acute care, for the treatment of a chronic condition of an\nenrollee, the prior authorization shall remain valid for the length of the\ntreatment._\n\n_(3) If a prior authorization is required for inpatient acute care for the\ntreatment of a chronic condition of an enrollee, the prior authorization shall\nremain valid for at least fourteen calendar days from the date the health care\nprovider receives the prior authorization approval. If an enrollee requires\ninpatient acute care beyond the length of stay that was previously approved by\nthe utilization review entity, then the utilization review entity shall\nevaluate any prior authorization requests for the continuation of inpatient\nacute care according to the provisions of the Ensuring Transparency in Prior\nAuthorization Act. a utilization review entity shall not use any stricter\ncriteria to determine medical necessity and appropriateness of the\ncontinuation of inpatient acute care than the criteria used to evaluate the\ninitial request for authorization of inpatient acute care. A utilization\nreview entity shall review any relevant and pertinent literature or data\nprovided by the health care provider to determine the medical necessity and\nappropriateness of the requested length of stay or continuation of inpatient\nacute care. A prior authorization for the continuation of inpatient acute care\nshall remain valid for a maximum of fourteen calendar days from the date the\nhealth care provider receives the prior authorization approval. If a\nutilization review entity fails to respond to a health care provider 's timely\nprior authorization request for the continuation of inpatient acute care\nbefore the termination of the previously approved length of stay, then the\nhealth benefit plan shall continue to compensate the health care provider at\nthe contracted rate for inpatient acute care provided until the utilization\nreview entity issues its determination on the prior authorization request. For\npurposes of this section, a timely prior authorization request for the\ncontinuation of inpatient acute care means a request that is submitted at\nleast seventy-two hours prior to the termination of the previously approved\nprior authorization and includes all necessary information for the utilization\nreview entity to make a determination. If a utilization review entity issues\nan adverse determination to a health care provider's prior authorization\nrequest for continuation of inpatient acute care and the health care provider\nappeals the adverse determination according to the provisions of the Ensuring\nTransparency in Prior Authorization Act, then the health benefit plan shall\ncontinue to compensate the health care provider at the contracted rate for\ninpatient acute care provided until the appeal has been finalized._\n\n_(4) This section does not require a health benefit plan to cover care,\ntreatment, or services for a health condition that the terms of coverage\notherwise completely exclude from the policy 's covered benefits without\nregard for whether the care, treatment, or services are medically necessary._\n\n**Sec. 11.** _(1) On receipt of information documenting a prior authorization\nfrom the enrollee or from the enrollee 's health care provider, a utilization\nreview entity shall honor a prior authorization granted to an enrollee from a\nprevious utilization review entity for at least the initial sixty days of an\nenrollee's coverage under a new health benefit plan. During such time period,\na utilization review entity may perform its own review to grant a prior\nauthorization._\n\n_(2) If there is a change in coverage of, or approval criteria for, a\npreviously authorized health care service, the change in coverage or approval\ncriteria does not affect an enrollee who received prior authorization before\nthe effective date of the change for the remainder of the enrollee 's plan\nyear._\n\n_(3) A utilization review entity shall continue to honor a prior authorization\nit has granted to an enrollee when the enrollee changes products under the\nsame health insurance company without any act on behalf of the health care\nprovider._\n\n**Sec. 12.** _(1) An artificial intelligence-based algorithm shall not be the\nsole basis of a utilization review entity 's decision to deny, delay, or\nmodify health care services based, in whole or in part, on medical necessity._\n\n_(2) A utilization review entity shall disclose to the department, to each\nhealth care provider in its network, to each enrollee, and on its public\nwebsite if artificial intelligence-based algorithms are used or will be used\nin the utilization review process._\n\n_(3) The department may, at any time, audit a utilization review entity 's\nautomated utilization management system. The department may contract with a\nthird-party entity to perform an audit pursuant to this section._\n\n**Sec. 13.** _A utilization review entity shall not:_\n\n_(1) Be compensated based on its volume of denials; or_\n\n_(2) Base any incentive or penalty for a medical reviewer of such entity based\non the volume of denials such reviewer issues or upholds._\n\n**Sec. 14.** _(1) On or before March 1, 2027, and on or before March_ 1 _of\neach year thereafter, each health carrier shall report to the department, on a\nform prescribed by the department, the following data related to the health\ncarrier 's prior authorization practices and experience for the most recently\ncompleted calendar year:_\n\n_(a) The number of prior authorization requests;_\n\n_(b) The number of prior authorization requests denied;_\n\n_(c) The number of appeals of adverse determinations received;_\n\n_(d) The number of adverse determinations reversed on appeal;_\n\n_(e) The ten individual health care services most frequently denied; and_\n\n_(f) The ten reasons most frequently used to deny prior authorization\nrequests._\n\n_(2) On or before June 1, 2027, and on or before June 1 of each year\nthereafter, the department shall report the data collected pursuant to\nsubsection (1) of this section. The report shall be posted on the department\n's website and shall be accessible to the public._\n\n**Sec. 15.** Sections 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, and 14 of this\nact become operative on January 1, 2026. The other sections of this act become\noperative on their effective date.\n\n**Sec. 16.** If any section in this act or any part of any section is declared\ninvalid or unconstitutional, the declaration shall not affect the validity or\nconstitutionality of the remaining portions.\n\nCopyright (C) 2025 State Net  \n  \n---\n\n",
      "latest_version": false
    },
    {
      "date": "05/09/2025",
      "label": "Amended",
      "url": "https://custom.statenet.com/public/resources.cgi?mode=show_text&id=ID:bill:NE2025000L77&verid=NE2025000L77_20250509_1_A&",
      "raw_html": "<html>\n<head>\n<title>Bill Resource</title>\n\n<!--   <link href=\"https://custom.statenet.com/network/Common/css/extregtext.css\" rel=\"stylesheet\" type=\"text/css\" />-->\n   <link href=\"https://custom.statenet.com/network/Common/css/xmltext-2.0.css\" rel=\"stylesheet\" type=\"text/css\" />\n   <link href=\"https://custom.statenet.com/network/Common/css/additional-text.css\" rel=\"stylesheet\" type=\"text/css\" />\n\n\t<style type=\"text/css\">\n<!--\n\ntd, body {\n     background-color: white;\n\tfont-family: Verdana, Arial, Helvetica, sans-serif;\n\tfont-size: 12px;\n}\n\n.resourceContainer {\n   border: 1px solid black;\n}\n-->\n</style>\n</head>\n<body>\n\n    <div style=\"width: 750px; margin: auto\">\n       <div style=\"font-size: .8em;margin-bottom: 10px\"><table width=\"100%\"><tr><td align=\"left\" style=\"font-size: .8em;\"><div>The following has special meaning:</div>\n<div><u class=\"amendmentInsertedText\">green underline denotes added text</u></div>\n<div><strike class=\"amendmentDeletedText\">red struck out text denotes deleted text</strike></div></td> <td align=\"right\"><a href=\"https://www.lexisnexis.com/statenet/\"><img alt=\"Powered by State Net\" src=\"https://custom.statenet.com/network/poweredby.gif\" /></a></td></tr></table></div><table id=\"text-identifier\"><tr><td class=\"key\">2025 NE L 77</td> <td><table><tr><td class=\"label\">Author:</td> <td>Bostar</td></tr> <tr><td class=\"label\">Version:</td> <td>Amended</td></tr> <tr><td class=\"label\">Version Date:</td> <td>05/09/2025</td></tr></table></td></tr></table><div class=\"documentBody\">\n  <a name=\"head_document_section\"></a><div class=\"head\">\n   <p class=\"center\">AM1187</p>\n   <p class=\"center\">MLU - 04/25/2025</p>\n   <p class=\"center\">AMENDMENTS TO LB77</p>\n   <p class=\"left\">Introduced by Banking, Commerce and Insurance.</p>\n  </div>\n  <a name=\"code_document_section\"></a><div class=\"code\">\n   <p class=\"indent\">1. Strike the original sections and insert the following new sections:</p>\n  </div>\n  <a name=\"text_document_section\"></a><div class=\"text\">\n   <p class=\"indent\">\n    <b>Section 1.</b>\n    <u class=\"amendmentInsertedText\">Sections 1 to 13 of this act shall be known and may be cited as the Ensuring Transparency in Prior Authorization Act.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 2.</b>\n    <u class=\"amendmentInsertedText\">For purposes of the Ensuring Transparency in Prior Authorization Act, unless the context otherwise requires:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(1) Adverse determination has the same meaning as in section 44-1303;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Clinical peer means a health care provider in the same, or in a similar, specialty that typically manages the medical condition or health care service under review;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) Clinical review criteria has the same meaning as in section 44-1303;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4) Department means the Department of Insurance;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(5) Emergency health care services means health care services medically necessary to screen and stabilize a patient in connection with an emergency medical condition until the health care provider determines such individual is able to travel using nonmedical transportation;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(6) Emergency medical condition has the same meaning as in section 44-1303;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(7) Enrollee means an individual who is enrolled in a health benefit plan, including covered dependents;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(8) General acute hospital has the same meaning as in section 71-412;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(9) Health benefit plan has the same meaning as in section 44-1303;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(10) Health care provider has the same meaning as in section 44-1303;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(11) Health care services has the same meaning as in section 44-1303;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(12) Health carrier has the same meaning as in section 44-1303, except that health carrier does not include a managed care agent;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(13) Medically necessary has the same meaning as in section 44-6845;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(14) Notice means communication delivered either electronically or through the United States Postal Service or a common carrier;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(15) Physician means an individual licensed under the Medicine and Surgery Practice Act to practice medicine and surgery or osteopathic medicine and surgery or an individual with an equivalent license from another United States jurisdiction;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(16) Prior authorization means the process by which a health carrier or utilization review agent makes a determination that a requested admission, extension of stay, or health care service has been reviewed and, based on the information provided, satisfies the health carrier&#39;s or utilization review agent&#39;s requirements for reimbursement under the applicable health benefit plan;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(17) Urgent health care service means a health care service with respect to which the application of the time periods prescribed under the Ensuring Transparency in Prior Authorization Act for making a nonexpedited prior authorization could, in the opinion of a physician with knowledge of the enrollee&#39;s medical condition:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) Seriously jeopardize the life or health of the enrollee or the ability of the enrollee to regain maximum function; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) Subject the enrollee to severe pain that cannot be adequately managed without the care or treatment that is the subject of the utilization review; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(18) Utilization review agent has the same meaning as in section 44-5418.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 3.</b>\n    <u class=\"amendmentInsertedText\">(1) A utilization review agent shall make prior authorization requirements and restrictions, including written clinical review criteria, accessible on its website. Such requirements, restrictions, and clinical review criteria shall be accurate and current and shall clearly communicate what information and documentation is needed to decide the prior authorization. Prior authorization requirements shall also be made available on the website in a searchable format no later than July 1, 2027.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) If a utilization review agent intends either to implement a new prior authorization requirement or restriction or to amend an existing requirement or restriction, the utilization review agent shall:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) Ensure that the new or amended requirement or restriction is not implemented unless the utilization review agent&#39;s website has been updated to reflect the new or amended requirement or restriction; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) Provide contracted health care providers with notice of the new or amended requirement or restriction no less than sixty days before the requirement or restriction is implemented.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 4.</b>\n    <u class=\"amendmentInsertedText\">(1) A utilization review agent shall ensure that all adverse determinations for prior authorization are made by a physician, except that if the requesting health care provider is not a physician, the adverse determination may be made by a clinical peer of the requesting health care provider. Such physician or clinical peer shall:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) Possess a current and valid nonrestricted license in a United States jurisdiction;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) Have the appropriate training, knowledge, or expertise to apply appropriate clinical guidelines to the health care service being requested; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) Make the adverse determination under the clinical direction of one of the utilization review agent&#39;s medical directors who is responsible for the provision of health care services provided to enrollees of Nebraska. All such medical directors must be physicians licensed in a United States jurisdiction.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) When an adverse determination for prior authorization is issued or a prior authorization is canceled or voided, the utilization review agent shall provide notice to the requesting health care provider. The notice shall include the reason for denial, citing written clinical review criteria.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3)(a) If an adverse determination for prior authorization questions the medical necessity, the appropriateness, or the experimental or investigational nature of a health care service, the enrollee&#39;s health care provider shall have the opportunity to discuss the health care service with the physician or clinical peer who is responsible for determining authorization of the health care service under review. The enrollee&#39;s health care provider may request that such discussion occur within three business days after receiving notice of the adverse determination. No discussion shall be required or allowed for an adverse determination that is due to contract exclusions or benefits that are not covered by the health benefit plan.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) Following any discussion under subdivision (3)(a) of this section, the utilization review agent shall notify the requesting health care provider whether the adverse determination decision remains the same. The notice under this subdivision shall be provided (i) within one business day after the discussion under subdivision (3)(a) of this section for an urgent health care service or (ii) within two business days after the discussion under subdivision (3)(a) of this section for a nonurgent health care service.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) A discussion under subdivision (3)(a) of this section shall not replace or eliminate the opportunity for any internal grievance or appeal process provided by the utilization review agent.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 5.</b>\n    <u class=\"amendmentInsertedText\">A utilization review agent shall ensure that all appeals of an adverse determination for prior authorization are reviewed by a physician. Such physician shall:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(1) Possess a current and valid unrestricted license in a United States jurisdiction;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Be of the same or similar specialty as the ordering physician or have the training and experience to treat the condition, which means that either:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) The physician maintains board certification for the same or similar specialty; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) The physician&#39;s training and experience (i) includes treating the condition, (ii) includes treating complications that may result from the health care service, and (iii) is sufficient for the physician to determine based on the physician&#39;s clinical judgment whether the health care service is medically necessary or clinically appropriate;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) Not have been directly involved in making the initial adverse determination;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4) Not have any financial interest in the outcome of the appeal; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(5) Consider all known clinical aspects of the health care service under review, including, but not limited to, a review of those medical records which are pertinent and relevant to the active condition provided to the utilization review agent by the enrollee&#39;s health care provider, or a health care facility, and any pertinent medical literature provided to the utilization review agent by the health care provider.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 6.</b>\n    <u class=\"amendmentInsertedText\">(1)(a) On or before November 1, 2025, the department shall approve a single uniform prior authorization request form for prescription drugs, devices, and durable medical equipment and a single uniform prior authorization request form for all other health care services. The uniform prior authorization request forms shall not exceed two printed pages in length. This two-page limit does not apply to information or documentation required by the utilization review agent, as published in accordance with subsection (1) of section 3 of this act, or a health care provider&#39;s notes or documentation submitted in support of a prior authorization request.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) Beginning January 1, 2026:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(i) All health care providers shall use only the approved uniform prior authorization request forms; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(ii) Except as provided in subsection (2) of this section, all utilization review agents shall accept and process prior authorization requests submitted using such forms.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) This subsection does not prohibit a utilization review agent from using a prior authorization methodology that uses an Internet webpage, an Internet webpage portal, or a similar web-based system if the methodology is consistent with the uniform prior authorization request forms approved by the department pursuant to this subsection.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) A utilization review agent may request from the department an exemption from the requirements of subsection (1) of this section if the utilization review agent implements and maintains a prior authorization application programming interface pursuant to 45 C.F.R. 156.223(b) or other electronic prior authorization methodology that automates and standardizes the prior authorization process for patients, health care providers, and health carriers. A utilization review agent shall provide notice to health care providers at least ninety days prior to implementing a prior authorization application programming interface or other electronic prior authorization methodology under this subsection.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 7.</b>\n    <u class=\"amendmentInsertedText\">(1) Prior to January 1, 2028, if a utilization review agent requires prior authorization of a health care service, the utilization review agent shall make a decision on the prior authorization request and provide notice of its decision to the enrollee and the enrollee&#39;s health care provider in accordance with the following timeframes:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) For a prior authorization request for urgent health care services, within seventy-two hours after obtaining all necessary information to make a decision; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) For a prior authorization request for nonurgent health care services, within seven days after obtaining all necessary information to make a decision.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Beginning January 1, 2028, if a utilization review agent requires prior authorization of a health care service, the utilization review agent shall make a decision on the prior authorization request and provide notice of its decision to the enrollee and the enrollee&#39;s health care provider in accordance with the following timeframes:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) For a prior authorization request for urgent health care services, within forty-eight hours after obtaining all necessary information to make a decision; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) For a prior authorization request for nonurgent health care services, within seven days after obtaining all necessary information to make a decision.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) Nothing in this section prohibits a health care provider and health carrier from contracting for shorter timeframes for using the prior authorization application programming interface or other electronic prior authorization methodology described in subsection (2) of section 6 of this act or as part of a risk-sharing agreement.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4) Health care services are deemed authorized if a utilization review agent fails to comply with the deadlines for making a decision as set forth in this section.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(5) In the notice to the health care provider that a prior authorization has been approved, the utilization review agent shall include the duration of the prior authorization or the date by which the prior authorization will expire.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 8.</b>\n    <u class=\"amendmentInsertedText\">No utilization review agent shall require prior authorization of:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(1) Emergency confinement or an emergency health care service;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Pre-hospital transportation for the provision of emergency health care services or for transfers between facilities as required by the federal Emergency Medical Treatment and Labor Act; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) Services that have a rating of A or B from the United States Preventive Services Task Force, immunizations recommended by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention, or preventive services and screenings provided to women as required by 45 C.F.R. 147.130.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 9.</b>\n    <u class=\"amendmentInsertedText\">(1) A utilization review agent shall not revoke, limit, condition, or restrict an approved prior authorization if care is provided within sixty days from the date the health care provider received the prior authorization approval unless the enrollee was no longer eligible for care on the day care was provided.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) A health carrier shall pay a contracted health care provider at the contracted payment rate for a health care service provided by the health care provider per an approved prior authorization request, unless:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) The health care provider knowingly and materially misrepresented the health care service or patient&#39;s medical history in the prior authorization request with the intent to deceive and obtain an unlawful payment under the health benefit plan;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) The health care service was no longer a covered benefit on the day it was provided;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) The health care provider was no longer contracted with the patient&#39;s health benefit plan on the date the care was provided;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(d) The health care provider failed to meet the utilization review agent&#39;s timely filing requirements;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(e) The patient was no longer eligible for health care coverage on the day the care was provided; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(f) The health care provider failed to obtain prior authorization approval before rendering health care services for which prior authorization was required.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 10.</b>\n    <u class=\"amendmentInsertedText\">(1) Except as otherwise provided in this section, prior authorization shall be valid for at least one year from the date the utilization review agent approves the prior authorization request, except for a prescription drug that has a treatment schedule or dosing limitation from the federal Food and Drug Administration of less than one year.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2)(a) If a prior authorization is required for inpatient care at a general acute hospital, the prior authorization shall remain valid for the length of stay approved by the utilization review agent.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) If the health care provider submits a timely request for the continuation of inpatient care, the utilization review agent shall respond to this request prior to the expiration of the current authorization for inpatient care.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) If a utilization review agent fails to respond to a timely request for the continuation of inpatient care prior to the termination of the previously approved length of stay, then the health carrier shall continue to compensate the health care provider at the contracted rate for inpatient care provided until the utilization review agent issues its determination on the prior authorization request.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(d) Nothing in this subsection shall be interpreted to prohibit a health care provider or enrollee from appealing an adverse determination as allowed under state law. If an adverse determination is overturned on appeal, and no other legal action related to the claim is pending, then the health carrier shall reimburse the health care provider at the contracted rate for inpatient care provided to the enrollee.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) This section does not require a health benefit plan to cover care, treatment, or services for a health condition that the terms of coverage otherwise completely exclude from the policy&#39;s covered benefits without regard for whether the care, treatment, or services are medically necessary.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 11.</b>\n    <u class=\"amendmentInsertedText\">(1) On receipt of information documenting an approved prior authorization from the enrollee or from the enrollee&#39;s health care provider, a utilization review agent shall honor the approved prior authorization granted to an enrollee from a previous utilization review agent for at least the initial sixty days of an enrollee&#39;s coverage under a new health benefit plan. During such time period, a utilization review agent may perform its own review to grant a prior authorization.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) If there is a change in coverage of, or approval criteria for, a previously authorized health care service, the change in coverage or approval criteria does not affect a prior authorization request approved before the effective date of the change.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) A utilization review agent shall continue to honor a prior authorization it has granted to an enrollee when the enrollee changes health insurance products under the same health insurance company without any action required by the health care provider.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 12.</b>\n    <u class=\"amendmentInsertedText\">(1) An artificial intelligence-based algorithm shall not be the sole basis of a utilization review agent&#39;s decision to deny, delay, or modify health care services based, in whole or in part, on medical necessity.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) A utilization review agent shall disclose to the department, to each health care provider in its network, to each enrollee, and on its public website if artificial intelligence-based algorithms are used or will be used in the utilization review process.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) The department may, at any time, audit a utilization review agent&#39;s automated utilization management system. The department may contract with a third-party entity to perform an audit pursuant to this section.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 13.</b>\n    <u class=\"amendmentInsertedText\">A utilization review agent shall not:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(1) Be compensated based on its volume of denials; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Base any incentive or penalty for a medical reviewer of such agent based on the volume of denials such reviewer issues or upholds.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 14.</b>\n    <u class=\"amendmentInsertedText\">For purposes of sections 14 to 16 of this act:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(1) Biomarker means a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a specific therapeutic intervention, including known gene-drug interactions for medications being considered for use or already being administered. Biomarkers include, but are not limited to, gene mutations, characteristics of genes, or protein expression;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Biomarker testing means the analysis of tissue, blood, or other biospecimen for the presence of a biomarker. Biomarker testing includes, but is not limited to, single-analyte tests, multi-plex panel tests, protein expression, and whole exome, whole genome, and whole transcriptome sequencing;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) Clinical utility means sufficient medical and scientific evidence indicating that the use of a biomarker test will provide meaningful information that affects treatment decisions and guides improvement of net health outcomes including an improved quality of life or longer survival;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4) Consensus statements means statements developed by an independent, multidisciplinary panel of experts utilizing a transparent methodology and reporting structure and with a conflict of interest policy. These statements are aimed at specific clinical circumstances and based on the best available evidence for the purpose of optimizing the outcomes of clinical care;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(5) Health carrier has the same meaning as in section 44-1303; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(6) Nationally recognized clinical practice guidelines means evidence-based clinical practice guidelines developed by independent organizations or medical professional societies utilizing a transparent methodology and reporting structure and with a conflict of interest policy. Clinical practice guidelines establish standards of care informed by a systematic review of evidence and an assessment of the benefits and risks of alternative care options and include recommendations intended to optimize patient care.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 15.</b>\n    <u class=\"amendmentInsertedText\">(1) On and after January 1, 2028, and notwithstanding section 44-3,131, (a) any individual or group sickness and accident insurance policy or subscriber contract delivered, issued for delivery, or renewed in this state and any hospital, medical, or surgical expense-incurred policy, except for policies that provide coverage for a specified disease or other limited-benefit coverage and (b) any self-funded employee benefit plan to the extent not preempted by federal law, shall include coverage for biomarker testing pursuant to the criteria established under subsection (2) of this section.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Biomarker testing shall be covered when:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) The test is used for:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(i) The diagnosis, treatment, appropriate management, or ongoing monitoring of cancer, an autoimmune or autoinflammatory disease, Parkinson&#39;s disease, amyotrophic lateral sclerosis, Alzheimer&#39;s disease, rheumatoid arthritis, preeclampsia, sickle cell anemia, or a cardiovascular condition;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(ii) An organ or tissue transplant; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(iii) Pharmacogenomic testing; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) The test provides clinical utility as demonstrated by medical and scientific evidence, including, but not limited to:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(i) Labeled indications for a test approved or cleared by the federal Food and Drug Administration;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(ii) Indicated tests for a drug approved by the federal Food and Drug Administration;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(iii) Warnings and precautions on drug labels approved by the federal Food and Drug Administration;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(iv) National coverage determinations by the federal Centers for Medicare and Medicaid Services or local coverage determinations by the medicare administrative contractor; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(v) Nationally recognized clinical practice guidelines and consensus statements.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) Coverage, as specified in subsection (2) of this section, shall be provided in a manner that limits disruptions in care, including the need for multiple biopsies or biospecimen samples.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4) The patient and prescribing practitioner shall have access to a clear, readily accessible, and convenient process to request an exception to a coverage policy. The process shall be made readily accessible on the health carrier&#39;s website.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 16.</b>\n    <u class=\"amendmentInsertedText\">(1) The medical assistance program shall cover biomarker testing no later than January 1, 2028.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Biomarker testing shall be covered when:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) The test is used for:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(i) The diagnosis, treatment, appropriate management, or ongoing monitoring of cancer, an autoimmune or autoinflammatory disease, Parkinson&#39;s disease, amyotrophic lateral sclerosis, Alzheimer&#39;s disease, rheumatoid arthritis, preeclampsia, sickle cell anemia, or a cardiovascular condition;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(ii) An organ or tissue transplant; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(iii) Pharmacogenomic testing; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) The test provides clinical utility as demonstrated by medical and scientific evidence, including, but not limited to:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(i) Labeled indications for a test approved or cleared by the federal Food and Drug Administration;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(ii) Indicated tests for a drug approved by the federal Food and Drug Administration;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(iii) Warnings and precautions on drug labels approved by the federal Food and Drug Administration;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(iv) National coverage determinations by the federal Centers for Medicare and Medicaid Services or local coverage determinations by the medicare administrative contractor; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(v) Nationally recognized clinical practice guidelines and consensus statements.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) Coverage, as specified in subsection (2) of this section, shall be provided in a manner that limits disruptions in care, including the need for multiple biopsies or biospecimen samples.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4) Entities contracting with the medical assistance program to deliver services to program recipients shall provide biomarker testing at the same scope, duration, and frequency as the medical assistance program otherwise provides to recipients.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(5) The recipient and participating medical assistance program provider shall have access to a clear, readily accessible, and convenient process to request an exception to a coverage policy of the medical assistance program. The process shall be made readily accessible on the Department of Health and Human Services&#39; website.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 17.</b> Sections 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, and 13 of this act become operative on January 1, 2026. The other sections of this act become operative on their effective date.</p>\n   <p class=\"indent\">\n    <b>Sec. 18.</b> If any section in this act or any part of any section is declared invalid or unconstitutional, the declaration shall not affect the validity or constitutionality of the remaining portions.</p>\n  </div>\n </div>\n    </div>\t\n<table cellpadding=0 cellspacing=0 width=\"100%\">\n   <tr>\n      <td>\n          Copyright &copy; 2025 State Net\n      </td>\n<BR>\n<!--???MOVED INTO resources.cgi      <td align=\"right\">\n          <img src=\"https://custom.statenet.com/network/poweredby.gif\" alt=\"Powered by State Net\">\n      </td>-->\n\n    </tr>\n</table>\n</body></html>\n",
      "markdown": "The following has special meaning: _green underline denotes added text_ ~~red struck out text denotes deleted text~~ | [![Powered by State Net](https://custom.statenet.com/network/poweredby.gif)](https://www.lexisnexis.com/statenet/)  \n---|---  \n  \n2025 NE L 77 | | Author: | Bostar  \n---|---  \nVersion: | Amended  \nVersion Date: | 05/09/2025  \n  \nAM1187\n\nMLU - 04/25/2025\n\nAMENDMENTS TO LB77\n\nIntroduced by Banking, Commerce and Insurance.\n\n1\\. Strike the original sections and insert the following new sections:\n\n**Section 1.** _Sections 1 to 13 of this act shall be known and may be cited\nas the Ensuring Transparency in Prior Authorization Act._\n\n**Sec. 2.** _For purposes of the Ensuring Transparency in Prior Authorization\nAct, unless the context otherwise requires:_\n\n_(1) Adverse determination has the same meaning as in section 44-1303;_\n\n_(2) Clinical peer means a health care provider in the same, or in a similar,\nspecialty that typically manages the medical condition or health care service\nunder review;_\n\n_(3) Clinical review criteria has the same meaning as in section 44-1303;_\n\n_(4) Department means the Department of Insurance;_\n\n_(5) Emergency health care services means health care services medically\nnecessary to screen and stabilize a patient in connection with an emergency\nmedical condition until the health care provider determines such individual is\nable to travel using nonmedical transportation;_\n\n_(6) Emergency medical condition has the same meaning as in section 44-1303;_\n\n_(7) Enrollee means an individual who is enrolled in a health benefit plan,\nincluding covered dependents;_\n\n_(8) General acute hospital has the same meaning as in section 71-412;_\n\n_(9) Health benefit plan has the same meaning as in section 44-1303;_\n\n_(10) Health care provider has the same meaning as in section 44-1303;_\n\n_(11) Health care services has the same meaning as in section 44-1303;_\n\n_(12) Health carrier has the same meaning as in section 44-1303, except that\nhealth carrier does not include a managed care agent;_\n\n_(13) Medically necessary has the same meaning as in section 44-6845;_\n\n_(14) Notice means communication delivered either electronically or through\nthe United States Postal Service or a common carrier;_\n\n_(15) Physician means an individual licensed under the Medicine and Surgery\nPractice Act to practice medicine and surgery or osteopathic medicine and\nsurgery or an individual with an equivalent license from another United States\njurisdiction;_\n\n_(16) Prior authorization means the process by which a health carrier or\nutilization review agent makes a determination that a requested admission,\nextension of stay, or health care service has been reviewed and, based on the\ninformation provided, satisfies the health carrier 's or utilization review\nagent's requirements for reimbursement under the applicable health benefit\nplan;_\n\n_(17) Urgent health care service means a health care service with respect to\nwhich the application of the time periods prescribed under the Ensuring\nTransparency in Prior Authorization Act for making a nonexpedited prior\nauthorization could, in the opinion of a physician with knowledge of the\nenrollee 's medical condition:_\n\n_(a) Seriously jeopardize the life or health of the enrollee or the ability of\nthe enrollee to regain maximum function; or_\n\n_(b) Subject the enrollee to severe pain that cannot be adequately managed\nwithout the care or treatment that is the subject of the utilization review;\nand_\n\n_(18) Utilization review agent has the same meaning as in section 44-5418._\n\n**Sec. 3.** _(1) A utilization review agent shall make prior authorization\nrequirements and restrictions, including written clinical review criteria,\naccessible on its website. Such requirements, restrictions, and clinical\nreview criteria shall be accurate and current and shall clearly communicate\nwhat information and documentation is needed to decide the prior\nauthorization. Prior authorization requirements shall also be made available\non the website in a searchable format no later than July 1, 2027._\n\n_(2) If a utilization review agent intends either to implement a new prior\nauthorization requirement or restriction or to amend an existing requirement\nor restriction, the utilization review agent shall:_\n\n_(a) Ensure that the new or amended requirement or restriction is not\nimplemented unless the utilization review agent 's website has been updated to\nreflect the new or amended requirement or restriction; and_\n\n_(b) Provide contracted health care providers with notice of the new or\namended requirement or restriction no less than sixty days before the\nrequirement or restriction is implemented._\n\n**Sec. 4.** _(1) A utilization review agent shall ensure that all adverse\ndeterminations for prior authorization are made by a physician, except that if\nthe requesting health care provider is not a physician, the adverse\ndetermination may be made by a clinical peer of the requesting health care\nprovider. Such physician or clinical peer shall:_\n\n_(a) Possess a current and valid nonrestricted license in a United States\njurisdiction;_\n\n_(b) Have the appropriate training, knowledge, or expertise to apply\nappropriate clinical guidelines to the health care service being requested;\nand_\n\n_(c) Make the adverse determination under the clinical direction of one of the\nutilization review agent 's medical directors who is responsible for the\nprovision of health care services provided to enrollees of Nebraska. All such\nmedical directors must be physicians licensed in a United States\njurisdiction._\n\n_(2) When an adverse determination for prior authorization is issued or a\nprior authorization is canceled or voided, the utilization review agent shall\nprovide notice to the requesting health care provider. The notice shall\ninclude the reason for denial, citing written clinical review criteria._\n\n_(3)(a) If an adverse determination for prior authorization questions the\nmedical necessity, the appropriateness, or the experimental or investigational\nnature of a health care service, the enrollee 's health care provider shall\nhave the opportunity to discuss the health care service with the physician or\nclinical peer who is responsible for determining authorization of the health\ncare service under review. The enrollee's health care provider may request\nthat such discussion occur within three business days after receiving notice\nof the adverse determination. No discussion shall be required or allowed for\nan adverse determination that is due to contract exclusions or benefits that\nare not covered by the health benefit plan._\n\n_(b) Following any discussion under subdivision (3)(a) of this section, the\nutilization review agent shall notify the requesting health care provider\nwhether the adverse determination decision remains the same. The notice under\nthis subdivision shall be provided (i) within one business day after the\ndiscussion under subdivision (3)(a) of this section for an urgent health care\nservice or (ii) within two business days after the discussion under\nsubdivision (3)(a) of this section for a nonurgent health care service._\n\n_(c) A discussion under subdivision (3)(a) of this section shall not replace\nor eliminate the opportunity for any internal grievance or appeal process\nprovided by the utilization review agent._\n\n**Sec. 5.** _A utilization review agent shall ensure that all appeals of an\nadverse determination for prior authorization are reviewed by a physician.\nSuch physician shall:_\n\n_(1) Possess a current and valid unrestricted license in a United States\njurisdiction;_\n\n_(2) Be of the same or similar specialty as the ordering physician or have the\ntraining and experience to treat the condition, which means that either:_\n\n_(a) The physician maintains board certification for the same or similar\nspecialty; or_\n\n_(b) The physician 's training and experience (i) includes treating the\ncondition, (ii) includes treating complications that may result from the\nhealth care service, and (iii) is sufficient for the physician to determine\nbased on the physician's clinical judgment whether the health care service is\nmedically necessary or clinically appropriate;_\n\n_(3) Not have been directly involved in making the initial adverse\ndetermination;_\n\n_(4) Not have any financial interest in the outcome of the appeal; and_\n\n_(5) Consider all known clinical aspects of the health care service under\nreview, including, but not limited to, a review of those medical records which\nare pertinent and relevant to the active condition provided to the utilization\nreview agent by the enrollee 's health care provider, or a health care\nfacility, and any pertinent medical literature provided to the utilization\nreview agent by the health care provider._\n\n**Sec. 6.** _(1)(a) On or before November 1, 2025, the department shall\napprove a single uniform prior authorization request form for prescription\ndrugs, devices, and durable medical equipment and a single uniform prior\nauthorization request form for all other health care services. The uniform\nprior authorization request forms shall not exceed two printed pages in\nlength. This two-page limit does not apply to information or documentation\nrequired by the utilization review agent, as published in accordance with\nsubsection (1) of section 3 of this act, or a health care provider 's notes or\ndocumentation submitted in support of a prior authorization request._\n\n_(b) Beginning January 1, 2026:_\n\n_(i) All health care providers shall use only the approved uniform prior\nauthorization request forms; and_\n\n_(ii) Except as provided in subsection (2) of this section, all utilization\nreview agents shall accept and process prior authorization requests submitted\nusing such forms._\n\n_(c) This subsection does not prohibit a utilization review agent from using a\nprior authorization methodology that uses an Internet webpage, an Internet\nwebpage portal, or a similar web-based system if the methodology is consistent\nwith the uniform prior authorization request forms approved by the department\npursuant to this subsection._\n\n_(2) A utilization review agent may request from the department an exemption\nfrom the requirements of subsection (1) of this section if the utilization\nreview agent implements and maintains a prior authorization application\nprogramming interface pursuant to 45 C.F.R. 156.223(b) or other electronic\nprior authorization methodology that automates and standardizes the prior\nauthorization process for patients, health care providers, and health\ncarriers. A utilization review agent shall provide notice to health care\nproviders at least ninety days prior to implementing a prior authorization\napplication programming interface or other electronic prior authorization\nmethodology under this subsection._\n\n**Sec. 7.** _(1) Prior to January 1, 2028, if a utilization review agent\nrequires prior authorization of a health care service, the utilization review\nagent shall make a decision on the prior authorization request and provide\nnotice of its decision to the enrollee and the enrollee 's health care\nprovider in accordance with the following timeframes:_\n\n_(a) For a prior authorization request for urgent health care services, within\nseventy-two hours after obtaining all necessary information to make a\ndecision; or_\n\n_(b) For a prior authorization request for nonurgent health care services,\nwithin seven days after obtaining all necessary information to make a\ndecision._\n\n_(2) Beginning January 1, 2028, if a utilization review agent requires prior\nauthorization of a health care service, the utilization review agent shall\nmake a decision on the prior authorization request and provide notice of its\ndecision to the enrollee and the enrollee 's health care provider in\naccordance with the following timeframes:_\n\n_(a) For a prior authorization request for urgent health care services, within\nforty-eight hours after obtaining all necessary information to make a\ndecision; or_\n\n_(b) For a prior authorization request for nonurgent health care services,\nwithin seven days after obtaining all necessary information to make a\ndecision._\n\n_(3) Nothing in this section prohibits a health care provider and health\ncarrier from contracting for shorter timeframes for using the prior\nauthorization application programming interface or other electronic prior\nauthorization methodology described in subsection (2) of section 6 of this act\nor as part of a risk-sharing agreement._\n\n_(4) Health care services are deemed authorized if a utilization review agent\nfails to comply with the deadlines for making a decision as set forth in this\nsection._\n\n_(5) In the notice to the health care provider that a prior authorization has\nbeen approved, the utilization review agent shall include the duration of the\nprior authorization or the date by which the prior authorization will expire._\n\n**Sec. 8.** _No utilization review agent shall require prior authorization\nof:_\n\n_(1) Emergency confinement or an emergency health care service;_\n\n_(2) Pre-hospital transportation for the provision of emergency health care\nservices or for transfers between facilities as required by the federal\nEmergency Medical Treatment and Labor Act; or_\n\n_(3) Services that have a rating of A or B from the United States Preventive\nServices Task Force, immunizations recommended by the Advisory Committee on\nImmunization Practices of the Centers for Disease Control and Prevention, or\npreventive services and screenings provided to women as required by 45 C.F.R.\n147.130._\n\n**Sec. 9.** _(1) A utilization review agent shall not revoke, limit,\ncondition, or restrict an approved prior authorization if care is provided\nwithin sixty days from the date the health care provider received the prior\nauthorization approval unless the enrollee was no longer eligible for care on\nthe day care was provided._\n\n_(2) A health carrier shall pay a contracted health care provider at the\ncontracted payment rate for a health care service provided by the health care\nprovider per an approved prior authorization request, unless:_\n\n_(a) The health care provider knowingly and materially misrepresented the\nhealth care service or patient 's medical history in the prior authorization\nrequest with the intent to deceive and obtain an unlawful payment under the\nhealth benefit plan;_\n\n_(b) The health care service was no longer a covered benefit on the day it was\nprovided;_\n\n_(c) The health care provider was no longer contracted with the patient 's\nhealth benefit plan on the date the care was provided;_\n\n_(d) The health care provider failed to meet the utilization review agent 's\ntimely filing requirements;_\n\n_(e) The patient was no longer eligible for health care coverage on the day\nthe care was provided; or_\n\n_(f) The health care provider failed to obtain prior authorization approval\nbefore rendering health care services for which prior authorization was\nrequired._\n\n**Sec. 10.** _(1) Except as otherwise provided in this section, prior\nauthorization shall be valid for at least one year from the date the\nutilization review agent approves the prior authorization request, except for\na prescription drug that has a treatment schedule or dosing limitation from\nthe federal Food and Drug Administration of less than one year._\n\n_(2)(a) If a prior authorization is required for inpatient care at a general\nacute hospital, the prior authorization shall remain valid for the length of\nstay approved by the utilization review agent._\n\n_(b) If the health care provider submits a timely request for the continuation\nof inpatient care, the utilization review agent shall respond to this request\nprior to the expiration of the current authorization for inpatient care._\n\n_(c) If a utilization review agent fails to respond to a timely request for\nthe continuation of inpatient care prior to the termination of the previously\napproved length of stay, then the health carrier shall continue to compensate\nthe health care provider at the contracted rate for inpatient care provided\nuntil the utilization review agent issues its determination on the prior\nauthorization request._\n\n_(d) Nothing in this subsection shall be interpreted to prohibit a health care\nprovider or enrollee from appealing an adverse determination as allowed under\nstate law. If an adverse determination is overturned on appeal, and no other\nlegal action related to the claim is pending, then the health carrier shall\nreimburse the health care provider at the contracted rate for inpatient care\nprovided to the enrollee._\n\n_(3) This section does not require a health benefit plan to cover care,\ntreatment, or services for a health condition that the terms of coverage\notherwise completely exclude from the policy 's covered benefits without\nregard for whether the care, treatment, or services are medically necessary._\n\n**Sec. 11.** _(1) On receipt of information documenting an approved prior\nauthorization from the enrollee or from the enrollee 's health care provider,\na utilization review agent shall honor the approved prior authorization\ngranted to an enrollee from a previous utilization review agent for at least\nthe initial sixty days of an enrollee's coverage under a new health benefit\nplan. During such time period, a utilization review agent may perform its own\nreview to grant a prior authorization._\n\n_(2) If there is a change in coverage of, or approval criteria for, a\npreviously authorized health care service, the change in coverage or approval\ncriteria does not affect a prior authorization request approved before the\neffective date of the change._\n\n_(3) A utilization review agent shall continue to honor a prior authorization\nit has granted to an enrollee when the enrollee changes health insurance\nproducts under the same health insurance company without any action required\nby the health care provider._\n\n**Sec. 12.** _(1) An artificial intelligence-based algorithm shall not be the\nsole basis of a utilization review agent 's decision to deny, delay, or modify\nhealth care services based, in whole or in part, on medical necessity._\n\n_(2) A utilization review agent shall disclose to the department, to each\nhealth care provider in its network, to each enrollee, and on its public\nwebsite if artificial intelligence-based algorithms are used or will be used\nin the utilization review process._\n\n_(3) The department may, at any time, audit a utilization review agent 's\nautomated utilization management system. The department may contract with a\nthird-party entity to perform an audit pursuant to this section._\n\n**Sec. 13.** _A utilization review agent shall not:_\n\n_(1) Be compensated based on its volume of denials; or_\n\n_(2) Base any incentive or penalty for a medical reviewer of such agent based\non the volume of denials such reviewer issues or upholds._\n\n**Sec. 14.** _For purposes of sections 14 to 16 of this act:_\n\n_(1) Biomarker means a characteristic that is objectively measured and\nevaluated as an indicator of normal biological processes, pathogenic\nprocesses, or pharmacologic responses to a specific therapeutic intervention,\nincluding known gene-drug interactions for medications being considered for\nuse or already being administered. Biomarkers include, but are not limited to,\ngene mutations, characteristics of genes, or protein expression;_\n\n_(2) Biomarker testing means the analysis of tissue, blood, or other\nbiospecimen for the presence of a biomarker. Biomarker testing includes, but\nis not limited to, single-analyte tests, multi-plex panel tests, protein\nexpression, and whole exome, whole genome, and whole transcriptome\nsequencing;_\n\n_(3) Clinical utility means sufficient medical and scientific evidence\nindicating that the use of a biomarker test will provide meaningful\ninformation that affects treatment decisions and guides improvement of net\nhealth outcomes including an improved quality of life or longer survival;_\n\n_(4) Consensus statements means statements developed by an independent,\nmultidisciplinary panel of experts utilizing a transparent methodology and\nreporting structure and with a conflict of interest policy. These statements\nare aimed at specific clinical circumstances and based on the best available\nevidence for the purpose of optimizing the outcomes of clinical care;_\n\n_(5) Health carrier has the same meaning as in section 44-1303; and_\n\n_(6) Nationally recognized clinical practice guidelines means evidence-based\nclinical practice guidelines developed by independent organizations or medical\nprofessional societies utilizing a transparent methodology and reporting\nstructure and with a conflict of interest policy. Clinical practice guidelines\nestablish standards of care informed by a systematic review of evidence and an\nassessment of the benefits and risks of alternative care options and include\nrecommendations intended to optimize patient care._\n\n**Sec. 15.** _(1) On and after January 1, 2028, and notwithstanding section\n44-3,131, (a) any individual or group sickness and accident insurance policy\nor subscriber contract delivered, issued for delivery, or renewed in this\nstate and any hospital, medical, or surgical expense-incurred policy, except\nfor policies that provide coverage for a specified disease or other limited-\nbenefit coverage and (b) any self-funded employee benefit plan to the extent\nnot preempted by federal law, shall include coverage for biomarker testing\npursuant to the criteria established under subsection (2) of this section._\n\n_(2) Biomarker testing shall be covered when:_\n\n_(a) The test is used for:_\n\n_(i) The diagnosis, treatment, appropriate management, or ongoing monitoring\nof cancer, an autoimmune or autoinflammatory disease, Parkinson 's disease,\namyotrophic lateral sclerosis, Alzheimer's disease, rheumatoid arthritis,\npreeclampsia, sickle cell anemia, or a cardiovascular condition;_\n\n_(ii) An organ or tissue transplant; or_\n\n_(iii) Pharmacogenomic testing; and_\n\n_(b) The test provides clinical utility as demonstrated by medical and\nscientific evidence, including, but not limited to:_\n\n_(i) Labeled indications for a test approved or cleared by the federal Food\nand Drug Administration;_\n\n_(ii) Indicated tests for a drug approved by the federal Food and Drug\nAdministration;_\n\n_(iii) Warnings and precautions on drug labels approved by the federal Food\nand Drug Administration;_\n\n_(iv) National coverage determinations by the federal Centers for Medicare and\nMedicaid Services or local coverage determinations by the medicare\nadministrative contractor; or_\n\n_(v) Nationally recognized clinical practice guidelines and consensus\nstatements._\n\n_(3) Coverage, as specified in subsection (2) of this section, shall be\nprovided in a manner that limits disruptions in care, including the need for\nmultiple biopsies or biospecimen samples._\n\n_(4) The patient and prescribing practitioner shall have access to a clear,\nreadily accessible, and convenient process to request an exception to a\ncoverage policy. The process shall be made readily accessible on the health\ncarrier 's website._\n\n**Sec. 16.** _(1) The medical assistance program shall cover biomarker testing\nno later than January 1, 2028._\n\n_(2) Biomarker testing shall be covered when:_\n\n_(a) The test is used for:_\n\n_(i) The diagnosis, treatment, appropriate management, or ongoing monitoring\nof cancer, an autoimmune or autoinflammatory disease, Parkinson 's disease,\namyotrophic lateral sclerosis, Alzheimer's disease, rheumatoid arthritis,\npreeclampsia, sickle cell anemia, or a cardiovascular condition;_\n\n_(ii) An organ or tissue transplant; or_\n\n_(iii) Pharmacogenomic testing; and_\n\n_(b) The test provides clinical utility as demonstrated by medical and\nscientific evidence, including, but not limited to:_\n\n_(i) Labeled indications for a test approved or cleared by the federal Food\nand Drug Administration;_\n\n_(ii) Indicated tests for a drug approved by the federal Food and Drug\nAdministration;_\n\n_(iii) Warnings and precautions on drug labels approved by the federal Food\nand Drug Administration;_\n\n_(iv) National coverage determinations by the federal Centers for Medicare and\nMedicaid Services or local coverage determinations by the medicare\nadministrative contractor; or_\n\n_(v) Nationally recognized clinical practice guidelines and consensus\nstatements._\n\n_(3) Coverage, as specified in subsection (2) of this section, shall be\nprovided in a manner that limits disruptions in care, including the need for\nmultiple biopsies or biospecimen samples._\n\n_(4) Entities contracting with the medical assistance program to deliver\nservices to program recipients shall provide biomarker testing at the same\nscope, duration, and frequency as the medical assistance program otherwise\nprovides to recipients._\n\n_(5) The recipient and participating medical assistance program provider shall\nhave access to a clear, readily accessible, and convenient process to request\nan exception to a coverage policy of the medical assistance program. The\nprocess shall be made readily accessible on the Department of Health and Human\nServices ' website._\n\n**Sec. 17.** Sections 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, and 13 of this act\nbecome operative on January 1, 2026. The other sections of this act become\noperative on their effective date.\n\n**Sec. 18.** If any section in this act or any part of any section is declared\ninvalid or unconstitutional, the declaration shall not affect the validity or\nconstitutionality of the remaining portions.\n\nCopyright (C) 2025 State Net  \n  \n---\n\n",
      "latest_version": false
    },
    {
      "date": "05/27/2025",
      "label": "Final Reading",
      "url": "https://custom.statenet.com/public/resources.cgi?mode=show_text&id=ID:bill:NE2025000L77&verid=NE2025000L77_20250527_0_FR&",
      "raw_html": "<html>\n<head>\n<title>Bill Resource</title>\n\n<!--   <link href=\"https://custom.statenet.com/network/Common/css/extregtext.css\" rel=\"stylesheet\" type=\"text/css\" />-->\n   <link href=\"https://custom.statenet.com/network/Common/css/xmltext-2.0.css\" rel=\"stylesheet\" type=\"text/css\" />\n   <link href=\"https://custom.statenet.com/network/Common/css/additional-text.css\" rel=\"stylesheet\" type=\"text/css\" />\n\n\t<style type=\"text/css\">\n<!--\n\ntd, body {\n     background-color: white;\n\tfont-family: Verdana, Arial, Helvetica, sans-serif;\n\tfont-size: 12px;\n}\n\n.resourceContainer {\n   border: 1px solid black;\n}\n-->\n</style>\n</head>\n<body>\n\n    <div style=\"width: 750px; margin: auto\">\n       <div style=\"font-size: .8em;margin-bottom: 10px\"><table width=\"100%\"><tr><td align=\"left\" style=\"font-size: .8em;\"><div>The following has special meaning:</div>\n<div><u class=\"amendmentInsertedText\">green underline denotes added text</u></div>\n<div><strike class=\"amendmentDeletedText\">red struck out text denotes deleted text</strike></div></td> <td align=\"right\"><a href=\"https://www.lexisnexis.com/statenet/\"><img alt=\"Powered by State Net\" src=\"https://custom.statenet.com/network/poweredby.gif\" /></a></td></tr></table></div><table id=\"text-identifier\"><tr><td class=\"key\">2025 NE L 77</td> <td><table><tr><td class=\"label\">Author:</td> <td>Bostar</td></tr> <tr><td class=\"label\">Version:</td> <td>Final Reading</td></tr> <tr><td class=\"label\">Version Date:</td> <td>05/27/2025</td></tr></table></td></tr></table><div class=\"documentBody\">\n  <a name=\"head_document_section\"></a><div class=\"head\">\n   <p class=\"center\">LEGISLATURE OF NEBRASKA</p>\n   <p class=\"center\">ONE HUNDRED NINTH LEGISLATURE</p>\n   <p class=\"center\">FIRST SESSION</p>\n   <p class=\"center\">\n    <b>LEGISLATIVE BILL 77</b>\n   </p>\n   <p class=\"center\">FINAL READING</p>\n   <p class=\"left\">Introduced by Bostar, 29.</p>\n   <p class=\"left\">Read first time January 09, 2025</p>\n   <p class=\"left\">Committee: Banking, Commerce and Insurance</p>\n  </div>\n  <a name=\"code_document_section\"></a><div class=\"code\">\n   <p class=\"left\">A BILL FOR AN ACT relating to insurance; to adopt the Ensuring Transparency in Prior Authorization Act; to provide for insurance and medicaid coverage of biomarker testing as prescribed; to provide operative dates; and to provide severability.</p>\n  </div>\n  <a name=\"text_document_section\"></a><div class=\"text\">\n   <span>\n    <p class=\"left\">Be it enacted by the people of the State of Nebraska,</p>\n   </span>\n   <p class=\"indent\">\n    <b>Section 1. </b>\n    <u class=\"amendmentInsertedText\">Sections 1 to 13 of this act shall be known and may be cited as the Ensuring Transparency in Prior Authorization Act.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 2. </b>\n    <u class=\"amendmentInsertedText\">For purposes of the Ensuring Transparency in Prior Authorization Act, unless the context otherwise requires:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(1) Adverse determination has the same meaning as in section 44-1303;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Clinical peer means a health care provider in the same, or in a similar, specialty that typically manages the medical condition or health care service under review;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) Clinical review criteria has the same meaning as in section 44-1303;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4) Department means the Department of Insurance;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(5) Emergency health care services means health care services medically necessary to screen and stabilize a patient in connection with an emergency medical condition until the health care provider determines such individual is able to travel using nonmedical transportation;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(6) Emergency medical condition has the same meaning as in section 44-1303;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(7) Enrollee means an individual who is enrolled in a health benefit plan, including covered dependents;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(8) General acute hospital has the same meaning as in section 71-412;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(9) Health benefit plan has the same meaning as in section 44-1303;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(10) Health care provider has the same meaning as in section 44-1303;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(11) Health care services has the same meaning as in section 44-1303;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(12) Health carrier has the same meaning as in section 44-1303, except that health carrier does not include a managed care agent;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(13) Medically necessary has the same meaning as in section 44-6845;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(14) Notice means communication delivered either electronically or through the United States Postal Service or a common carrier;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(15) Physician means an individual licensed under the Medicine and Surgery Practice Act to practice medicine and surgery or osteopathic medicine and surgery or an individual with an equivalent license from another United States jurisdiction;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(16) Prior authorization means the process by which a health carrier or utilization review agent makes a determination that a requested admission, extension of stay, or health care service has been reviewed and, based on the information provided, satisfies the health carrier&#39;s or utilization review agent&#39;s requirements for reimbursement under the applicable health benefit plan;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(17) Urgent health care service means a health care service with respect to which the application of the time periods prescribed under the Ensuring Transparency in Prior Authorization Act for making a nonexpedited prior authorization could, in the opinion of a physician with knowledge of the enrollee&#39;s medical condition:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) Seriously jeopardize the life or health of the enrollee or the ability of the enrollee to regain maximum function; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) Subject the enrollee to severe pain that cannot be adequately managed without the care or treatment that is the subject of the utilization review; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(18) Utilization review agent has the same meaning as in section 44-5418.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 3. </b>\n    <u class=\"amendmentInsertedText\">(1) A utilization review agent shall make prior authorization requirements and restrictions, including written clinical review criteria, accessible on its website. Such requirements, restrictions, and clinical review criteria shall be accurate and current and shall clearly communicate what information and documentation is needed to decide the prior authorization. Prior authorization requirements shall also be made available on the website in a searchable format no later than July 1, 2027.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) If a utilization review agent intends either to implement a new prior authorization requirement or restriction or to amend an existing requirement or restriction, the utilization review agent shall:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) Ensure that the new or amended requirement or restriction is not implemented unless the utilization review agent&#39;s website has been updated to reflect the new or amended requirement or restriction; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) Provide contracted health care providers with notice of the new or amended requirement or restriction no less than sixty days before the requirement or restriction is implemented.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 4. </b>\n    <u class=\"amendmentInsertedText\">(1) A utilization review agent shall ensure that all adverse determinations for prior authorization are made by a physician, except that if the requesting health care provider is not a physician, the adverse determination may be made by a clinical peer of the requesting health care provider. Such physician or clinical peer shall:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) Possess a current and valid nonrestricted license in a United States jurisdiction;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) Have the appropriate training, knowledge, or expertise to apply appropriate clinical guidelines to the health care service being requested; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) Make the adverse determination under the clinical direction of one of the utilization review agent&#39;s medical directors who is responsible for the provision of health care services provided to enrollees of Nebraska. All such medical directors must be physicians licensed in a United States jurisdiction.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) When an adverse determination for prior authorization is issued or a prior authorization is canceled or voided, the utilization review agent shall provide notice to the requesting health care provider. The notice shall include the reason for denial, citing written clinical review criteria.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3)(a) If an adverse determination for prior authorization questions the medical necessity, the appropriateness, or the experimental or investigational nature of a health care service, the enrollee&#39;s health care provider shall have the opportunity to discuss the health care service with the physician or clinical peer who is responsible for determining authorization of the health care service under review. The enrollee&#39;s health care provider may request that such discussion occur within three business days after receiving notice of the adverse determination. No discussion shall be required or allowed for an adverse determination that is due to contract exclusions or benefits that are not covered by the health benefit plan.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) Following any discussion under subdivision (3)(a) of this section, the utilization review agent shall notify the requesting health care provider whether the adverse determination decision remains the same. The notice under this subdivision shall be provided (i) within one business day after the discussion under subdivision (3)(a) of this section for an urgent health care service or (ii) within two business days after the discussion under subdivision (3)(a) of this section for a nonurgent health care service.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) A discussion under subdivision (3)(a) of this section shall not replace or eliminate the opportunity for any internal grievance or appeal process provided by the utilization review agent.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 5. </b>\n    <u class=\"amendmentInsertedText\">A utilization review agent shall ensure that all appeals of an adverse determination for prior authorization are reviewed by a physician. Such physician shall:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(1) Possess a current and valid unrestricted license in a United States jurisdiction;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Be of the same or similar specialty as the ordering physician or have the training and experience to treat the condition, which means that either:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) The physician maintains board certification for the same or similar specialty; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) The physician&#39;s training and experience (i) includes treating the condition, (ii) includes treating complications that may result from the health care service, and (iii) is sufficient for the physician to determine based on the physician&#39;s clinical judgment whether the health care service is medically necessary or clinically appropriate;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) Not have been directly involved in making the initial adverse determination;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4) Not have any financial interest in the outcome of the appeal; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(5) Consider all known clinical aspects of the health care service under review, including, but not limited to, a review of those medical records which are pertinent and relevant to the active condition provided to the utilization review agent by the enrollee&#39;s health care provider, or a health care facility, and any pertinent medical literature provided to the utilization review agent by the health care provider.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 6. </b>\n    <u class=\"amendmentInsertedText\">(1)(a) On or before November 1, 2025, the department shall approve a single uniform prior authorization request form for prescription drugs, devices, and durable medical equipment and a single uniform prior authorization request form for all other health care services. The uniform prior authorization request forms shall not exceed two printed pages in length. This two-page limit does not apply to information or documentation required by the utilization review agent, as published in accordance with subsection (1) of section 3 of this act, or a health care provider&#39;s notes or documentation submitted in support of a prior authorization request.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) Beginning January 1, 2026:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(i) All health care providers shall use only the approved uniform prior authorization request forms; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(ii) Except as provided in subsection (2) of this section, all utilization review agents shall accept and process prior authorization requests submitted using such forms.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) This subsection does not prohibit a utilization review agent from using a prior authorization methodology that uses an Internet webpage, an Internet webpage portal, or a similar web-based system if the methodology is consistent with the uniform prior authorization request forms approved by the department pursuant to this subsection.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) A utilization review agent may request from the department an exemption from the requirements of subsection (1) of this section if the utilization review agent implements and maintains a prior authorization application programming interface pursuant to 45 C.F.R. 156.223(b) or other electronic prior authorization methodology that automates and standardizes the prior authorization process for patients, health care providers, and health carriers. A utilization review agent shall provide notice to health care providers at least ninety days prior to implementing a prior authorization application programming interface or other electronic prior authorization methodology under this subsection.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 7. </b>\n    <u class=\"amendmentInsertedText\">(1) Prior to January 1, 2028, if a utilization review agent requires prior authorization of a health care service, the utilization review agent shall make a decision on the prior authorization request and provide notice of its decision to the enrollee and the enrollee&#39;s health care provider in accordance with the following timeframes:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) For a prior authorization request for urgent health care services, within seventy-two hours after obtaining all necessary information to make a decision; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) For a prior authorization request for nonurgent health care services, within seven days after obtaining all necessary information to make a decision.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Beginning January 1, 2028, if a utilization review agent requires prior authorization of a health care service, the utilization review agent shall make a decision on the prior authorization request and provide notice of its decision to the enrollee and the enrollee&#39;s health care provider in accordance with the following timeframes:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) For a prior authorization request for urgent health care services, within forty-eight hours after obtaining all necessary information to make a decision; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) For a prior authorization request for nonurgent health care services, within seven days after obtaining all necessary information to make a decision.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) Nothing in this section prohibits a health care provider and health carrier from contracting for shorter timeframes for using the prior authorization application programming interface or other electronic prior authorization methodology described in subsection (2) of section 6 of this act or as part of a risk-sharing agreement.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4) Health care services are deemed authorized if a utilization review agent fails to comply with the deadlines for making a decision as set forth in this section.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(5) In the notice to the health care provider that a prior authorization has been approved, the utilization review agent shall include the duration of the prior authorization or the date by which the prior authorization will expire.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 8. </b>\n    <u class=\"amendmentInsertedText\">No utilization review agent shall require prior authorization of:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(1) Emergency confinement or an emergency health care service;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Pre-hospital transportation for the provision of emergency health care services or for transfers between facilities as required by the federal Emergency Medical Treatment and Labor Act; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) Services that have a rating of A or B from the United States Preventive Services Task Force, immunizations recommended by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention, or preventive services and screenings provided to women as required by 45 C.F.R. 147.130.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 9. </b>\n    <u class=\"amendmentInsertedText\">(1) A utilization review agent shall not revoke, limit, condition, or restrict an approved prior authorization if care is provided within sixty days from the date the health care provider received the prior authorization approval unless the enrollee was no longer eligible for care on the day care was provided.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) A health carrier shall pay a contracted health care provider at the contracted payment rate for a health care service provided by the health care provider per an approved prior authorization request, unless:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) The health care provider knowingly and materially misrepresented the health care service or patient&#39;s medical history in the prior authorization request with the intent to deceive and obtain an unlawful payment under the health benefit plan;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) The health care service was no longer a covered benefit on the day it was provided;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) The health care provider was no longer contracted with the patient&#39;s health benefit plan on the date the care was provided;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(d) The health care provider failed to meet the utilization review agent&#39;s timely filing requirements;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(e) The patient was no longer eligible for health care coverage on the day the care was provided; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(f) The health care provider failed to obtain prior authorization approval before rendering health care services for which prior authorization was required.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 10. </b>\n    <u class=\"amendmentInsertedText\">(1) Except as otherwise provided in this section, prior authorization shall be valid for at least one year from the date the utilization review agent approves the prior authorization request, except for a prescription drug that has a treatment schedule or dosing limitation from the federal Food and Drug Administration of less than one year.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2)(a) If a prior authorization is required for inpatient care at a general acute hospital, the prior authorization shall remain valid for the length of stay approved by the utilization review agent.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) If the health care provider submits a timely request for the continuation of inpatient care, the utilization review agent shall respond to this request prior to the expiration of the current authorization for inpatient care.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) If a utilization review agent fails to respond to a timely request for the continuation of inpatient care prior to the termination of the previously approved length of stay, then the health carrier shall continue to compensate the health care provider at the contracted rate for inpatient care provided until the utilization review agent issues its determination on the prior authorization request.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(d) Nothing in this subsection shall be interpreted to prohibit a health care provider or enrollee from appealing an adverse determination as allowed under state law. If an adverse determination is overturned on appeal, and no other legal action related to the claim is pending, then the health carrier shall reimburse the health care provider at the contracted rate for inpatient care provided to the enrollee.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) This section does not require a health benefit plan to cover care, treatment, or services for a health condition that the terms of coverage otherwise completely exclude from the policy&#39;s covered benefits without regard for whether the care, treatment, or services are medically necessary.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 11. </b>\n    <u class=\"amendmentInsertedText\">(1) On receipt of information documenting an approved prior authorization from the enrollee or from the enrollee&#39;s health care provider, a utilization review agent shall honor the approved prior authorization granted to an enrollee from a previous utilization review agent for at least the initial sixty days of an enrollee&#39;s coverage under a new health benefit plan. During such time period, a utilization review agent may perform its own review to grant a prior authorization.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) If there is a change in coverage of, or approval criteria for, a previously authorized health care service, the change in coverage or approval criteria does not affect a prior authorization request approved before the effective date of the change.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) A utilization review agent shall continue to honor a prior authorization it has granted to an enrollee when the enrollee changes health insurance products under the same health insurance company without any action required by the health care provider.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 12. </b>\n    <u class=\"amendmentInsertedText\">(1) An artificial intelligence-based algorithm shall not be the sole basis of a utilization review agent&#39;s decision to deny, delay, or modify health care services based, in whole or in part, on medical necessity.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) A utilization review agent shall disclose to the department, to each health care provider in its network, to each enrollee, and on its public website if artificial intelligence-based algorithms are used or will be used in the utilization review process.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) The department may, at any time, audit a utilization review agent&#39;s automated utilization management system. The department may contract with a third-party entity to perform an audit pursuant to this section.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 13. </b>\n    <u class=\"amendmentInsertedText\">A utilization review agent shall not:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(1) Be compensated based on its volume of denials; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Base any incentive or penalty for a medical reviewer of such agent based on the volume of denials such reviewer issues or upholds.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 14. </b>\n    <u class=\"amendmentInsertedText\">For purposes of sections 14 to 16 of this act:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(1) Biomarker means a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a specific therapeutic intervention, including known gene-drug interactions for medications being considered for use or already being administered. Biomarkers include, but are not limited to, gene mutations, characteristics of genes, or protein expression;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Biomarker testing means the analysis of tissue, blood, or other biospecimen for the presence of a biomarker. Biomarker testing includes, but is not limited to, single-analyte tests, multi-plex panel tests, protein expression, and whole exome, whole genome, and whole transcriptome sequencing;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) Clinical utility means sufficient medical and scientific evidence indicating that the use of a biomarker test will provide meaningful information that affects treatment decisions and guides improvement of net health outcomes including an improved quality of life or longer survival;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4) Consensus statements means statements developed by an independent, multidisciplinary panel of experts utilizing a transparent methodology and reporting structure and with a conflict of interest policy. These statements are aimed at specific clinical circumstances and based on the best available evidence for the purpose of optimizing the outcomes of clinical care;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(5) Health carrier has the same meaning as in section 44-1303; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(6) Nationally recognized clinical practice guidelines means evidence-based clinical practice guidelines developed by independent organizations or medical professional societies utilizing a transparent methodology and reporting structure and with a conflict of interest policy. Clinical practice guidelines establish standards of care informed by a systematic review of evidence and an assessment of the benefits and risks of alternative care options and include recommendations intended to optimize patient care.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 15. </b>\n    <u class=\"amendmentInsertedText\">(1) On and after January 1, 2028, and notwithstanding section 44-3,131, (a) any individual or group sickness and accident insurance policy or subscriber contract delivered, issued for delivery, or renewed in this state and any hospital, medical, or surgical expense-incurred policy, except for policies that provide coverage for a specified disease or other limited-benefit coverage and (b) any self-funded employee benefit plan to the extent not preempted by federal law, shall include coverage for biomarker testing pursuant to the criteria established under subsection (2) of this section.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Biomarker testing shall be covered when:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) The test is used for:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(i) The diagnosis, treatment, appropriate management, or ongoing monitoring of cancer, an autoimmune or autoinflammatory disease, Parkinson&#39;s disease, amyotrophic lateral sclerosis, Alzheimer&#39;s disease and related dementias, rheumatoid arthritis, preeclampsia, sickle cell anemia, or a cardiovascular condition;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(ii) An organ or tissue transplant; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(iii) Pharmacogenomic testing; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) The test provides clinical utility as demonstrated by medical and scientific evidence, including, but not limited to:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(i) Labeled indications for a test approved or cleared by the federal Food and Drug Administration;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(ii) Indicated tests for a drug approved by the federal Food and Drug Administration;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(iii) Warnings and precautions on drug labels approved by the federal Food and Drug Administration;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(iv) National coverage determinations by the federal Centers for Medicare and Medicaid Services or local coverage determinations by the medicare administrative contractor; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(v) Nationally recognized clinical practice guidelines and consensus statements.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) Coverage, as specified in subsection (2) of this section, shall be provided in a manner that limits disruptions in care, including the need for multiple biopsies or biospecimen samples.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4) The patient and prescribing practitioner shall have access to a clear, readily accessible, and convenient process to request an exception to a coverage policy. The process shall be made readily accessible on the health carrier&#39;s website.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 16. </b>\n    <u class=\"amendmentInsertedText\">(1) The medical assistance program shall cover biomarker testing no later than January 1, 2028.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Biomarker testing shall be covered when:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) The test is used for:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(i) The diagnosis, treatment, appropriate management, or ongoing monitoring of cancer, an autoimmune or autoinflammatory disease, Parkinson&#39;s disease, amyotrophic lateral sclerosis, Alzheimer&#39;s disease and related dementias, rheumatoid arthritis, preeclampsia, sickle cell anemia, or a cardiovascular condition;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(ii) An organ or tissue transplant; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(iii) Pharmacogenomic testing; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) The test provides clinical utility as demonstrated by medical and scientific evidence, including, but not limited to:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(i) Labeled indications for a test approved or cleared by the federal Food and Drug Administration;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(ii) Indicated tests for a drug approved by the federal Food and Drug Administration;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(iii) Warnings and precautions on drug labels approved by the federal Food and Drug Administration;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(iv) National coverage determinations by the federal Centers for Medicare and Medicaid Services or local coverage determinations by the medicare administrative contractor; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(v) Nationally recognized clinical practice guidelines and consensus statements.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) Coverage, as specified in subsection (2) of this section, shall be provided in a manner that limits disruptions in care, including the need for multiple biopsies or biospecimen samples.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4) Entities contracting with the medical assistance program to deliver services to program recipients shall provide biomarker testing at the same scope, duration, and frequency as the medical assistance program otherwise provides to recipients.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(5) The recipient and participating medical assistance program provider shall have access to a clear, readily accessible, and convenient process to request an exception to a coverage policy of the medical assistance program. The process shall be made readily accessible on the Department of Health and Human Services&#39; website.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 17. </b> Sections 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, and 13 of this act become operative on January 1, 2026. The other sections of this act become operative on their effective date.</p>\n   <p class=\"indent\">\n    <b>Sec. 18. </b> If any section in this act or any part of any section is declared invalid or unconstitutional, the declaration shall not affect the validity or constitutionality of the remaining portions.</p>\n  </div>\n </div>\n    </div>\t\n<table cellpadding=0 cellspacing=0 width=\"100%\">\n   <tr>\n      <td>\n          Copyright &copy; 2025 State Net\n      </td>\n<BR>\n<!--???MOVED INTO resources.cgi      <td align=\"right\">\n          <img src=\"https://custom.statenet.com/network/poweredby.gif\" alt=\"Powered by State Net\">\n      </td>-->\n\n    </tr>\n</table>\n</body></html>\n",
      "markdown": "The following has special meaning: _green underline denotes added text_ ~~red struck out text denotes deleted text~~ | [![Powered by State Net](https://custom.statenet.com/network/poweredby.gif)](https://www.lexisnexis.com/statenet/)  \n---|---  \n  \n2025 NE L 77 | | Author: | Bostar  \n---|---  \nVersion: | Final Reading  \nVersion Date: | 05/27/2025  \n  \nLEGISLATURE OF NEBRASKA\n\nONE HUNDRED NINTH LEGISLATURE\n\nFIRST SESSION\n\n**LEGISLATIVE BILL 77**\n\nFINAL READING\n\nIntroduced by Bostar, 29.\n\nRead first time January 09, 2025\n\nCommittee: Banking, Commerce and Insurance\n\nA BILL FOR AN ACT relating to insurance; to adopt the Ensuring Transparency in\nPrior Authorization Act; to provide for insurance and medicaid coverage of\nbiomarker testing as prescribed; to provide operative dates; and to provide\nseverability.\n\nBe it enacted by the people of the State of Nebraska,\n\n**Section 1.** _Sections 1 to 13 of this act shall be known and may be cited\nas the Ensuring Transparency in Prior Authorization Act._\n\n**Sec. 2.** _For purposes of the Ensuring Transparency in Prior Authorization\nAct, unless the context otherwise requires:_\n\n_(1) Adverse determination has the same meaning as in section 44-1303;_\n\n_(2) Clinical peer means a health care provider in the same, or in a similar,\nspecialty that typically manages the medical condition or health care service\nunder review;_\n\n_(3) Clinical review criteria has the same meaning as in section 44-1303;_\n\n_(4) Department means the Department of Insurance;_\n\n_(5) Emergency health care services means health care services medically\nnecessary to screen and stabilize a patient in connection with an emergency\nmedical condition until the health care provider determines such individual is\nable to travel using nonmedical transportation;_\n\n_(6) Emergency medical condition has the same meaning as in section 44-1303;_\n\n_(7) Enrollee means an individual who is enrolled in a health benefit plan,\nincluding covered dependents;_\n\n_(8) General acute hospital has the same meaning as in section 71-412;_\n\n_(9) Health benefit plan has the same meaning as in section 44-1303;_\n\n_(10) Health care provider has the same meaning as in section 44-1303;_\n\n_(11) Health care services has the same meaning as in section 44-1303;_\n\n_(12) Health carrier has the same meaning as in section 44-1303, except that\nhealth carrier does not include a managed care agent;_\n\n_(13) Medically necessary has the same meaning as in section 44-6845;_\n\n_(14) Notice means communication delivered either electronically or through\nthe United States Postal Service or a common carrier;_\n\n_(15) Physician means an individual licensed under the Medicine and Surgery\nPractice Act to practice medicine and surgery or osteopathic medicine and\nsurgery or an individual with an equivalent license from another United States\njurisdiction;_\n\n_(16) Prior authorization means the process by which a health carrier or\nutilization review agent makes a determination that a requested admission,\nextension of stay, or health care service has been reviewed and, based on the\ninformation provided, satisfies the health carrier 's or utilization review\nagent's requirements for reimbursement under the applicable health benefit\nplan;_\n\n_(17) Urgent health care service means a health care service with respect to\nwhich the application of the time periods prescribed under the Ensuring\nTransparency in Prior Authorization Act for making a nonexpedited prior\nauthorization could, in the opinion of a physician with knowledge of the\nenrollee 's medical condition:_\n\n_(a) Seriously jeopardize the life or health of the enrollee or the ability of\nthe enrollee to regain maximum function; or_\n\n_(b) Subject the enrollee to severe pain that cannot be adequately managed\nwithout the care or treatment that is the subject of the utilization review;\nand_\n\n_(18) Utilization review agent has the same meaning as in section 44-5418._\n\n**Sec. 3.** _(1) A utilization review agent shall make prior authorization\nrequirements and restrictions, including written clinical review criteria,\naccessible on its website. Such requirements, restrictions, and clinical\nreview criteria shall be accurate and current and shall clearly communicate\nwhat information and documentation is needed to decide the prior\nauthorization. Prior authorization requirements shall also be made available\non the website in a searchable format no later than July 1, 2027._\n\n_(2) If a utilization review agent intends either to implement a new prior\nauthorization requirement or restriction or to amend an existing requirement\nor restriction, the utilization review agent shall:_\n\n_(a) Ensure that the new or amended requirement or restriction is not\nimplemented unless the utilization review agent 's website has been updated to\nreflect the new or amended requirement or restriction; and_\n\n_(b) Provide contracted health care providers with notice of the new or\namended requirement or restriction no less than sixty days before the\nrequirement or restriction is implemented._\n\n**Sec. 4.** _(1) A utilization review agent shall ensure that all adverse\ndeterminations for prior authorization are made by a physician, except that if\nthe requesting health care provider is not a physician, the adverse\ndetermination may be made by a clinical peer of the requesting health care\nprovider. Such physician or clinical peer shall:_\n\n_(a) Possess a current and valid nonrestricted license in a United States\njurisdiction;_\n\n_(b) Have the appropriate training, knowledge, or expertise to apply\nappropriate clinical guidelines to the health care service being requested;\nand_\n\n_(c) Make the adverse determination under the clinical direction of one of the\nutilization review agent 's medical directors who is responsible for the\nprovision of health care services provided to enrollees of Nebraska. All such\nmedical directors must be physicians licensed in a United States\njurisdiction._\n\n_(2) When an adverse determination for prior authorization is issued or a\nprior authorization is canceled or voided, the utilization review agent shall\nprovide notice to the requesting health care provider. The notice shall\ninclude the reason for denial, citing written clinical review criteria._\n\n_(3)(a) If an adverse determination for prior authorization questions the\nmedical necessity, the appropriateness, or the experimental or investigational\nnature of a health care service, the enrollee 's health care provider shall\nhave the opportunity to discuss the health care service with the physician or\nclinical peer who is responsible for determining authorization of the health\ncare service under review. The enrollee's health care provider may request\nthat such discussion occur within three business days after receiving notice\nof the adverse determination. No discussion shall be required or allowed for\nan adverse determination that is due to contract exclusions or benefits that\nare not covered by the health benefit plan._\n\n_(b) Following any discussion under subdivision (3)(a) of this section, the\nutilization review agent shall notify the requesting health care provider\nwhether the adverse determination decision remains the same. The notice under\nthis subdivision shall be provided (i) within one business day after the\ndiscussion under subdivision (3)(a) of this section for an urgent health care\nservice or (ii) within two business days after the discussion under\nsubdivision (3)(a) of this section for a nonurgent health care service._\n\n_(c) A discussion under subdivision (3)(a) of this section shall not replace\nor eliminate the opportunity for any internal grievance or appeal process\nprovided by the utilization review agent._\n\n**Sec. 5.** _A utilization review agent shall ensure that all appeals of an\nadverse determination for prior authorization are reviewed by a physician.\nSuch physician shall:_\n\n_(1) Possess a current and valid unrestricted license in a United States\njurisdiction;_\n\n_(2) Be of the same or similar specialty as the ordering physician or have the\ntraining and experience to treat the condition, which means that either:_\n\n_(a) The physician maintains board certification for the same or similar\nspecialty; or_\n\n_(b) The physician 's training and experience (i) includes treating the\ncondition, (ii) includes treating complications that may result from the\nhealth care service, and (iii) is sufficient for the physician to determine\nbased on the physician's clinical judgment whether the health care service is\nmedically necessary or clinically appropriate;_\n\n_(3) Not have been directly involved in making the initial adverse\ndetermination;_\n\n_(4) Not have any financial interest in the outcome of the appeal; and_\n\n_(5) Consider all known clinical aspects of the health care service under\nreview, including, but not limited to, a review of those medical records which\nare pertinent and relevant to the active condition provided to the utilization\nreview agent by the enrollee 's health care provider, or a health care\nfacility, and any pertinent medical literature provided to the utilization\nreview agent by the health care provider._\n\n**Sec. 6.** _(1)(a) On or before November 1, 2025, the department shall\napprove a single uniform prior authorization request form for prescription\ndrugs, devices, and durable medical equipment and a single uniform prior\nauthorization request form for all other health care services. The uniform\nprior authorization request forms shall not exceed two printed pages in\nlength. This two-page limit does not apply to information or documentation\nrequired by the utilization review agent, as published in accordance with\nsubsection (1) of section 3 of this act, or a health care provider 's notes or\ndocumentation submitted in support of a prior authorization request._\n\n_(b) Beginning January 1, 2026:_\n\n_(i) All health care providers shall use only the approved uniform prior\nauthorization request forms; and_\n\n_(ii) Except as provided in subsection (2) of this section, all utilization\nreview agents shall accept and process prior authorization requests submitted\nusing such forms._\n\n_(c) This subsection does not prohibit a utilization review agent from using a\nprior authorization methodology that uses an Internet webpage, an Internet\nwebpage portal, or a similar web-based system if the methodology is consistent\nwith the uniform prior authorization request forms approved by the department\npursuant to this subsection._\n\n_(2) A utilization review agent may request from the department an exemption\nfrom the requirements of subsection (1) of this section if the utilization\nreview agent implements and maintains a prior authorization application\nprogramming interface pursuant to 45 C.F.R. 156.223(b) or other electronic\nprior authorization methodology that automates and standardizes the prior\nauthorization process for patients, health care providers, and health\ncarriers. A utilization review agent shall provide notice to health care\nproviders at least ninety days prior to implementing a prior authorization\napplication programming interface or other electronic prior authorization\nmethodology under this subsection._\n\n**Sec. 7.** _(1) Prior to January 1, 2028, if a utilization review agent\nrequires prior authorization of a health care service, the utilization review\nagent shall make a decision on the prior authorization request and provide\nnotice of its decision to the enrollee and the enrollee 's health care\nprovider in accordance with the following timeframes:_\n\n_(a) For a prior authorization request for urgent health care services, within\nseventy-two hours after obtaining all necessary information to make a\ndecision; or_\n\n_(b) For a prior authorization request for nonurgent health care services,\nwithin seven days after obtaining all necessary information to make a\ndecision._\n\n_(2) Beginning January 1, 2028, if a utilization review agent requires prior\nauthorization of a health care service, the utilization review agent shall\nmake a decision on the prior authorization request and provide notice of its\ndecision to the enrollee and the enrollee 's health care provider in\naccordance with the following timeframes:_\n\n_(a) For a prior authorization request for urgent health care services, within\nforty-eight hours after obtaining all necessary information to make a\ndecision; or_\n\n_(b) For a prior authorization request for nonurgent health care services,\nwithin seven days after obtaining all necessary information to make a\ndecision._\n\n_(3) Nothing in this section prohibits a health care provider and health\ncarrier from contracting for shorter timeframes for using the prior\nauthorization application programming interface or other electronic prior\nauthorization methodology described in subsection (2) of section 6 of this act\nor as part of a risk-sharing agreement._\n\n_(4) Health care services are deemed authorized if a utilization review agent\nfails to comply with the deadlines for making a decision as set forth in this\nsection._\n\n_(5) In the notice to the health care provider that a prior authorization has\nbeen approved, the utilization review agent shall include the duration of the\nprior authorization or the date by which the prior authorization will expire._\n\n**Sec. 8.** _No utilization review agent shall require prior authorization\nof:_\n\n_(1) Emergency confinement or an emergency health care service;_\n\n_(2) Pre-hospital transportation for the provision of emergency health care\nservices or for transfers between facilities as required by the federal\nEmergency Medical Treatment and Labor Act; or_\n\n_(3) Services that have a rating of A or B from the United States Preventive\nServices Task Force, immunizations recommended by the Advisory Committee on\nImmunization Practices of the Centers for Disease Control and Prevention, or\npreventive services and screenings provided to women as required by 45 C.F.R.\n147.130._\n\n**Sec. 9.** _(1) A utilization review agent shall not revoke, limit,\ncondition, or restrict an approved prior authorization if care is provided\nwithin sixty days from the date the health care provider received the prior\nauthorization approval unless the enrollee was no longer eligible for care on\nthe day care was provided._\n\n_(2) A health carrier shall pay a contracted health care provider at the\ncontracted payment rate for a health care service provided by the health care\nprovider per an approved prior authorization request, unless:_\n\n_(a) The health care provider knowingly and materially misrepresented the\nhealth care service or patient 's medical history in the prior authorization\nrequest with the intent to deceive and obtain an unlawful payment under the\nhealth benefit plan;_\n\n_(b) The health care service was no longer a covered benefit on the day it was\nprovided;_\n\n_(c) The health care provider was no longer contracted with the patient 's\nhealth benefit plan on the date the care was provided;_\n\n_(d) The health care provider failed to meet the utilization review agent 's\ntimely filing requirements;_\n\n_(e) The patient was no longer eligible for health care coverage on the day\nthe care was provided; or_\n\n_(f) The health care provider failed to obtain prior authorization approval\nbefore rendering health care services for which prior authorization was\nrequired._\n\n**Sec. 10.** _(1) Except as otherwise provided in this section, prior\nauthorization shall be valid for at least one year from the date the\nutilization review agent approves the prior authorization request, except for\na prescription drug that has a treatment schedule or dosing limitation from\nthe federal Food and Drug Administration of less than one year._\n\n_(2)(a) If a prior authorization is required for inpatient care at a general\nacute hospital, the prior authorization shall remain valid for the length of\nstay approved by the utilization review agent._\n\n_(b) If the health care provider submits a timely request for the continuation\nof inpatient care, the utilization review agent shall respond to this request\nprior to the expiration of the current authorization for inpatient care._\n\n_(c) If a utilization review agent fails to respond to a timely request for\nthe continuation of inpatient care prior to the termination of the previously\napproved length of stay, then the health carrier shall continue to compensate\nthe health care provider at the contracted rate for inpatient care provided\nuntil the utilization review agent issues its determination on the prior\nauthorization request._\n\n_(d) Nothing in this subsection shall be interpreted to prohibit a health care\nprovider or enrollee from appealing an adverse determination as allowed under\nstate law. If an adverse determination is overturned on appeal, and no other\nlegal action related to the claim is pending, then the health carrier shall\nreimburse the health care provider at the contracted rate for inpatient care\nprovided to the enrollee._\n\n_(3) This section does not require a health benefit plan to cover care,\ntreatment, or services for a health condition that the terms of coverage\notherwise completely exclude from the policy 's covered benefits without\nregard for whether the care, treatment, or services are medically necessary._\n\n**Sec. 11.** _(1) On receipt of information documenting an approved prior\nauthorization from the enrollee or from the enrollee 's health care provider,\na utilization review agent shall honor the approved prior authorization\ngranted to an enrollee from a previous utilization review agent for at least\nthe initial sixty days of an enrollee's coverage under a new health benefit\nplan. During such time period, a utilization review agent may perform its own\nreview to grant a prior authorization._\n\n_(2) If there is a change in coverage of, or approval criteria for, a\npreviously authorized health care service, the change in coverage or approval\ncriteria does not affect a prior authorization request approved before the\neffective date of the change._\n\n_(3) A utilization review agent shall continue to honor a prior authorization\nit has granted to an enrollee when the enrollee changes health insurance\nproducts under the same health insurance company without any action required\nby the health care provider._\n\n**Sec. 12.** _(1) An artificial intelligence-based algorithm shall not be the\nsole basis of a utilization review agent 's decision to deny, delay, or modify\nhealth care services based, in whole or in part, on medical necessity._\n\n_(2) A utilization review agent shall disclose to the department, to each\nhealth care provider in its network, to each enrollee, and on its public\nwebsite if artificial intelligence-based algorithms are used or will be used\nin the utilization review process._\n\n_(3) The department may, at any time, audit a utilization review agent 's\nautomated utilization management system. The department may contract with a\nthird-party entity to perform an audit pursuant to this section._\n\n**Sec. 13.** _A utilization review agent shall not:_\n\n_(1) Be compensated based on its volume of denials; or_\n\n_(2) Base any incentive or penalty for a medical reviewer of such agent based\non the volume of denials such reviewer issues or upholds._\n\n**Sec. 14.** _For purposes of sections 14 to 16 of this act:_\n\n_(1) Biomarker means a characteristic that is objectively measured and\nevaluated as an indicator of normal biological processes, pathogenic\nprocesses, or pharmacologic responses to a specific therapeutic intervention,\nincluding known gene-drug interactions for medications being considered for\nuse or already being administered. Biomarkers include, but are not limited to,\ngene mutations, characteristics of genes, or protein expression;_\n\n_(2) Biomarker testing means the analysis of tissue, blood, or other\nbiospecimen for the presence of a biomarker. Biomarker testing includes, but\nis not limited to, single-analyte tests, multi-plex panel tests, protein\nexpression, and whole exome, whole genome, and whole transcriptome\nsequencing;_\n\n_(3) Clinical utility means sufficient medical and scientific evidence\nindicating that the use of a biomarker test will provide meaningful\ninformation that affects treatment decisions and guides improvement of net\nhealth outcomes including an improved quality of life or longer survival;_\n\n_(4) Consensus statements means statements developed by an independent,\nmultidisciplinary panel of experts utilizing a transparent methodology and\nreporting structure and with a conflict of interest policy. These statements\nare aimed at specific clinical circumstances and based on the best available\nevidence for the purpose of optimizing the outcomes of clinical care;_\n\n_(5) Health carrier has the same meaning as in section 44-1303; and_\n\n_(6) Nationally recognized clinical practice guidelines means evidence-based\nclinical practice guidelines developed by independent organizations or medical\nprofessional societies utilizing a transparent methodology and reporting\nstructure and with a conflict of interest policy. Clinical practice guidelines\nestablish standards of care informed by a systematic review of evidence and an\nassessment of the benefits and risks of alternative care options and include\nrecommendations intended to optimize patient care._\n\n**Sec. 15.** _(1) On and after January 1, 2028, and notwithstanding section\n44-3,131, (a) any individual or group sickness and accident insurance policy\nor subscriber contract delivered, issued for delivery, or renewed in this\nstate and any hospital, medical, or surgical expense-incurred policy, except\nfor policies that provide coverage for a specified disease or other limited-\nbenefit coverage and (b) any self-funded employee benefit plan to the extent\nnot preempted by federal law, shall include coverage for biomarker testing\npursuant to the criteria established under subsection (2) of this section._\n\n_(2) Biomarker testing shall be covered when:_\n\n_(a) The test is used for:_\n\n_(i) The diagnosis, treatment, appropriate management, or ongoing monitoring\nof cancer, an autoimmune or autoinflammatory disease, Parkinson 's disease,\namyotrophic lateral sclerosis, Alzheimer's disease and related dementias,\nrheumatoid arthritis, preeclampsia, sickle cell anemia, or a cardiovascular\ncondition;_\n\n_(ii) An organ or tissue transplant; or_\n\n_(iii) Pharmacogenomic testing; and_\n\n_(b) The test provides clinical utility as demonstrated by medical and\nscientific evidence, including, but not limited to:_\n\n_(i) Labeled indications for a test approved or cleared by the federal Food\nand Drug Administration;_\n\n_(ii) Indicated tests for a drug approved by the federal Food and Drug\nAdministration;_\n\n_(iii) Warnings and precautions on drug labels approved by the federal Food\nand Drug Administration;_\n\n_(iv) National coverage determinations by the federal Centers for Medicare and\nMedicaid Services or local coverage determinations by the medicare\nadministrative contractor; or_\n\n_(v) Nationally recognized clinical practice guidelines and consensus\nstatements._\n\n_(3) Coverage, as specified in subsection (2) of this section, shall be\nprovided in a manner that limits disruptions in care, including the need for\nmultiple biopsies or biospecimen samples._\n\n_(4) The patient and prescribing practitioner shall have access to a clear,\nreadily accessible, and convenient process to request an exception to a\ncoverage policy. The process shall be made readily accessible on the health\ncarrier 's website._\n\n**Sec. 16.** _(1) The medical assistance program shall cover biomarker testing\nno later than January 1, 2028._\n\n_(2) Biomarker testing shall be covered when:_\n\n_(a) The test is used for:_\n\n_(i) The diagnosis, treatment, appropriate management, or ongoing monitoring\nof cancer, an autoimmune or autoinflammatory disease, Parkinson 's disease,\namyotrophic lateral sclerosis, Alzheimer's disease and related dementias,\nrheumatoid arthritis, preeclampsia, sickle cell anemia, or a cardiovascular\ncondition;_\n\n_(ii) An organ or tissue transplant; or_\n\n_(iii) Pharmacogenomic testing; and_\n\n_(b) The test provides clinical utility as demonstrated by medical and\nscientific evidence, including, but not limited to:_\n\n_(i) Labeled indications for a test approved or cleared by the federal Food\nand Drug Administration;_\n\n_(ii) Indicated tests for a drug approved by the federal Food and Drug\nAdministration;_\n\n_(iii) Warnings and precautions on drug labels approved by the federal Food\nand Drug Administration;_\n\n_(iv) National coverage determinations by the federal Centers for Medicare and\nMedicaid Services or local coverage determinations by the medicare\nadministrative contractor; or_\n\n_(v) Nationally recognized clinical practice guidelines and consensus\nstatements._\n\n_(3) Coverage, as specified in subsection (2) of this section, shall be\nprovided in a manner that limits disruptions in care, including the need for\nmultiple biopsies or biospecimen samples._\n\n_(4) Entities contracting with the medical assistance program to deliver\nservices to program recipients shall provide biomarker testing at the same\nscope, duration, and frequency as the medical assistance program otherwise\nprovides to recipients._\n\n_(5) The recipient and participating medical assistance program provider shall\nhave access to a clear, readily accessible, and convenient process to request\nan exception to a coverage policy of the medical assistance program. The\nprocess shall be made readily accessible on the Department of Health and Human\nServices ' website._\n\n**Sec. 17.** Sections 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, and 13 of this act\nbecome operative on January 1, 2026. The other sections of this act become\noperative on their effective date.\n\n**Sec. 18.** If any section in this act or any part of any section is declared\ninvalid or unconstitutional, the declaration shall not affect the validity or\nconstitutionality of the remaining portions.\n\nCopyright (C) 2025 State Net  \n  \n---\n\n",
      "latest_version": false
    },
    {
      "date": "06/04/2025",
      "label": "Enacted - Interim",
      "url": "https://custom.statenet.com/public/resources.cgi?mode=show_text&id=ID:bill:NE2025000L77&verid=NE2025000L77_20250604_0_EI&",
      "raw_html": "<html>\n<head>\n<title>Bill Resource</title>\n\n<!--   <link href=\"https://custom.statenet.com/network/Common/css/extregtext.css\" rel=\"stylesheet\" type=\"text/css\" />-->\n   <link href=\"https://custom.statenet.com/network/Common/css/xmltext-2.0.css\" rel=\"stylesheet\" type=\"text/css\" />\n   <link href=\"https://custom.statenet.com/network/Common/css/additional-text.css\" rel=\"stylesheet\" type=\"text/css\" />\n\n\t<style type=\"text/css\">\n<!--\n\ntd, body {\n     background-color: white;\n\tfont-family: Verdana, Arial, Helvetica, sans-serif;\n\tfont-size: 12px;\n}\n\n.resourceContainer {\n   border: 1px solid black;\n}\n-->\n</style>\n</head>\n<body>\n\n    <div style=\"width: 750px; margin: auto\">\n       <div style=\"font-size: .8em;margin-bottom: 10px\"><table width=\"100%\"><tr><td align=\"left\" style=\"font-size: .8em;\"><div>The following has special meaning:</div>\n<div><u class=\"amendmentInsertedText\">green underline denotes added text</u></div>\n<div><strike class=\"amendmentDeletedText\">red struck out text denotes deleted text</strike></div></td> <td align=\"right\"><a href=\"https://www.lexisnexis.com/statenet/\"><img alt=\"Powered by State Net\" src=\"https://custom.statenet.com/network/poweredby.gif\" /></a></td></tr></table></div><table id=\"text-identifier\"><tr><td class=\"key\">2025 NE L 77</td> <td><table><tr><td class=\"label\">Author:</td> <td>Bostar</td></tr> <tr><td class=\"label\">Version:</td> <td>Enacted - Interim</td></tr> <tr><td class=\"label\">Version Date:</td> <td>06/04/2025</td></tr></table></td></tr></table><div class=\"documentBody\">\n  <a name=\"head_document_section\"></a><div class=\"head\">\n   <p class=\"center\">LEGISLATURE OF NEBRASKA</p>\n   <p class=\"center\">ONE HUNDRED NINTH LEGISLATURE</p>\n   <p class=\"center\">FIRST SESSION</p>\n   <p class=\"center\">\n    <b>LEGISLATIVE BILL 77</b>\n   </p>\n   <p class=\"center\">FINAL READING</p>\n   <p class=\"left\">Introduced by Bostar, 29.</p>\n   <p class=\"left\">Read first time January 09, 2025</p>\n   <p class=\"left\">Committee: Banking, Commerce and Insurance</p>\n  </div>\n  <a name=\"code_document_section\"></a><div class=\"code\">\n   <p class=\"left\">A BILL FOR AN ACT relating to insurance; to adopt the Ensuring Transparency in Prior Authorization Act; to provide for insurance and medicaid coverage of biomarker testing as prescribed; to provide operative dates; and to provide severability.</p>\n  </div>\n  <a name=\"text_document_section\"></a><div class=\"text\">\n   <span>\n    <p class=\"left\">Be it enacted by the people of the State of Nebraska,</p>\n   </span>\n   <p class=\"indent\">\n    <b>Section 1. </b>\n    <u class=\"amendmentInsertedText\">Sections 1 to 13 of this act shall be known and may be cited as the Ensuring Transparency in Prior Authorization Act.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 2. </b>\n    <u class=\"amendmentInsertedText\">For purposes of the Ensuring Transparency in Prior Authorization Act, unless the context otherwise requires:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(1) Adverse determination has the same meaning as in section 44-1303;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Clinical peer means a health care provider in the same, or in a similar, specialty that typically manages the medical condition or health care service under review;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) Clinical review criteria has the same meaning as in section 44-1303;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4) Department means the Department of Insurance;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(5) Emergency health care services means health care services medically necessary to screen and stabilize a patient in connection with an emergency medical condition until the health care provider determines such individual is able to travel using nonmedical transportation;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(6) Emergency medical condition has the same meaning as in section 44-1303;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(7) Enrollee means an individual who is enrolled in a health benefit plan, including covered dependents;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(8) General acute hospital has the same meaning as in section 71-412;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(9) Health benefit plan has the same meaning as in section 44-1303;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(10) Health care provider has the same meaning as in section 44-1303;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(11) Health care services has the same meaning as in section 44-1303;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(12) Health carrier has the same meaning as in section 44-1303, except that health carrier does not include a managed care agent;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(13) Medically necessary has the same meaning as in section 44-6845;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(14) Notice means communication delivered either electronically or through the United States Postal Service or a common carrier;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(15) Physician means an individual licensed under the Medicine and Surgery Practice Act to practice medicine and surgery or osteopathic medicine and surgery or an individual with an equivalent license from another United States jurisdiction;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(16) Prior authorization means the process by which a health carrier or utilization review agent makes a determination that a requested admission, extension of stay, or health care service has been reviewed and, based on the information provided, satisfies the health carrier&#39;s or utilization review agent&#39;s requirements for reimbursement under the applicable health benefit plan;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(17) Urgent health care service means a health care service with respect to which the application of the time periods prescribed under the Ensuring Transparency in Prior Authorization Act for making a nonexpedited prior authorization could, in the opinion of a physician with knowledge of the enrollee&#39;s medical condition:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) Seriously jeopardize the life or health of the enrollee or the ability of the enrollee to regain maximum function; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) Subject the enrollee to severe pain that cannot be adequately managed without the care or treatment that is the subject of the utilization review; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(18) Utilization review agent has the same meaning as in section 44-5418.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 3. </b>\n    <u class=\"amendmentInsertedText\">(1) A utilization review agent shall make prior authorization requirements and restrictions, including written clinical review criteria, accessible on its website. Such requirements, restrictions, and clinical review criteria shall be accurate and current and shall clearly communicate what information and documentation is needed to decide the prior authorization. Prior authorization requirements shall also be made available on the website in a searchable format no later than July 1, 2027.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) If a utilization review agent intends either to implement a new prior authorization requirement or restriction or to amend an existing requirement or restriction, the utilization review agent shall:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) Ensure that the new or amended requirement or restriction is not implemented unless the utilization review agent&#39;s website has been updated to reflect the new or amended requirement or restriction; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) Provide contracted health care providers with notice of the new or amended requirement or restriction no less than sixty days before the requirement or restriction is implemented.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 4. </b>\n    <u class=\"amendmentInsertedText\">(1) A utilization review agent shall ensure that all adverse determinations for prior authorization are made by a physician, except that if the requesting health care provider is not a physician, the adverse determination may be made by a clinical peer of the requesting health care provider. Such physician or clinical peer shall:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) Possess a current and valid nonrestricted license in a United States jurisdiction;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) Have the appropriate training, knowledge, or expertise to apply appropriate clinical guidelines to the health care service being requested; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) Make the adverse determination under the clinical direction of one of the utilization review agent&#39;s medical directors who is responsible for the provision of health care services provided to enrollees of Nebraska. All such medical directors must be physicians licensed in a United States jurisdiction.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) When an adverse determination for prior authorization is issued or a prior authorization is canceled or voided, the utilization review agent shall provide notice to the requesting health care provider. The notice shall include the reason for denial, citing written clinical review criteria.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3)(a) If an adverse determination for prior authorization questions the medical necessity, the appropriateness, or the experimental or investigational nature of a health care service, the enrollee&#39;s health care provider shall have the opportunity to discuss the health care service with the physician or clinical peer who is responsible for determining authorization of the health care service under review. The enrollee&#39;s health care provider may request that such discussion occur within three business days after receiving notice of the adverse determination. No discussion shall be required or allowed for an adverse determination that is due to contract exclusions or benefits that are not covered by the health benefit plan.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) Following any discussion under subdivision (3)(a) of this section, the utilization review agent shall notify the requesting health care provider whether the adverse determination decision remains the same. The notice under this subdivision shall be provided (i) within one business day after the discussion under subdivision (3)(a) of this section for an urgent health care service or (ii) within two business days after the discussion under subdivision (3)(a) of this section for a nonurgent health care service.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) A discussion under subdivision (3)(a) of this section shall not replace or eliminate the opportunity for any internal grievance or appeal process provided by the utilization review agent.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 5. </b>\n    <u class=\"amendmentInsertedText\">A utilization review agent shall ensure that all appeals of an adverse determination for prior authorization are reviewed by a physician. Such physician shall:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(1) Possess a current and valid unrestricted license in a United States jurisdiction;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Be of the same or similar specialty as the ordering physician or have the training and experience to treat the condition, which means that either:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) The physician maintains board certification for the same or similar specialty; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) The physician&#39;s training and experience (i) includes treating the condition, (ii) includes treating complications that may result from the health care service, and (iii) is sufficient for the physician to determine based on the physician&#39;s clinical judgment whether the health care service is medically necessary or clinically appropriate;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) Not have been directly involved in making the initial adverse determination;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4) Not have any financial interest in the outcome of the appeal; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(5) Consider all known clinical aspects of the health care service under review, including, but not limited to, a review of those medical records which are pertinent and relevant to the active condition provided to the utilization review agent by the enrollee&#39;s health care provider, or a health care facility, and any pertinent medical literature provided to the utilization review agent by the health care provider.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 6. </b>\n    <u class=\"amendmentInsertedText\">(1)(a) On or before November 1, 2025, the department shall approve a single uniform prior authorization request form for prescription drugs, devices, and durable medical equipment and a single uniform prior authorization request form for all other health care services. The uniform prior authorization request forms shall not exceed two printed pages in length. This two-page limit does not apply to information or documentation required by the utilization review agent, as published in accordance with subsection (1) of section 3 of this act, or a health care provider&#39;s notes or documentation submitted in support of a prior authorization request.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) Beginning January 1, 2026:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(i) All health care providers shall use only the approved uniform prior authorization request forms; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(ii) Except as provided in subsection (2) of this section, all utilization review agents shall accept and process prior authorization requests submitted using such forms.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) This subsection does not prohibit a utilization review agent from using a prior authorization methodology that uses an Internet webpage, an Internet webpage portal, or a similar web-based system if the methodology is consistent with the uniform prior authorization request forms approved by the department pursuant to this subsection.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) A utilization review agent may request from the department an exemption from the requirements of subsection (1) of this section if the utilization review agent implements and maintains a prior authorization application programming interface pursuant to 45 C.F.R. 156.223(b) or other electronic prior authorization methodology that automates and standardizes the prior authorization process for patients, health care providers, and health carriers. A utilization review agent shall provide notice to health care providers at least ninety days prior to implementing a prior authorization application programming interface or other electronic prior authorization methodology under this subsection.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 7. </b>\n    <u class=\"amendmentInsertedText\">(1) Prior to January 1, 2028, if a utilization review agent requires prior authorization of a health care service, the utilization review agent shall make a decision on the prior authorization request and provide notice of its decision to the enrollee and the enrollee&#39;s health care provider in accordance with the following timeframes:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) For a prior authorization request for urgent health care services, within seventy-two hours after obtaining all necessary information to make a decision; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) For a prior authorization request for nonurgent health care services, within seven days after obtaining all necessary information to make a decision.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Beginning January 1, 2028, if a utilization review agent requires prior authorization of a health care service, the utilization review agent shall make a decision on the prior authorization request and provide notice of its decision to the enrollee and the enrollee&#39;s health care provider in accordance with the following timeframes:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) For a prior authorization request for urgent health care services, within forty-eight hours after obtaining all necessary information to make a decision; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) For a prior authorization request for nonurgent health care services, within seven days after obtaining all necessary information to make a decision.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) Nothing in this section prohibits a health care provider and health carrier from contracting for shorter timeframes for using the prior authorization application programming interface or other electronic prior authorization methodology described in subsection (2) of section 6 of this act or as part of a risk-sharing agreement.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4) Health care services are deemed authorized if a utilization review agent fails to comply with the deadlines for making a decision as set forth in this section.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(5) In the notice to the health care provider that a prior authorization has been approved, the utilization review agent shall include the duration of the prior authorization or the date by which the prior authorization will expire.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 8. </b>\n    <u class=\"amendmentInsertedText\">No utilization review agent shall require prior authorization of:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(1) Emergency confinement or an emergency health care service;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Pre-hospital transportation for the provision of emergency health care services or for transfers between facilities as required by the federal Emergency Medical Treatment and Labor Act; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) Services that have a rating of A or B from the United States Preventive Services Task Force, immunizations recommended by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention, or preventive services and screenings provided to women as required by 45 C.F.R. 147.130.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 9. </b>\n    <u class=\"amendmentInsertedText\">(1) A utilization review agent shall not revoke, limit, condition, or restrict an approved prior authorization if care is provided within sixty days from the date the health care provider received the prior authorization approval unless the enrollee was no longer eligible for care on the day care was provided.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) A health carrier shall pay a contracted health care provider at the contracted payment rate for a health care service provided by the health care provider per an approved prior authorization request, unless:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) The health care provider knowingly and materially misrepresented the health care service or patient&#39;s medical history in the prior authorization request with the intent to deceive and obtain an unlawful payment under the health benefit plan;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) The health care service was no longer a covered benefit on the day it was provided;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) The health care provider was no longer contracted with the patient&#39;s health benefit plan on the date the care was provided;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(d) The health care provider failed to meet the utilization review agent&#39;s timely filing requirements;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(e) The patient was no longer eligible for health care coverage on the day the care was provided; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(f) The health care provider failed to obtain prior authorization approval before rendering health care services for which prior authorization was required.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 10. </b>\n    <u class=\"amendmentInsertedText\">(1) Except as otherwise provided in this section, prior authorization shall be valid for at least one year from the date the utilization review agent approves the prior authorization request, except for a prescription drug that has a treatment schedule or dosing limitation from the federal Food and Drug Administration of less than one year.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2)(a) If a prior authorization is required for inpatient care at a general acute hospital, the prior authorization shall remain valid for the length of stay approved by the utilization review agent.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) If the health care provider submits a timely request for the continuation of inpatient care, the utilization review agent shall respond to this request prior to the expiration of the current authorization for inpatient care.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) If a utilization review agent fails to respond to a timely request for the continuation of inpatient care prior to the termination of the previously approved length of stay, then the health carrier shall continue to compensate the health care provider at the contracted rate for inpatient care provided until the utilization review agent issues its determination on the prior authorization request.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(d) Nothing in this subsection shall be interpreted to prohibit a health care provider or enrollee from appealing an adverse determination as allowed under state law. If an adverse determination is overturned on appeal, and no other legal action related to the claim is pending, then the health carrier shall reimburse the health care provider at the contracted rate for inpatient care provided to the enrollee.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) This section does not require a health benefit plan to cover care, treatment, or services for a health condition that the terms of coverage otherwise completely exclude from the policy&#39;s covered benefits without regard for whether the care, treatment, or services are medically necessary.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 11. </b>\n    <u class=\"amendmentInsertedText\">(1) On receipt of information documenting an approved prior authorization from the enrollee or from the enrollee&#39;s health care provider, a utilization review agent shall honor the approved prior authorization granted to an enrollee from a previous utilization review agent for at least the initial sixty days of an enrollee&#39;s coverage under a new health benefit plan. During such time period, a utilization review agent may perform its own review to grant a prior authorization.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) If there is a change in coverage of, or approval criteria for, a previously authorized health care service, the change in coverage or approval criteria does not affect a prior authorization request approved before the effective date of the change.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) A utilization review agent shall continue to honor a prior authorization it has granted to an enrollee when the enrollee changes health insurance products under the same health insurance company without any action required by the health care provider.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 12. </b>\n    <u class=\"amendmentInsertedText\">(1) An artificial intelligence-based algorithm shall not be the sole basis of a utilization review agent&#39;s decision to deny, delay, or modify health care services based, in whole or in part, on medical necessity.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) A utilization review agent shall disclose to the department, to each health care provider in its network, to each enrollee, and on its public website if artificial intelligence-based algorithms are used or will be used in the utilization review process.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) The department may, at any time, audit a utilization review agent&#39;s automated utilization management system. The department may contract with a third-party entity to perform an audit pursuant to this section.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 13. </b>\n    <u class=\"amendmentInsertedText\">A utilization review agent shall not:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(1) Be compensated based on its volume of denials; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Base any incentive or penalty for a medical reviewer of such agent based on the volume of denials such reviewer issues or upholds.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 14. </b>\n    <u class=\"amendmentInsertedText\">For purposes of sections 14 to 16 of this act:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(1) Biomarker means a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a specific therapeutic intervention, including known gene-drug interactions for medications being considered for use or already being administered. Biomarkers include, but are not limited to, gene mutations, characteristics of genes, or protein expression;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Biomarker testing means the analysis of tissue, blood, or other biospecimen for the presence of a biomarker. Biomarker testing includes, but is not limited to, single-analyte tests, multi-plex panel tests, protein expression, and whole exome, whole genome, and whole transcriptome sequencing;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) Clinical utility means sufficient medical and scientific evidence indicating that the use of a biomarker test will provide meaningful information that affects treatment decisions and guides improvement of net health outcomes including an improved quality of life or longer survival;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4) Consensus statements means statements developed by an independent, multidisciplinary panel of experts utilizing a transparent methodology and reporting structure and with a conflict of interest policy. These statements are aimed at specific clinical circumstances and based on the best available evidence for the purpose of optimizing the outcomes of clinical care;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(5) Health carrier has the same meaning as in section 44-1303; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(6) Nationally recognized clinical practice guidelines means evidence-based clinical practice guidelines developed by independent organizations or medical professional societies utilizing a transparent methodology and reporting structure and with a conflict of interest policy. Clinical practice guidelines establish standards of care informed by a systematic review of evidence and an assessment of the benefits and risks of alternative care options and include recommendations intended to optimize patient care.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 15. </b>\n    <u class=\"amendmentInsertedText\">(1) On and after January 1, 2028, and notwithstanding section 44-3,131, (a) any individual or group sickness and accident insurance policy or subscriber contract delivered, issued for delivery, or renewed in this state and any hospital, medical, or surgical expense-incurred policy, except for policies that provide coverage for a specified disease or other limited-benefit coverage and (b) any self-funded employee benefit plan to the extent not preempted by federal law, shall include coverage for biomarker testing pursuant to the criteria established under subsection (2) of this section.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Biomarker testing shall be covered when:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) The test is used for:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(i) The diagnosis, treatment, appropriate management, or ongoing monitoring of cancer, an autoimmune or autoinflammatory disease, Parkinson&#39;s disease, amyotrophic lateral sclerosis, Alzheimer&#39;s disease and related dementias, rheumatoid arthritis, preeclampsia, sickle cell anemia, or a cardiovascular condition;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(ii) An organ or tissue transplant; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(iii) Pharmacogenomic testing; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) The test provides clinical utility as demonstrated by medical and scientific evidence, including, but not limited to:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(i) Labeled indications for a test approved or cleared by the federal Food and Drug Administration;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(ii) Indicated tests for a drug approved by the federal Food and Drug Administration;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(iii) Warnings and precautions on drug labels approved by the federal Food and Drug Administration;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(iv) National coverage determinations by the federal Centers for Medicare and Medicaid Services or local coverage determinations by the medicare administrative contractor; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(v) Nationally recognized clinical practice guidelines and consensus statements.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) Coverage, as specified in subsection (2) of this section, shall be provided in a manner that limits disruptions in care, including the need for multiple biopsies or biospecimen samples.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4) The patient and prescribing practitioner shall have access to a clear, readily accessible, and convenient process to request an exception to a coverage policy. The process shall be made readily accessible on the health carrier&#39;s website.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 16. </b>\n    <u class=\"amendmentInsertedText\">(1) The medical assistance program shall cover biomarker testing no later than January 1, 2028.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) Biomarker testing shall be covered when:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) The test is used for:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(i) The diagnosis, treatment, appropriate management, or ongoing monitoring of cancer, an autoimmune or autoinflammatory disease, Parkinson&#39;s disease, amyotrophic lateral sclerosis, Alzheimer&#39;s disease and related dementias, rheumatoid arthritis, preeclampsia, sickle cell anemia, or a cardiovascular condition;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(ii) An organ or tissue transplant; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(iii) Pharmacogenomic testing; and</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) The test provides clinical utility as demonstrated by medical and scientific evidence, including, but not limited to:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(i) Labeled indications for a test approved or cleared by the federal Food and Drug Administration;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(ii) Indicated tests for a drug approved by the federal Food and Drug Administration;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(iii) Warnings and precautions on drug labels approved by the federal Food and Drug Administration;</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(iv) National coverage determinations by the federal Centers for Medicare and Medicaid Services or local coverage determinations by the medicare administrative contractor; or</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(v) Nationally recognized clinical practice guidelines and consensus statements.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3) Coverage, as specified in subsection (2) of this section, shall be provided in a manner that limits disruptions in care, including the need for multiple biopsies or biospecimen samples.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4) Entities contracting with the medical assistance program to deliver services to program recipients shall provide biomarker testing at the same scope, duration, and frequency as the medical assistance program otherwise provides to recipients.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(5) The recipient and participating medical assistance program provider shall have access to a clear, readily accessible, and convenient process to request an exception to a coverage policy of the medical assistance program. The process shall be made readily accessible on the Department of Health and Human Services&#39; website.</u>\n   </p>\n   <p class=\"indent\">\n    <b>Sec. 17. </b> Sections 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, and 13 of this act become operative on January 1, 2026. The other sections of this act become operative on their effective date.</p>\n   <p class=\"indent\">\n    <b>Sec. 18. </b> If any section in this act or any part of any section is declared invalid or unconstitutional, the declaration shall not affect the validity or constitutionality of the remaining portions.</p>\n  </div>\n </div>\n    </div>\t\n<table cellpadding=0 cellspacing=0 width=\"100%\">\n   <tr>\n      <td>\n          Copyright &copy; 2025 State Net\n      </td>\n<BR>\n<!--???MOVED INTO resources.cgi      <td align=\"right\">\n          <img src=\"https://custom.statenet.com/network/poweredby.gif\" alt=\"Powered by State Net\">\n      </td>-->\n\n    </tr>\n</table>\n</body></html>\n",
      "markdown": "The following has special meaning: _green underline denotes added text_ ~~red struck out text denotes deleted text~~ | [![Powered by State Net](https://custom.statenet.com/network/poweredby.gif)](https://www.lexisnexis.com/statenet/)  \n---|---  \n  \n2025 NE L 77 | | Author: | Bostar  \n---|---  \nVersion: | Enacted - Interim  \nVersion Date: | 06/04/2025  \n  \nLEGISLATURE OF NEBRASKA\n\nONE HUNDRED NINTH LEGISLATURE\n\nFIRST SESSION\n\n**LEGISLATIVE BILL 77**\n\nFINAL READING\n\nIntroduced by Bostar, 29.\n\nRead first time January 09, 2025\n\nCommittee: Banking, Commerce and Insurance\n\nA BILL FOR AN ACT relating to insurance; to adopt the Ensuring Transparency in\nPrior Authorization Act; to provide for insurance and medicaid coverage of\nbiomarker testing as prescribed; to provide operative dates; and to provide\nseverability.\n\nBe it enacted by the people of the State of Nebraska,\n\n**Section 1.** _Sections 1 to 13 of this act shall be known and may be cited\nas the Ensuring Transparency in Prior Authorization Act._\n\n**Sec. 2.** _For purposes of the Ensuring Transparency in Prior Authorization\nAct, unless the context otherwise requires:_\n\n_(1) Adverse determination has the same meaning as in section 44-1303;_\n\n_(2) Clinical peer means a health care provider in the same, or in a similar,\nspecialty that typically manages the medical condition or health care service\nunder review;_\n\n_(3) Clinical review criteria has the same meaning as in section 44-1303;_\n\n_(4) Department means the Department of Insurance;_\n\n_(5) Emergency health care services means health care services medically\nnecessary to screen and stabilize a patient in connection with an emergency\nmedical condition until the health care provider determines such individual is\nable to travel using nonmedical transportation;_\n\n_(6) Emergency medical condition has the same meaning as in section 44-1303;_\n\n_(7) Enrollee means an individual who is enrolled in a health benefit plan,\nincluding covered dependents;_\n\n_(8) General acute hospital has the same meaning as in section 71-412;_\n\n_(9) Health benefit plan has the same meaning as in section 44-1303;_\n\n_(10) Health care provider has the same meaning as in section 44-1303;_\n\n_(11) Health care services has the same meaning as in section 44-1303;_\n\n_(12) Health carrier has the same meaning as in section 44-1303, except that\nhealth carrier does not include a managed care agent;_\n\n_(13) Medically necessary has the same meaning as in section 44-6845;_\n\n_(14) Notice means communication delivered either electronically or through\nthe United States Postal Service or a common carrier;_\n\n_(15) Physician means an individual licensed under the Medicine and Surgery\nPractice Act to practice medicine and surgery or osteopathic medicine and\nsurgery or an individual with an equivalent license from another United States\njurisdiction;_\n\n_(16) Prior authorization means the process by which a health carrier or\nutilization review agent makes a determination that a requested admission,\nextension of stay, or health care service has been reviewed and, based on the\ninformation provided, satisfies the health carrier 's or utilization review\nagent's requirements for reimbursement under the applicable health benefit\nplan;_\n\n_(17) Urgent health care service means a health care service with respect to\nwhich the application of the time periods prescribed under the Ensuring\nTransparency in Prior Authorization Act for making a nonexpedited prior\nauthorization could, in the opinion of a physician with knowledge of the\nenrollee 's medical condition:_\n\n_(a) Seriously jeopardize the life or health of the enrollee or the ability of\nthe enrollee to regain maximum function; or_\n\n_(b) Subject the enrollee to severe pain that cannot be adequately managed\nwithout the care or treatment that is the subject of the utilization review;\nand_\n\n_(18) Utilization review agent has the same meaning as in section 44-5418._\n\n**Sec. 3.** _(1) A utilization review agent shall make prior authorization\nrequirements and restrictions, including written clinical review criteria,\naccessible on its website. Such requirements, restrictions, and clinical\nreview criteria shall be accurate and current and shall clearly communicate\nwhat information and documentation is needed to decide the prior\nauthorization. Prior authorization requirements shall also be made available\non the website in a searchable format no later than July 1, 2027._\n\n_(2) If a utilization review agent intends either to implement a new prior\nauthorization requirement or restriction or to amend an existing requirement\nor restriction, the utilization review agent shall:_\n\n_(a) Ensure that the new or amended requirement or restriction is not\nimplemented unless the utilization review agent 's website has been updated to\nreflect the new or amended requirement or restriction; and_\n\n_(b) Provide contracted health care providers with notice of the new or\namended requirement or restriction no less than sixty days before the\nrequirement or restriction is implemented._\n\n**Sec. 4.** _(1) A utilization review agent shall ensure that all adverse\ndeterminations for prior authorization are made by a physician, except that if\nthe requesting health care provider is not a physician, the adverse\ndetermination may be made by a clinical peer of the requesting health care\nprovider. Such physician or clinical peer shall:_\n\n_(a) Possess a current and valid nonrestricted license in a United States\njurisdiction;_\n\n_(b) Have the appropriate training, knowledge, or expertise to apply\nappropriate clinical guidelines to the health care service being requested;\nand_\n\n_(c) Make the adverse determination under the clinical direction of one of the\nutilization review agent 's medical directors who is responsible for the\nprovision of health care services provided to enrollees of Nebraska. All such\nmedical directors must be physicians licensed in a United States\njurisdiction._\n\n_(2) When an adverse determination for prior authorization is issued or a\nprior authorization is canceled or voided, the utilization review agent shall\nprovide notice to the requesting health care provider. The notice shall\ninclude the reason for denial, citing written clinical review criteria._\n\n_(3)(a) If an adverse determination for prior authorization questions the\nmedical necessity, the appropriateness, or the experimental or investigational\nnature of a health care service, the enrollee 's health care provider shall\nhave the opportunity to discuss the health care service with the physician or\nclinical peer who is responsible for determining authorization of the health\ncare service under review. The enrollee's health care provider may request\nthat such discussion occur within three business days after receiving notice\nof the adverse determination. No discussion shall be required or allowed for\nan adverse determination that is due to contract exclusions or benefits that\nare not covered by the health benefit plan._\n\n_(b) Following any discussion under subdivision (3)(a) of this section, the\nutilization review agent shall notify the requesting health care provider\nwhether the adverse determination decision remains the same. The notice under\nthis subdivision shall be provided (i) within one business day after the\ndiscussion under subdivision (3)(a) of this section for an urgent health care\nservice or (ii) within two business days after the discussion under\nsubdivision (3)(a) of this section for a nonurgent health care service._\n\n_(c) A discussion under subdivision (3)(a) of this section shall not replace\nor eliminate the opportunity for any internal grievance or appeal process\nprovided by the utilization review agent._\n\n**Sec. 5.** _A utilization review agent shall ensure that all appeals of an\nadverse determination for prior authorization are reviewed by a physician.\nSuch physician shall:_\n\n_(1) Possess a current and valid unrestricted license in a United States\njurisdiction;_\n\n_(2) Be of the same or similar specialty as the ordering physician or have the\ntraining and experience to treat the condition, which means that either:_\n\n_(a) The physician maintains board certification for the same or similar\nspecialty; or_\n\n_(b) The physician 's training and experience (i) includes treating the\ncondition, (ii) includes treating complications that may result from the\nhealth care service, and (iii) is sufficient for the physician to determine\nbased on the physician's clinical judgment whether the health care service is\nmedically necessary or clinically appropriate;_\n\n_(3) Not have been directly involved in making the initial adverse\ndetermination;_\n\n_(4) Not have any financial interest in the outcome of the appeal; and_\n\n_(5) Consider all known clinical aspects of the health care service under\nreview, including, but not limited to, a review of those medical records which\nare pertinent and relevant to the active condition provided to the utilization\nreview agent by the enrollee 's health care provider, or a health care\nfacility, and any pertinent medical literature provided to the utilization\nreview agent by the health care provider._\n\n**Sec. 6.** _(1)(a) On or before November 1, 2025, the department shall\napprove a single uniform prior authorization request form for prescription\ndrugs, devices, and durable medical equipment and a single uniform prior\nauthorization request form for all other health care services. The uniform\nprior authorization request forms shall not exceed two printed pages in\nlength. This two-page limit does not apply to information or documentation\nrequired by the utilization review agent, as published in accordance with\nsubsection (1) of section 3 of this act, or a health care provider 's notes or\ndocumentation submitted in support of a prior authorization request._\n\n_(b) Beginning January 1, 2026:_\n\n_(i) All health care providers shall use only the approved uniform prior\nauthorization request forms; and_\n\n_(ii) Except as provided in subsection (2) of this section, all utilization\nreview agents shall accept and process prior authorization requests submitted\nusing such forms._\n\n_(c) This subsection does not prohibit a utilization review agent from using a\nprior authorization methodology that uses an Internet webpage, an Internet\nwebpage portal, or a similar web-based system if the methodology is consistent\nwith the uniform prior authorization request forms approved by the department\npursuant to this subsection._\n\n_(2) A utilization review agent may request from the department an exemption\nfrom the requirements of subsection (1) of this section if the utilization\nreview agent implements and maintains a prior authorization application\nprogramming interface pursuant to 45 C.F.R. 156.223(b) or other electronic\nprior authorization methodology that automates and standardizes the prior\nauthorization process for patients, health care providers, and health\ncarriers. A utilization review agent shall provide notice to health care\nproviders at least ninety days prior to implementing a prior authorization\napplication programming interface or other electronic prior authorization\nmethodology under this subsection._\n\n**Sec. 7.** _(1) Prior to January 1, 2028, if a utilization review agent\nrequires prior authorization of a health care service, the utilization review\nagent shall make a decision on the prior authorization request and provide\nnotice of its decision to the enrollee and the enrollee 's health care\nprovider in accordance with the following timeframes:_\n\n_(a) For a prior authorization request for urgent health care services, within\nseventy-two hours after obtaining all necessary information to make a\ndecision; or_\n\n_(b) For a prior authorization request for nonurgent health care services,\nwithin seven days after obtaining all necessary information to make a\ndecision._\n\n_(2) Beginning January 1, 2028, if a utilization review agent requires prior\nauthorization of a health care service, the utilization review agent shall\nmake a decision on the prior authorization request and provide notice of its\ndecision to the enrollee and the enrollee 's health care provider in\naccordance with the following timeframes:_\n\n_(a) For a prior authorization request for urgent health care services, within\nforty-eight hours after obtaining all necessary information to make a\ndecision; or_\n\n_(b) For a prior authorization request for nonurgent health care services,\nwithin seven days after obtaining all necessary information to make a\ndecision._\n\n_(3) Nothing in this section prohibits a health care provider and health\ncarrier from contracting for shorter timeframes for using the prior\nauthorization application programming interface or other electronic prior\nauthorization methodology described in subsection (2) of section 6 of this act\nor as part of a risk-sharing agreement._\n\n_(4) Health care services are deemed authorized if a utilization review agent\nfails to comply with the deadlines for making a decision as set forth in this\nsection._\n\n_(5) In the notice to the health care provider that a prior authorization has\nbeen approved, the utilization review agent shall include the duration of the\nprior authorization or the date by which the prior authorization will expire._\n\n**Sec. 8.** _No utilization review agent shall require prior authorization\nof:_\n\n_(1) Emergency confinement or an emergency health care service;_\n\n_(2) Pre-hospital transportation for the provision of emergency health care\nservices or for transfers between facilities as required by the federal\nEmergency Medical Treatment and Labor Act; or_\n\n_(3) Services that have a rating of A or B from the United States Preventive\nServices Task Force, immunizations recommended by the Advisory Committee on\nImmunization Practices of the Centers for Disease Control and Prevention, or\npreventive services and screenings provided to women as required by 45 C.F.R.\n147.130._\n\n**Sec. 9.** _(1) A utilization review agent shall not revoke, limit,\ncondition, or restrict an approved prior authorization if care is provided\nwithin sixty days from the date the health care provider received the prior\nauthorization approval unless the enrollee was no longer eligible for care on\nthe day care was provided._\n\n_(2) A health carrier shall pay a contracted health care provider at the\ncontracted payment rate for a health care service provided by the health care\nprovider per an approved prior authorization request, unless:_\n\n_(a) The health care provider knowingly and materially misrepresented the\nhealth care service or patient 's medical history in the prior authorization\nrequest with the intent to deceive and obtain an unlawful payment under the\nhealth benefit plan;_\n\n_(b) The health care service was no longer a covered benefit on the day it was\nprovided;_\n\n_(c) The health care provider was no longer contracted with the patient 's\nhealth benefit plan on the date the care was provided;_\n\n_(d) The health care provider failed to meet the utilization review agent 's\ntimely filing requirements;_\n\n_(e) The patient was no longer eligible for health care coverage on the day\nthe care was provided; or_\n\n_(f) The health care provider failed to obtain prior authorization approval\nbefore rendering health care services for which prior authorization was\nrequired._\n\n**Sec. 10.** _(1) Except as otherwise provided in this section, prior\nauthorization shall be valid for at least one year from the date the\nutilization review agent approves the prior authorization request, except for\na prescription drug that has a treatment schedule or dosing limitation from\nthe federal Food and Drug Administration of less than one year._\n\n_(2)(a) If a prior authorization is required for inpatient care at a general\nacute hospital, the prior authorization shall remain valid for the length of\nstay approved by the utilization review agent._\n\n_(b) If the health care provider submits a timely request for the continuation\nof inpatient care, the utilization review agent shall respond to this request\nprior to the expiration of the current authorization for inpatient care._\n\n_(c) If a utilization review agent fails to respond to a timely request for\nthe continuation of inpatient care prior to the termination of the previously\napproved length of stay, then the health carrier shall continue to compensate\nthe health care provider at the contracted rate for inpatient care provided\nuntil the utilization review agent issues its determination on the prior\nauthorization request._\n\n_(d) Nothing in this subsection shall be interpreted to prohibit a health care\nprovider or enrollee from appealing an adverse determination as allowed under\nstate law. If an adverse determination is overturned on appeal, and no other\nlegal action related to the claim is pending, then the health carrier shall\nreimburse the health care provider at the contracted rate for inpatient care\nprovided to the enrollee._\n\n_(3) This section does not require a health benefit plan to cover care,\ntreatment, or services for a health condition that the terms of coverage\notherwise completely exclude from the policy 's covered benefits without\nregard for whether the care, treatment, or services are medically necessary._\n\n**Sec. 11.** _(1) On receipt of information documenting an approved prior\nauthorization from the enrollee or from the enrollee 's health care provider,\na utilization review agent shall honor the approved prior authorization\ngranted to an enrollee from a previous utilization review agent for at least\nthe initial sixty days of an enrollee's coverage under a new health benefit\nplan. During such time period, a utilization review agent may perform its own\nreview to grant a prior authorization._\n\n_(2) If there is a change in coverage of, or approval criteria for, a\npreviously authorized health care service, the change in coverage or approval\ncriteria does not affect a prior authorization request approved before the\neffective date of the change._\n\n_(3) A utilization review agent shall continue to honor a prior authorization\nit has granted to an enrollee when the enrollee changes health insurance\nproducts under the same health insurance company without any action required\nby the health care provider._\n\n**Sec. 12.** _(1) An artificial intelligence-based algorithm shall not be the\nsole basis of a utilization review agent 's decision to deny, delay, or modify\nhealth care services based, in whole or in part, on medical necessity._\n\n_(2) A utilization review agent shall disclose to the department, to each\nhealth care provider in its network, to each enrollee, and on its public\nwebsite if artificial intelligence-based algorithms are used or will be used\nin the utilization review process._\n\n_(3) The department may, at any time, audit a utilization review agent 's\nautomated utilization management system. The department may contract with a\nthird-party entity to perform an audit pursuant to this section._\n\n**Sec. 13.** _A utilization review agent shall not:_\n\n_(1) Be compensated based on its volume of denials; or_\n\n_(2) Base any incentive or penalty for a medical reviewer of such agent based\non the volume of denials such reviewer issues or upholds._\n\n**Sec. 14.** _For purposes of sections 14 to 16 of this act:_\n\n_(1) Biomarker means a characteristic that is objectively measured and\nevaluated as an indicator of normal biological processes, pathogenic\nprocesses, or pharmacologic responses to a specific therapeutic intervention,\nincluding known gene-drug interactions for medications being considered for\nuse or already being administered. Biomarkers include, but are not limited to,\ngene mutations, characteristics of genes, or protein expression;_\n\n_(2) Biomarker testing means the analysis of tissue, blood, or other\nbiospecimen for the presence of a biomarker. Biomarker testing includes, but\nis not limited to, single-analyte tests, multi-plex panel tests, protein\nexpression, and whole exome, whole genome, and whole transcriptome\nsequencing;_\n\n_(3) Clinical utility means sufficient medical and scientific evidence\nindicating that the use of a biomarker test will provide meaningful\ninformation that affects treatment decisions and guides improvement of net\nhealth outcomes including an improved quality of life or longer survival;_\n\n_(4) Consensus statements means statements developed by an independent,\nmultidisciplinary panel of experts utilizing a transparent methodology and\nreporting structure and with a conflict of interest policy. These statements\nare aimed at specific clinical circumstances and based on the best available\nevidence for the purpose of optimizing the outcomes of clinical care;_\n\n_(5) Health carrier has the same meaning as in section 44-1303; and_\n\n_(6) Nationally recognized clinical practice guidelines means evidence-based\nclinical practice guidelines developed by independent organizations or medical\nprofessional societies utilizing a transparent methodology and reporting\nstructure and with a conflict of interest policy. Clinical practice guidelines\nestablish standards of care informed by a systematic review of evidence and an\nassessment of the benefits and risks of alternative care options and include\nrecommendations intended to optimize patient care._\n\n**Sec. 15.** _(1) On and after January 1, 2028, and notwithstanding section\n44-3,131, (a) any individual or group sickness and accident insurance policy\nor subscriber contract delivered, issued for delivery, or renewed in this\nstate and any hospital, medical, or surgical expense-incurred policy, except\nfor policies that provide coverage for a specified disease or other limited-\nbenefit coverage and (b) any self-funded employee benefit plan to the extent\nnot preempted by federal law, shall include coverage for biomarker testing\npursuant to the criteria established under subsection (2) of this section._\n\n_(2) Biomarker testing shall be covered when:_\n\n_(a) The test is used for:_\n\n_(i) The diagnosis, treatment, appropriate management, or ongoing monitoring\nof cancer, an autoimmune or autoinflammatory disease, Parkinson 's disease,\namyotrophic lateral sclerosis, Alzheimer's disease and related dementias,\nrheumatoid arthritis, preeclampsia, sickle cell anemia, or a cardiovascular\ncondition;_\n\n_(ii) An organ or tissue transplant; or_\n\n_(iii) Pharmacogenomic testing; and_\n\n_(b) The test provides clinical utility as demonstrated by medical and\nscientific evidence, including, but not limited to:_\n\n_(i) Labeled indications for a test approved or cleared by the federal Food\nand Drug Administration;_\n\n_(ii) Indicated tests for a drug approved by the federal Food and Drug\nAdministration;_\n\n_(iii) Warnings and precautions on drug labels approved by the federal Food\nand Drug Administration;_\n\n_(iv) National coverage determinations by the federal Centers for Medicare and\nMedicaid Services or local coverage determinations by the medicare\nadministrative contractor; or_\n\n_(v) Nationally recognized clinical practice guidelines and consensus\nstatements._\n\n_(3) Coverage, as specified in subsection (2) of this section, shall be\nprovided in a manner that limits disruptions in care, including the need for\nmultiple biopsies or biospecimen samples._\n\n_(4) The patient and prescribing practitioner shall have access to a clear,\nreadily accessible, and convenient process to request an exception to a\ncoverage policy. The process shall be made readily accessible on the health\ncarrier 's website._\n\n**Sec. 16.** _(1) The medical assistance program shall cover biomarker testing\nno later than January 1, 2028._\n\n_(2) Biomarker testing shall be covered when:_\n\n_(a) The test is used for:_\n\n_(i) The diagnosis, treatment, appropriate management, or ongoing monitoring\nof cancer, an autoimmune or autoinflammatory disease, Parkinson 's disease,\namyotrophic lateral sclerosis, Alzheimer's disease and related dementias,\nrheumatoid arthritis, preeclampsia, sickle cell anemia, or a cardiovascular\ncondition;_\n\n_(ii) An organ or tissue transplant; or_\n\n_(iii) Pharmacogenomic testing; and_\n\n_(b) The test provides clinical utility as demonstrated by medical and\nscientific evidence, including, but not limited to:_\n\n_(i) Labeled indications for a test approved or cleared by the federal Food\nand Drug Administration;_\n\n_(ii) Indicated tests for a drug approved by the federal Food and Drug\nAdministration;_\n\n_(iii) Warnings and precautions on drug labels approved by the federal Food\nand Drug Administration;_\n\n_(iv) National coverage determinations by the federal Centers for Medicare and\nMedicaid Services or local coverage determinations by the medicare\nadministrative contractor; or_\n\n_(v) Nationally recognized clinical practice guidelines and consensus\nstatements._\n\n_(3) Coverage, as specified in subsection (2) of this section, shall be\nprovided in a manner that limits disruptions in care, including the need for\nmultiple biopsies or biospecimen samples._\n\n_(4) Entities contracting with the medical assistance program to deliver\nservices to program recipients shall provide biomarker testing at the same\nscope, duration, and frequency as the medical assistance program otherwise\nprovides to recipients._\n\n_(5) The recipient and participating medical assistance program provider shall\nhave access to a clear, readily accessible, and convenient process to request\nan exception to a coverage policy of the medical assistance program. The\nprocess shall be made readily accessible on the Department of Health and Human\nServices ' website._\n\n**Sec. 17.** Sections 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, and 13 of this act\nbecome operative on January 1, 2026. The other sections of this act become\noperative on their effective date.\n\n**Sec. 18.** If any section in this act or any part of any section is declared\ninvalid or unconstitutional, the declaration shall not affect the validity or\nconstitutionality of the remaining portions.\n\nCopyright (C) 2025 State Net  \n  \n---\n\n",
      "latest_version": true
    },
    {
      "date": "06/04/2025",
      "label": "Enacted - Slip Law",
      "url": "https://custom.statenet.com/public/resources.cgi?mode=show_text&id=ID:bill:NE2025000L77&verid=NE2025000L77_20250604_0_ESL&",
      "raw_html": "<html>\n<head>\n<title>Bill Resource</title>\n\n<!--   <link href=\"https://custom.statenet.com/network/Common/css/extregtext.css\" rel=\"stylesheet\" type=\"text/css\" />-->\n   <link href=\"https://custom.statenet.com/network/Common/css/xmltext-2.0.css\" rel=\"stylesheet\" type=\"text/css\" />\n   <link href=\"https://custom.statenet.com/network/Common/css/additional-text.css\" rel=\"stylesheet\" type=\"text/css\" />\n\n\t<style type=\"text/css\">\n<!--\n\ntd, body {\n     background-color: white;\n\tfont-family: Verdana, Arial, Helvetica, sans-serif;\n\tfont-size: 12px;\n}\n\n.resourceContainer {\n   border: 1px solid black;\n}\n-->\n</style>\n</head>\n<body>\n\n    <div style=\"width: 750px; margin: auto\">\n       <div style=\"font-size: .8em;margin-bottom: 10px\"><table width=\"100%\"><tr><td align=\"left\" style=\"font-size: .8em;\"><div>The following has special meaning:</div>\n<div><u class=\"amendmentInsertedText\">green underline denotes added text</u></div>\n<div><strike class=\"amendmentDeletedText\">red struck out text denotes deleted text</strike></div></td> <td align=\"right\"><a href=\"https://www.lexisnexis.com/statenet/\"><img alt=\"Powered by State Net\" src=\"https://custom.statenet.com/network/poweredby.gif\" /></a></td></tr></table></div><table id=\"text-identifier\"><tr><td class=\"key\">2025 NE L 77</td> <td><table><tr><td class=\"label\">Author:</td> <td>Bostar</td></tr> <tr><td class=\"label\">Version:</td> <td>Enacted - Slip Law</td></tr> <tr><td class=\"label\">Version Date:</td> <td>06/04/2025</td></tr></table></td></tr></table><div class=\"documentBody\">\n  <a name=\"head_document_section\"></a><div class=\"head\">\n   <p class=\"center\">\n    <b>LEGISLATIVE BILL 77</b>\n   </p>\n   <p class=\"center\">Approved by the Governor June 4, 2025</p>\n   <p class=\"left\">Introduced by Bostar, 29.</p>\n  </div>\n  <a name=\"code_document_section\"></a><div class=\"code\">\n   <p class=\"indent\">A BILL FOR AN ACT relating to insurance; to adopt the Ensuring Transparency in Prior Authorization Act; to provide for insurance and medicaid coverage of biomarker testing as prescribed; to provide operative dates; and to provide severability.</p>\n  </div>\n  <a name=\"text_document_section\"></a><div class=\"text\">\n   <span>\n    <p class=\"left\">Be it enacted by the people of the State of Nebraska,</p>\n   </span>\n   <a name=\"section-__-___-new\"></a><div title=\"Section: __-___, Action: &quot;new&quot;\" class=\"sectionContent\">\n    <p class=\"indent\">\n     <b>Section 1. </b>\n     <u class=\"amendmentInsertedText\">Sections 1 to 13 of this act shall be known and may be cited as the Ensuring Transparency in Prior Authorization Act.</u>\n    </p>\n   </div>\n   <a name=\"section-__-___-new\"></a><div class=\"sectionContent\" title=\"Section: __-___, Action: &quot;new&quot;\">\n    <p class=\"indent\">\n     <b>Sec. 2. </b>\n     <u class=\"amendmentInsertedText\">For purposes of the Ensuring Transparency in Prior Authorization Act, unless the context otherwise requires:</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(1) Adverse determination has the same meaning as in section 44-1303;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(2) Clinical peer means a health care provider in the same, or in a similar, specialty that typically manages the medical condition or health care service under review;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(3) Clinical review criteria has the same meaning as in section 44-1303;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(4) Department means the Department of Insurance;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(5) Emergency health care services means health care services medically necessary to screen and stabilize a patient in connection with an emergency medical condition until the health care provider determines such individual is able to travel using nonmedical transportation;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(6) Emergency medical condition has the same meaning as in section 44-1303;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(7) Enrollee means an individual who is enrolled in a health benefit plan, including covered dependents;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(8) General acute hospital has the same meaning as in section 71-412;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(9) Health benefit plan has the same meaning as in section 44-1303;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(10) Health care provider has the same meaning as in section 44-1303;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(11) Health care services has the same meaning as in section 44-1303;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(12) Health carrier has the same meaning as in section 44-1303, except that health carrier does not include a managed care agent;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(13) Medically necessary has the same meaning as in section 44-6845;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(14) Notice means communication delivered either electronically or through the United States Postal Service or a common carrier;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(15) Physician means an individual licensed under the Medicine and Surgery Practice Act to practice medicine and surgery or osteopathic medicine and surgery or an individual with an equivalent license from another United States jurisdiction;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(16) Prior authorization means the process by which a health carrier or utilization review agent makes a determination that a requested admission, extension of stay, or health care service has been reviewed and, based on the information provided, satisfies the health carrier&#39;s or utilization review agent&#39;s requirements for reimbursement under the applicable health benefit plan;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(17) Urgent health care service means a health care service with respect to which the application of the time periods prescribed under the Ensuring Transparency in Prior Authorization Act for making a nonexpedited prior authorization could, in the opinion of a physician with knowledge of the enrollee&#39;s medical condition:</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(a) Seriously jeopardize the life or health of the enrollee or the ability of the enrollee to regain maximum function; or</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(b) Subject the enrollee to severe pain that cannot be adequately managed without the care or treatment that is the subject of the utilization review; and</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(18) Utilization review agent has the same meaning as in section 44-5418.</u>\n    </p>\n   </div>\n   <a name=\"section-__-___-new\"></a><div class=\"sectionContent\" title=\"Section: __-___, Action: &quot;new&quot;\">\n    <p class=\"indent\">\n     <b>Sec. 3. </b>\n     <u class=\"amendmentInsertedText\">(1) A utilization review agent shall make prior authorization requirements and restrictions, including written clinical review criteria, accessible on its website. Such requirements, restrictions, and clinical review criteria shall be accurate and current and shall clearly communicate what information and documentation is needed to decide the prior authorization. Prior authorization requirements shall also be made available on the website in a searchable format no later than July 1, 2027.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(2) If a utilization review agent intends either to implement a new prior authorization requirement or restriction or to amend an existing requirement or restriction, the utilization review agent shall:</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(a) Ensure that the new or amended requirement or restriction is not implemented unless the utilization review agent&#39;s website has been updated to reflect the new or amended requirement or restriction; and</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(b) Provide contracted health care providers with notice of the new or amended requirement or restriction no less than sixty days before the requirement or restriction is implemented.</u>\n    </p>\n   </div>\n   <a name=\"section-__-___-new\"></a><div title=\"Section: __-___, Action: &quot;new&quot;\" class=\"sectionContent\">\n    <p class=\"indent\">\n     <b>Sec. 4. </b>\n     <u class=\"amendmentInsertedText\">(1) A utilization review agent shall ensure that all adverse determinations for prior authorization are made by a physician, except that if the requesting health care provider is not a physician, the adverse determination may be made by a clinical peer of the requesting health care provider. Such physician or clinical peer shall:</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(a) Possess a current and valid nonrestricted license in a United States jurisdiction;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(b) Have the appropriate training, knowledge, or expertise to apply appropriate clinical guidelines to the health care service being requested; and</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(c) Make the adverse determination under the clinical direction of one of the utilization review agent&#39;s medical directors who is responsible for the provision of health care services provided to enrollees of Nebraska. All such medical directors must be physicians licensed in a United States jurisdiction.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(2) When an adverse determination for prior authorization is issued or a prior authorization is canceled or voided, the utilization review agent shall provide notice to the requesting health care provider. The notice shall include the reason for denial, citing written clinical review criteria.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(3)(a) If an adverse determination for prior authorization questions the medical necessity, the appropriateness, or the experimental or investigational nature of a health care service, the enrollee&#39;s health care provider shall have the opportunity to discuss the health care service with the physician or clinical peer who is responsible for determining authorization of the health care service under review. The enrollee&#39;s health care provider may request that such discussion occur within three business days after receiving notice of the adverse determination. No discussion shall be required or allowed for an adverse determination that is due to contract exclusions or benefits that are not covered by the health benefit plan.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(b) Following any discussion under subdivision (3)(a) of this section, the utilization review agent shall notify the requesting health care provider whether the adverse determination decision remains the same. The notice under this subdivision shall be provided (i) within one business day after the discussion under subdivision (3)(a) of this section for an urgent health care service or (ii) within two business days after the discussion under subdivision (3)(a) of this section for a nonurgent health care service.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(c) A discussion under subdivision (3)(a) of this section shall not replace or eliminate the opportunity for any internal grievance or appeal process provided by the utilization review agent.</u>\n    </p>\n   </div>\n   <a name=\"section-__-___-new\"></a><div title=\"Section: __-___, Action: &quot;new&quot;\" class=\"sectionContent\">\n    <p class=\"indent\">\n     <b>Sec. 5. </b>\n     <u class=\"amendmentInsertedText\">A utilization review agent shall ensure that all appeals of an adverse determination for prior authorization are reviewed by a physician. Such physician shall:</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(1) Possess a current and valid unrestricted license in a United States jurisdiction;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(2) Be of the same or similar specialty as the ordering physician or have the training and experience to treat the condition, which means that either:</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(a) The physician maintains board certification for the same or similar specialty; or</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(b) The physician&#39;s training and experience (i) includes treating the condition, (ii) includes treating complications that may result from the health care service, and (iii) is sufficient for the physician to determine based on the physician&#39;s clinical judgment whether the health care service is medically necessary or clinically appropriate;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(3) Not have been directly involved in making the initial adverse determination;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(4) Not have any financial interest in the outcome of the appeal; and</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(5) Consider all known clinical aspects of the health care service under review, including, but not limited to, a review of those medical records which are pertinent and relevant to the active condition provided to the utilization review agent by the enrollee&#39;s health care provider, or a health care facility, and any pertinent medical literature provided to the utilization review agent by the health care provider.</u>\n    </p>\n   </div>\n   <a name=\"section-__-___-new\"></a><div class=\"sectionContent\" title=\"Section: __-___, Action: &quot;new&quot;\">\n    <p class=\"indent\">\n     <b>Sec. 6. </b>\n     <u class=\"amendmentInsertedText\">(1)(a) On or before November 1, 2025, the department shall approve a single uniform prior authorization request form for prescription drugs, devices, and durable medical equipment and a single uniform prior authorization request form for all other health care services. The uniform prior authorization request forms shall not exceed two printed pages in length. This two-page limit does not apply to information or documentation required by the utilization review agent, as published in accordance with subsection (1) of section 3 of this act, or a health care provider&#39;s notes or documentation submitted in support of a prior authorization request.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(b) Beginning January 1, 2026:</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(i) All health care providers shall use only the approved uniform prior authorization request forms; and</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(ii) Except as provided in subsection (2) of this section, all utilization review agents shall accept and process prior authorization requests submitted using such forms.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(c) This subsection does not prohibit a utilization review agent from using a prior authorization methodology that uses an Internet webpage, an Internet webpage portal, or a similar web-based system if the methodology is consistent with the uniform prior authorization request forms approved by the department pursuant to this subsection.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(2) A utilization review agent may request from the department an exemption from the requirements of subsection (1) of this section if the utilization review agent implements and maintains a prior authorization application programming interface pursuant to 45 C.F.R. 156.223(b) or other electronic prior authorization methodology that automates and standardizes the prior authorization process for patients, health care providers, and health carriers. A utilization review agent shall provide notice to health care providers at least ninety days prior to implementing a prior authorization application programming interface or other electronic prior authorization methodology under this subsection.</u>\n    </p>\n   </div>\n   <a name=\"section-__-___-new\"></a><div class=\"sectionContent\" title=\"Section: __-___, Action: &quot;new&quot;\">\n    <p class=\"indent\">\n     <b>Sec. 7. </b>\n     <u class=\"amendmentInsertedText\">(1) Prior to January 1, 2028, if a utilization review agent requires prior authorization of a health care service, the utilization review agent shall make a decision on the prior authorization request and provide notice of its decision to the enrollee and the enrollee&#39;s health care provider in accordance with the following timeframes:</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(a) For a prior authorization request for urgent health care services, within seventy-two hours after obtaining all necessary information to make a decision; or</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(b) For a prior authorization request for nonurgent health care services, within seven days after obtaining all necessary information to make a decision.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(2) Beginning January 1, 2028, if a utilization review agent requires prior authorization of a health care service, the utilization review agent shall make a decision on the prior authorization request and provide notice of its decision to the enrollee and the enrollee&#39;s health care provider in accordance with the following timeframes:</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(a) For a prior authorization request for urgent health care services, within forty-eight hours after obtaining all necessary information to make a decision; or</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(b) For a prior authorization request for nonurgent health care services, within seven days after obtaining all necessary information to make a decision.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(3) Nothing in this section prohibits a health care provider and health carrier from contracting for shorter timeframes for using the prior authorization application programming interface or other electronic prior authorization methodology described in subsection (2) of section 6 of this act or as part of a risk-sharing agreement.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(4) Health care services are deemed authorized if a utilization review agent fails to comply with the deadlines for making a decision as set forth in this section.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(5) In the notice to the health care provider that a prior authorization has been approved, the utilization review agent shall include the duration of the prior authorization or the date by which the prior authorization will expire.</u>\n    </p>\n   </div>\n   <a name=\"section-__-___-new\"></a><div title=\"Section: __-___, Action: &quot;new&quot;\" class=\"sectionContent\">\n    <p class=\"indent\">\n     <b>Sec. 8. </b>\n     <u class=\"amendmentInsertedText\">No utilization review agent shall require prior authorization of:</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(1) Emergency confinement or an emergency health care service;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(2) Pre-hospital transportation for the provision of emergency health care services or for transfers between facilities as required by the federal Emergency Medical Treatment and Labor Act; or</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(3) Services that have a rating of A or B from the United States Preventive Services Task Force, immunizations recommended by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention, or preventive services and screenings provided to women as required by 45 C.F.R. 147.130.</u>\n    </p>\n   </div>\n   <a name=\"section-__-___-new\"></a><div title=\"Section: __-___, Action: &quot;new&quot;\" class=\"sectionContent\">\n    <p class=\"indent\">\n     <b>Sec. 9. </b>\n     <u class=\"amendmentInsertedText\">(1) A utilization review agent shall not revoke, limit, condition, or restrict an approved prior authorization if care is provided within sixty days from the date the health care provider received the prior authorization approval unless the enrollee was no longer eligible for care on the day care was provided.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(2) A health carrier shall pay a contracted health care provider at the contracted payment rate for a health care service provided by the health care provider per an approved prior authorization request, unless:</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(a) The health care provider knowingly and materially misrepresented the health care service or patient&#39;s medical history in the prior authorization request with the intent to deceive and obtain an unlawful payment under the health benefit plan;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(b) The health care service was no longer a covered benefit on the day it was provided;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(c) The health care provider was no longer contracted with the patient&#39;s health benefit plan on the date the care was provided;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(d) The health care provider failed to meet the utilization review agent&#39;s timely filing requirements;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(e) The patient was no longer eligible for health care coverage on the day the care was provided; or</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(f) The health care provider failed to obtain prior authorization approval before rendering health care services for which prior authorization was required.</u>\n    </p>\n   </div>\n   <a name=\"section-__-___-new\"></a><div class=\"sectionContent\" title=\"Section: __-___, Action: &quot;new&quot;\">\n    <p class=\"indent\">\n     <b>Sec. 10. </b>\n     <u class=\"amendmentInsertedText\">(1) Except as otherwise provided in this section, prior authorization shall be valid for at least one year from the date the utilization review agent approves the prior authorization request, except for a prescription drug that has a treatment schedule or dosing limitation from the federal Food and Drug Administration of less than one year.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(2)(a) If a prior authorization is required for inpatient care at a general acute hospital, the prior authorization shall remain valid for the length of stay approved by the utilization review agent.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(b) If the health care provider submits a timely request for the continuation of inpatient care, the utilization review agent shall respond to this request prior to the expiration of the current authorization for inpatient care.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(c) If a utilization review agent fails to respond to a timely request for the continuation of inpatient care prior to the termination of the previously approved length of stay, then the health carrier shall continue to compensate the health care provider at the contracted rate for inpatient care provided until the utilization review agent issues its determination on the prior authorization request.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(d) Nothing in this subsection shall be interpreted to prohibit a health care provider or enrollee from appealing an adverse determination as allowed under state law. If an adverse determination is overturned on appeal, and no other legal action related to the claim is pending, then the health carrier shall reimburse the health care provider at the contracted rate for inpatient care provided to the enrollee.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(3) This section does not require a health benefit plan to cover care, treatment, or services for a health condition that the terms of coverage otherwise completely exclude from the policy&#39;s covered benefits without regard for whether the care, treatment, or services are medically necessary.</u>\n    </p>\n   </div>\n   <a name=\"section-__-___-new\"></a><div class=\"sectionContent\" title=\"Section: __-___, Action: &quot;new&quot;\">\n    <p class=\"indent\">\n     <b>Sec. 11. </b>\n     <u class=\"amendmentInsertedText\">(1) On receipt of information documenting an approved prior authorization from the enrollee or from the enrollee&#39;s health care provider, a utilization review agent shall honor the approved prior authorization granted to an enrollee from a previous utilization review agent for at least the initial sixty days of an enrollee&#39;s coverage under a new health benefit plan. During such time period, a utilization review agent may perform its own review to grant a prior authorization.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(2) If there is a change in coverage of, or approval criteria for, a previously authorized health care service, the change in coverage or approval criteria does not affect a prior authorization request approved before the effective date of the change.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(3) A utilization review agent shall continue to honor a prior authorization it has granted to an enrollee when the enrollee changes health insurance products under the same health insurance company without any action required by the health care provider.</u>\n    </p>\n   </div>\n   <a name=\"section-__-___-new\"></a><div class=\"sectionContent\" title=\"Section: __-___, Action: &quot;new&quot;\">\n    <p class=\"indent\">\n     <b>Sec. 12. </b>\n     <u class=\"amendmentInsertedText\">(1) An artificial intelligence-based algorithm shall not be the sole basis of a utilization review agent&#39;s decision to deny, delay, or modify health care services based, in whole or in part, on medical necessity.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(2) A utilization review agent shall disclose to the department, to each health care provider in its network, to each enrollee, and on its public website if artificial intelligence-based algorithms are used or will be used in the utilization review process.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(3) The department may, at any time, audit a utilization review agent&#39;s automated utilization management system. The department may contract with a third-party entity to perform an audit pursuant to this section.</u>\n    </p>\n   </div>\n   <a name=\"section-__-___-new\"></a><div class=\"sectionContent\" title=\"Section: __-___, Action: &quot;new&quot;\">\n    <p class=\"indent\">\n     <b>Sec. 13. </b>\n     <u class=\"amendmentInsertedText\">A utilization review agent shall not:</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(1) Be compensated based on its volume of denials; or</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(2) Base any incentive or penalty for a medical reviewer of such agent based on the volume of denials such reviewer issues or upholds.</u>\n    </p>\n   </div>\n   <a name=\"section-__-___-new\"></a><div title=\"Section: __-___, Action: &quot;new&quot;\" class=\"sectionContent\">\n    <p class=\"indent\">\n     <b>Sec. 14. </b>\n     <u class=\"amendmentInsertedText\">For purposes of sections 14 to 16 of this act:</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(1) Biomarker means a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a specific therapeutic intervention, including known gene-drug interactions for medications being considered for use or already being administered. Biomarkers include, but are not limited to, gene mutations, characteristics of genes, or protein expression;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(2) Biomarker testing means the analysis of tissue, blood, or other biospecimen for the presence of a biomarker. Biomarker testing includes, but is not limited to, single-analyte tests, multi-plex panel tests, protein expression, and whole exome, whole genome, and whole transcriptome sequencing;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(3) Clinical utility means sufficient medical and scientific evidence indicating that the use of a biomarker test will provide meaningful information that affects treatment decisions and guides improvement of net health outcomes including an improved quality of life or longer survival;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(4) Consensus statements means statements developed by an independent, multidisciplinary panel of experts utilizing a transparent methodology and reporting structure and with a conflict of interest policy. These statements are aimed at specific clinical circumstances and based on the best available evidence for the purpose of optimizing the outcomes of clinical care;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(5) Health carrier has the same meaning as in section 44-1303; and</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(6) Nationally recognized clinical practice guidelines means evidence-based clinical practice guidelines developed by independent organizations or medical professional societies utilizing a transparent methodology and reporting structure and with a conflict of interest policy. Clinical practice guidelines establish standards of care informed by a systematic review of evidence and an assessment of the benefits and risks of alternative care options and include recommendations intended to optimize patient care.</u>\n    </p>\n   </div>\n   <a name=\"section-__-___-new\"></a><div title=\"Section: __-___, Action: &quot;new&quot;\" class=\"sectionContent\">\n    <p class=\"indent\">\n     <b>Sec. 15. </b>\n     <u class=\"amendmentInsertedText\">(1) On and after January 1, 2028, and notwithstanding section 44-3,131, (a) any individual or group sickness and accident insurance policy or subscriber contract delivered, issued for delivery, or renewed in this state and any hospital, medical, or surgical expense-incurred policy, except for policies that provide coverage for a specified disease or other limited-benefit coverage and (b) any self-funded employee benefit plan to the extent not preempted by federal law, shall include coverage for biomarker testing pursuant to the criteria established under subsection (2) of this section.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(2) Biomarker testing shall be covered when:</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(a) The test is used for:</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(i) The diagnosis, treatment, appropriate management, or ongoing monitoring of cancer, an autoimmune or autoinflammatory disease, Parkinson&#39;s disease, amyotrophic lateral sclerosis, Alzheimer&#39;s disease and related dementias, rheumatoid arthritis, preeclampsia, sickle cell anemia, or a cardiovascular condition;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(ii) An organ or tissue transplant; or</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(iii) Pharmacogenomic testing; and</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(b) The test provides clinical utility as demonstrated by medical and scientific evidence, including, but not limited to:</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(i) Labeled indications for a test approved or cleared by the federal Food and Drug Administration;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(ii) Indicated tests for a drug approved by the federal Food and Drug Administration;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(iii) Warnings and precautions on drug labels approved by the federal Food and Drug Administration;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(iv) National coverage determinations by the federal Centers for Medicare and Medicaid Services or local coverage determinations by the medicare administrative contractor; or</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(v) Nationally recognized clinical practice guidelines and consensus statements.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(3) Coverage, as specified in subsection (2) of this section, shall be provided in a manner that limits disruptions in care, including the need for multiple biopsies or biospecimen samples.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(4) The patient and prescribing practitioner shall have access to a clear, readily accessible, and convenient process to request an exception to a coverage policy. The process shall be made readily accessible on the health carrier&#39;s website.</u>\n    </p>\n   </div>\n   <a name=\"section-__-___-new\"></a><div class=\"sectionContent\" title=\"Section: __-___, Action: &quot;new&quot;\">\n    <p class=\"indent\">\n     <b>Sec. 16. </b>\n     <u class=\"amendmentInsertedText\">(1) The medical assistance program shall cover biomarker testing no later than January 1, 2028.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(2) Biomarker testing shall be covered when:</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(a) The test is used for:</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(i) The diagnosis, treatment, appropriate management, or ongoing monitoring of cancer, an autoimmune or autoinflammatory disease, Parkinson&#39;s disease, amyotrophic lateral sclerosis, Alzheimer&#39;s disease and related dementias, rheumatoid arthritis, preeclampsia, sickle cell anemia, or a cardiovascular condition;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(ii) An organ or tissue transplant; or</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(iii) Pharmacogenomic testing; and</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(b) The test provides clinical utility as demonstrated by medical and scientific evidence, including, but not limited to:</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(i) Labeled indications for a test approved or cleared by the federal Food and Drug Administration;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(ii) Indicated tests for a drug approved by the federal Food and Drug Administration;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(iii) Warnings and precautions on drug labels approved by the federal Food and Drug Administration;</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(iv) National coverage determinations by the federal Centers for Medicare and Medicaid Services or local coverage determinations by the medicare administrative contractor; or</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(v) Nationally recognized clinical practice guidelines and consensus statements.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(3) Coverage, as specified in subsection (2) of this section, shall be provided in a manner that limits disruptions in care, including the need for multiple biopsies or biospecimen samples.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(4) Entities contracting with the medical assistance program to deliver services to program recipients shall provide biomarker testing at the same scope, duration, and frequency as the medical assistance program otherwise provides to recipients.</u>\n    </p>\n    <p class=\"indent\">\n     <u class=\"amendmentInsertedText\">(5) The recipient and participating medical assistance program provider shall have access to a clear, readily accessible, and convenient process to request an exception to a coverage policy of the medical assistance program. The process shall be made readily accessible on the Department of Health and Human Services&#39; website.</u>\n    </p>\n   </div>\n   <a name=\"section-LB 77, Section 17-new\"></a><div title=\"Section: LB 77, Section 17, Action: &quot;new&quot;\" class=\"sectionContent\">\n    <p class=\"indent\">\n     <b>Sec. 17. </b> Sections 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, and 13 of this act become operative on January 1, 2026. The other sections of this act become operative on their effective date.</p>\n   </div>\n   <a name=\"section-LB 77, Section 18-new\"></a><div title=\"Section: LB 77, Section 18, Action: &quot;new&quot;\" class=\"sectionContent\">\n    <p class=\"indent\">\n     <b>Sec. 18. </b> If any section in this act or any part of any section is declared invalid or unconstitutional, the declaration shall not affect the validity or constitutionality of the remaining portions.</p>\n   </div>\n  </div>\n </div>\n    </div>\t\n<table cellpadding=0 cellspacing=0 width=\"100%\">\n   <tr>\n      <td>\n          Copyright &copy; 2025 State Net\n      </td>\n<BR>\n<!--???MOVED INTO resources.cgi      <td align=\"right\">\n          <img src=\"https://custom.statenet.com/network/poweredby.gif\" alt=\"Powered by State Net\">\n      </td>-->\n\n    </tr>\n</table>\n</body></html>\n",
      "markdown": "The following has special meaning: _green underline denotes added text_ ~~red struck out text denotes deleted text~~ | [![Powered by State Net](https://custom.statenet.com/network/poweredby.gif)](https://www.lexisnexis.com/statenet/)  \n---|---  \n  \n2025 NE L 77 | | Author: | Bostar  \n---|---  \nVersion: | Enacted - Slip Law  \nVersion Date: | 06/04/2025  \n  \n**LEGISLATIVE BILL 77**\n\nApproved by the Governor June 4, 2025\n\nIntroduced by Bostar, 29.\n\nA BILL FOR AN ACT relating to insurance; to adopt the Ensuring Transparency in\nPrior Authorization Act; to provide for insurance and medicaid coverage of\nbiomarker testing as prescribed; to provide operative dates; and to provide\nseverability.\n\nBe it enacted by the people of the State of Nebraska,\n\n**Section 1.** _Sections 1 to 13 of this act shall be known and may be cited\nas the Ensuring Transparency in Prior Authorization Act._\n\n**Sec. 2.** _For purposes of the Ensuring Transparency in Prior Authorization\nAct, unless the context otherwise requires:_\n\n_(1) Adverse determination has the same meaning as in section 44-1303;_\n\n_(2) Clinical peer means a health care provider in the same, or in a similar,\nspecialty that typically manages the medical condition or health care service\nunder review;_\n\n_(3) Clinical review criteria has the same meaning as in section 44-1303;_\n\n_(4) Department means the Department of Insurance;_\n\n_(5) Emergency health care services means health care services medically\nnecessary to screen and stabilize a patient in connection with an emergency\nmedical condition until the health care provider determines such individual is\nable to travel using nonmedical transportation;_\n\n_(6) Emergency medical condition has the same meaning as in section 44-1303;_\n\n_(7) Enrollee means an individual who is enrolled in a health benefit plan,\nincluding covered dependents;_\n\n_(8) General acute hospital has the same meaning as in section 71-412;_\n\n_(9) Health benefit plan has the same meaning as in section 44-1303;_\n\n_(10) Health care provider has the same meaning as in section 44-1303;_\n\n_(11) Health care services has the same meaning as in section 44-1303;_\n\n_(12) Health carrier has the same meaning as in section 44-1303, except that\nhealth carrier does not include a managed care agent;_\n\n_(13) Medically necessary has the same meaning as in section 44-6845;_\n\n_(14) Notice means communication delivered either electronically or through\nthe United States Postal Service or a common carrier;_\n\n_(15) Physician means an individual licensed under the Medicine and Surgery\nPractice Act to practice medicine and surgery or osteopathic medicine and\nsurgery or an individual with an equivalent license from another United States\njurisdiction;_\n\n_(16) Prior authorization means the process by which a health carrier or\nutilization review agent makes a determination that a requested admission,\nextension of stay, or health care service has been reviewed and, based on the\ninformation provided, satisfies the health carrier 's or utilization review\nagent's requirements for reimbursement under the applicable health benefit\nplan;_\n\n_(17) Urgent health care service means a health care service with respect to\nwhich the application of the time periods prescribed under the Ensuring\nTransparency in Prior Authorization Act for making a nonexpedited prior\nauthorization could, in the opinion of a physician with knowledge of the\nenrollee 's medical condition:_\n\n_(a) Seriously jeopardize the life or health of the enrollee or the ability of\nthe enrollee to regain maximum function; or_\n\n_(b) Subject the enrollee to severe pain that cannot be adequately managed\nwithout the care or treatment that is the subject of the utilization review;\nand_\n\n_(18) Utilization review agent has the same meaning as in section 44-5418._\n\n**Sec. 3.** _(1) A utilization review agent shall make prior authorization\nrequirements and restrictions, including written clinical review criteria,\naccessible on its website. Such requirements, restrictions, and clinical\nreview criteria shall be accurate and current and shall clearly communicate\nwhat information and documentation is needed to decide the prior\nauthorization. Prior authorization requirements shall also be made available\non the website in a searchable format no later than July 1, 2027._\n\n_(2) If a utilization review agent intends either to implement a new prior\nauthorization requirement or restriction or to amend an existing requirement\nor restriction, the utilization review agent shall:_\n\n_(a) Ensure that the new or amended requirement or restriction is not\nimplemented unless the utilization review agent 's website has been updated to\nreflect the new or amended requirement or restriction; and_\n\n_(b) Provide contracted health care providers with notice of the new or\namended requirement or restriction no less than sixty days before the\nrequirement or restriction is implemented._\n\n**Sec. 4.** _(1) A utilization review agent shall ensure that all adverse\ndeterminations for prior authorization are made by a physician, except that if\nthe requesting health care provider is not a physician, the adverse\ndetermination may be made by a clinical peer of the requesting health care\nprovider. Such physician or clinical peer shall:_\n\n_(a) Possess a current and valid nonrestricted license in a United States\njurisdiction;_\n\n_(b) Have the appropriate training, knowledge, or expertise to apply\nappropriate clinical guidelines to the health care service being requested;\nand_\n\n_(c) Make the adverse determination under the clinical direction of one of the\nutilization review agent 's medical directors who is responsible for the\nprovision of health care services provided to enrollees of Nebraska. All such\nmedical directors must be physicians licensed in a United States\njurisdiction._\n\n_(2) When an adverse determination for prior authorization is issued or a\nprior authorization is canceled or voided, the utilization review agent shall\nprovide notice to the requesting health care provider. The notice shall\ninclude the reason for denial, citing written clinical review criteria._\n\n_(3)(a) If an adverse determination for prior authorization questions the\nmedical necessity, the appropriateness, or the experimental or investigational\nnature of a health care service, the enrollee 's health care provider shall\nhave the opportunity to discuss the health care service with the physician or\nclinical peer who is responsible for determining authorization of the health\ncare service under review. The enrollee's health care provider may request\nthat such discussion occur within three business days after receiving notice\nof the adverse determination. No discussion shall be required or allowed for\nan adverse determination that is due to contract exclusions or benefits that\nare not covered by the health benefit plan._\n\n_(b) Following any discussion under subdivision (3)(a) of this section, the\nutilization review agent shall notify the requesting health care provider\nwhether the adverse determination decision remains the same. The notice under\nthis subdivision shall be provided (i) within one business day after the\ndiscussion under subdivision (3)(a) of this section for an urgent health care\nservice or (ii) within two business days after the discussion under\nsubdivision (3)(a) of this section for a nonurgent health care service._\n\n_(c) A discussion under subdivision (3)(a) of this section shall not replace\nor eliminate the opportunity for any internal grievance or appeal process\nprovided by the utilization review agent._\n\n**Sec. 5.** _A utilization review agent shall ensure that all appeals of an\nadverse determination for prior authorization are reviewed by a physician.\nSuch physician shall:_\n\n_(1) Possess a current and valid unrestricted license in a United States\njurisdiction;_\n\n_(2) Be of the same or similar specialty as the ordering physician or have the\ntraining and experience to treat the condition, which means that either:_\n\n_(a) The physician maintains board certification for the same or similar\nspecialty; or_\n\n_(b) The physician 's training and experience (i) includes treating the\ncondition, (ii) includes treating complications that may result from the\nhealth care service, and (iii) is sufficient for the physician to determine\nbased on the physician's clinical judgment whether the health care service is\nmedically necessary or clinically appropriate;_\n\n_(3) Not have been directly involved in making the initial adverse\ndetermination;_\n\n_(4) Not have any financial interest in the outcome of the appeal; and_\n\n_(5) Consider all known clinical aspects of the health care service under\nreview, including, but not limited to, a review of those medical records which\nare pertinent and relevant to the active condition provided to the utilization\nreview agent by the enrollee 's health care provider, or a health care\nfacility, and any pertinent medical literature provided to the utilization\nreview agent by the health care provider._\n\n**Sec. 6.** _(1)(a) On or before November 1, 2025, the department shall\napprove a single uniform prior authorization request form for prescription\ndrugs, devices, and durable medical equipment and a single uniform prior\nauthorization request form for all other health care services. The uniform\nprior authorization request forms shall not exceed two printed pages in\nlength. This two-page limit does not apply to information or documentation\nrequired by the utilization review agent, as published in accordance with\nsubsection (1) of section 3 of this act, or a health care provider 's notes or\ndocumentation submitted in support of a prior authorization request._\n\n_(b) Beginning January 1, 2026:_\n\n_(i) All health care providers shall use only the approved uniform prior\nauthorization request forms; and_\n\n_(ii) Except as provided in subsection (2) of this section, all utilization\nreview agents shall accept and process prior authorization requests submitted\nusing such forms._\n\n_(c) This subsection does not prohibit a utilization review agent from using a\nprior authorization methodology that uses an Internet webpage, an Internet\nwebpage portal, or a similar web-based system if the methodology is consistent\nwith the uniform prior authorization request forms approved by the department\npursuant to this subsection._\n\n_(2) A utilization review agent may request from the department an exemption\nfrom the requirements of subsection (1) of this section if the utilization\nreview agent implements and maintains a prior authorization application\nprogramming interface pursuant to 45 C.F.R. 156.223(b) or other electronic\nprior authorization methodology that automates and standardizes the prior\nauthorization process for patients, health care providers, and health\ncarriers. A utilization review agent shall provide notice to health care\nproviders at least ninety days prior to implementing a prior authorization\napplication programming interface or other electronic prior authorization\nmethodology under this subsection._\n\n**Sec. 7.** _(1) Prior to January 1, 2028, if a utilization review agent\nrequires prior authorization of a health care service, the utilization review\nagent shall make a decision on the prior authorization request and provide\nnotice of its decision to the enrollee and the enrollee 's health care\nprovider in accordance with the following timeframes:_\n\n_(a) For a prior authorization request for urgent health care services, within\nseventy-two hours after obtaining all necessary information to make a\ndecision; or_\n\n_(b) For a prior authorization request for nonurgent health care services,\nwithin seven days after obtaining all necessary information to make a\ndecision._\n\n_(2) Beginning January 1, 2028, if a utilization review agent requires prior\nauthorization of a health care service, the utilization review agent shall\nmake a decision on the prior authorization request and provide notice of its\ndecision to the enrollee and the enrollee 's health care provider in\naccordance with the following timeframes:_\n\n_(a) For a prior authorization request for urgent health care services, within\nforty-eight hours after obtaining all necessary information to make a\ndecision; or_\n\n_(b) For a prior authorization request for nonurgent health care services,\nwithin seven days after obtaining all necessary information to make a\ndecision._\n\n_(3) Nothing in this section prohibits a health care provider and health\ncarrier from contracting for shorter timeframes for using the prior\nauthorization application programming interface or other electronic prior\nauthorization methodology described in subsection (2) of section 6 of this act\nor as part of a risk-sharing agreement._\n\n_(4) Health care services are deemed authorized if a utilization review agent\nfails to comply with the deadlines for making a decision as set forth in this\nsection._\n\n_(5) In the notice to the health care provider that a prior authorization has\nbeen approved, the utilization review agent shall include the duration of the\nprior authorization or the date by which the prior authorization will expire._\n\n**Sec. 8.** _No utilization review agent shall require prior authorization\nof:_\n\n_(1) Emergency confinement or an emergency health care service;_\n\n_(2) Pre-hospital transportation for the provision of emergency health care\nservices or for transfers between facilities as required by the federal\nEmergency Medical Treatment and Labor Act; or_\n\n_(3) Services that have a rating of A or B from the United States Preventive\nServices Task Force, immunizations recommended by the Advisory Committee on\nImmunization Practices of the Centers for Disease Control and Prevention, or\npreventive services and screenings provided to women as required by 45 C.F.R.\n147.130._\n\n**Sec. 9.** _(1) A utilization review agent shall not revoke, limit,\ncondition, or restrict an approved prior authorization if care is provided\nwithin sixty days from the date the health care provider received the prior\nauthorization approval unless the enrollee was no longer eligible for care on\nthe day care was provided._\n\n_(2) A health carrier shall pay a contracted health care provider at the\ncontracted payment rate for a health care service provided by the health care\nprovider per an approved prior authorization request, unless:_\n\n_(a) The health care provider knowingly and materially misrepresented the\nhealth care service or patient 's medical history in the prior authorization\nrequest with the intent to deceive and obtain an unlawful payment under the\nhealth benefit plan;_\n\n_(b) The health care service was no longer a covered benefit on the day it was\nprovided;_\n\n_(c) The health care provider was no longer contracted with the patient 's\nhealth benefit plan on the date the care was provided;_\n\n_(d) The health care provider failed to meet the utilization review agent 's\ntimely filing requirements;_\n\n_(e) The patient was no longer eligible for health care coverage on the day\nthe care was provided; or_\n\n_(f) The health care provider failed to obtain prior authorization approval\nbefore rendering health care services for which prior authorization was\nrequired._\n\n**Sec. 10.** _(1) Except as otherwise provided in this section, prior\nauthorization shall be valid for at least one year from the date the\nutilization review agent approves the prior authorization request, except for\na prescription drug that has a treatment schedule or dosing limitation from\nthe federal Food and Drug Administration of less than one year._\n\n_(2)(a) If a prior authorization is required for inpatient care at a general\nacute hospital, the prior authorization shall remain valid for the length of\nstay approved by the utilization review agent._\n\n_(b) If the health care provider submits a timely request for the continuation\nof inpatient care, the utilization review agent shall respond to this request\nprior to the expiration of the current authorization for inpatient care._\n\n_(c) If a utilization review agent fails to respond to a timely request for\nthe continuation of inpatient care prior to the termination of the previously\napproved length of stay, then the health carrier shall continue to compensate\nthe health care provider at the contracted rate for inpatient care provided\nuntil the utilization review agent issues its determination on the prior\nauthorization request._\n\n_(d) Nothing in this subsection shall be interpreted to prohibit a health care\nprovider or enrollee from appealing an adverse determination as allowed under\nstate law. If an adverse determination is overturned on appeal, and no other\nlegal action related to the claim is pending, then the health carrier shall\nreimburse the health care provider at the contracted rate for inpatient care\nprovided to the enrollee._\n\n_(3) This section does not require a health benefit plan to cover care,\ntreatment, or services for a health condition that the terms of coverage\notherwise completely exclude from the policy 's covered benefits without\nregard for whether the care, treatment, or services are medically necessary._\n\n**Sec. 11.** _(1) On receipt of information documenting an approved prior\nauthorization from the enrollee or from the enrollee 's health care provider,\na utilization review agent shall honor the approved prior authorization\ngranted to an enrollee from a previous utilization review agent for at least\nthe initial sixty days of an enrollee's coverage under a new health benefit\nplan. During such time period, a utilization review agent may perform its own\nreview to grant a prior authorization._\n\n_(2) If there is a change in coverage of, or approval criteria for, a\npreviously authorized health care service, the change in coverage or approval\ncriteria does not affect a prior authorization request approved before the\neffective date of the change._\n\n_(3) A utilization review agent shall continue to honor a prior authorization\nit has granted to an enrollee when the enrollee changes health insurance\nproducts under the same health insurance company without any action required\nby the health care provider._\n\n**Sec. 12.** _(1) An artificial intelligence-based algorithm shall not be the\nsole basis of a utilization review agent 's decision to deny, delay, or modify\nhealth care services based, in whole or in part, on medical necessity._\n\n_(2) A utilization review agent shall disclose to the department, to each\nhealth care provider in its network, to each enrollee, and on its public\nwebsite if artificial intelligence-based algorithms are used or will be used\nin the utilization review process._\n\n_(3) The department may, at any time, audit a utilization review agent 's\nautomated utilization management system. The department may contract with a\nthird-party entity to perform an audit pursuant to this section._\n\n**Sec. 13.** _A utilization review agent shall not:_\n\n_(1) Be compensated based on its volume of denials; or_\n\n_(2) Base any incentive or penalty for a medical reviewer of such agent based\non the volume of denials such reviewer issues or upholds._\n\n**Sec. 14.** _For purposes of sections 14 to 16 of this act:_\n\n_(1) Biomarker means a characteristic that is objectively measured and\nevaluated as an indicator of normal biological processes, pathogenic\nprocesses, or pharmacologic responses to a specific therapeutic intervention,\nincluding known gene-drug interactions for medications being considered for\nuse or already being administered. Biomarkers include, but are not limited to,\ngene mutations, characteristics of genes, or protein expression;_\n\n_(2) Biomarker testing means the analysis of tissue, blood, or other\nbiospecimen for the presence of a biomarker. Biomarker testing includes, but\nis not limited to, single-analyte tests, multi-plex panel tests, protein\nexpression, and whole exome, whole genome, and whole transcriptome\nsequencing;_\n\n_(3) Clinical utility means sufficient medical and scientific evidence\nindicating that the use of a biomarker test will provide meaningful\ninformation that affects treatment decisions and guides improvement of net\nhealth outcomes including an improved quality of life or longer survival;_\n\n_(4) Consensus statements means statements developed by an independent,\nmultidisciplinary panel of experts utilizing a transparent methodology and\nreporting structure and with a conflict of interest policy. These statements\nare aimed at specific clinical circumstances and based on the best available\nevidence for the purpose of optimizing the outcomes of clinical care;_\n\n_(5) Health carrier has the same meaning as in section 44-1303; and_\n\n_(6) Nationally recognized clinical practice guidelines means evidence-based\nclinical practice guidelines developed by independent organizations or medical\nprofessional societies utilizing a transparent methodology and reporting\nstructure and with a conflict of interest policy. Clinical practice guidelines\nestablish standards of care informed by a systematic review of evidence and an\nassessment of the benefits and risks of alternative care options and include\nrecommendations intended to optimize patient care._\n\n**Sec. 15.** _(1) On and after January 1, 2028, and notwithstanding section\n44-3,131, (a) any individual or group sickness and accident insurance policy\nor subscriber contract delivered, issued for delivery, or renewed in this\nstate and any hospital, medical, or surgical expense-incurred policy, except\nfor policies that provide coverage for a specified disease or other limited-\nbenefit coverage and (b) any self-funded employee benefit plan to the extent\nnot preempted by federal law, shall include coverage for biomarker testing\npursuant to the criteria established under subsection (2) of this section._\n\n_(2) Biomarker testing shall be covered when:_\n\n_(a) The test is used for:_\n\n_(i) The diagnosis, treatment, appropriate management, or ongoing monitoring\nof cancer, an autoimmune or autoinflammatory disease, Parkinson 's disease,\namyotrophic lateral sclerosis, Alzheimer's disease and related dementias,\nrheumatoid arthritis, preeclampsia, sickle cell anemia, or a cardiovascular\ncondition;_\n\n_(ii) An organ or tissue transplant; or_\n\n_(iii) Pharmacogenomic testing; and_\n\n_(b) The test provides clinical utility as demonstrated by medical and\nscientific evidence, including, but not limited to:_\n\n_(i) Labeled indications for a test approved or cleared by the federal Food\nand Drug Administration;_\n\n_(ii) Indicated tests for a drug approved by the federal Food and Drug\nAdministration;_\n\n_(iii) Warnings and precautions on drug labels approved by the federal Food\nand Drug Administration;_\n\n_(iv) National coverage determinations by the federal Centers for Medicare and\nMedicaid Services or local coverage determinations by the medicare\nadministrative contractor; or_\n\n_(v) Nationally recognized clinical practice guidelines and consensus\nstatements._\n\n_(3) Coverage, as specified in subsection (2) of this section, shall be\nprovided in a manner that limits disruptions in care, including the need for\nmultiple biopsies or biospecimen samples._\n\n_(4) The patient and prescribing practitioner shall have access to a clear,\nreadily accessible, and convenient process to request an exception to a\ncoverage policy. The process shall be made readily accessible on the health\ncarrier 's website._\n\n**Sec. 16.** _(1) The medical assistance program shall cover biomarker testing\nno later than January 1, 2028._\n\n_(2) Biomarker testing shall be covered when:_\n\n_(a) The test is used for:_\n\n_(i) The diagnosis, treatment, appropriate management, or ongoing monitoring\nof cancer, an autoimmune or autoinflammatory disease, Parkinson 's disease,\namyotrophic lateral sclerosis, Alzheimer's disease and related dementias,\nrheumatoid arthritis, preeclampsia, sickle cell anemia, or a cardiovascular\ncondition;_\n\n_(ii) An organ or tissue transplant; or_\n\n_(iii) Pharmacogenomic testing; and_\n\n_(b) The test provides clinical utility as demonstrated by medical and\nscientific evidence, including, but not limited to:_\n\n_(i) Labeled indications for a test approved or cleared by the federal Food\nand Drug Administration;_\n\n_(ii) Indicated tests for a drug approved by the federal Food and Drug\nAdministration;_\n\n_(iii) Warnings and precautions on drug labels approved by the federal Food\nand Drug Administration;_\n\n_(iv) National coverage determinations by the federal Centers for Medicare and\nMedicaid Services or local coverage determinations by the medicare\nadministrative contractor; or_\n\n_(v) Nationally recognized clinical practice guidelines and consensus\nstatements._\n\n_(3) Coverage, as specified in subsection (2) of this section, shall be\nprovided in a manner that limits disruptions in care, including the need for\nmultiple biopsies or biospecimen samples._\n\n_(4) Entities contracting with the medical assistance program to deliver\nservices to program recipients shall provide biomarker testing at the same\nscope, duration, and frequency as the medical assistance program otherwise\nprovides to recipients._\n\n_(5) The recipient and participating medical assistance program provider shall\nhave access to a clear, readily accessible, and convenient process to request\nan exception to a coverage policy of the medical assistance program. The\nprocess shall be made readily accessible on the Department of Health and Human\nServices ' website._\n\n**Sec. 17.** Sections 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, and 13 of this act\nbecome operative on January 1, 2026. The other sections of this act become\noperative on their effective date.\n\n**Sec. 18.** If any section in this act or any part of any section is declared\ninvalid or unconstitutional, the declaration shall not affect the validity or\nconstitutionality of the remaining portions.\n\nCopyright (C) 2025 State Net  \n  \n---\n\n",
      "latest_version": true
    }
  ]
}